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SUMMARY
An immune neutralization in vivo model, using antiglucagon immunoglobulins, 
was characterized and found to be capable of specifically and effectively blocking 
A-cell secretion in rats. This was applied to the study of the mechanism of 
insulin secretion by different secretagogues. Results indicated that arginine and 
the sulphonylurea drugs acted on the B-cell via glucagon, whereas glucose, leucine 
and GIP acted directly. Results also supported the possibility of GIP having an 
incretin effect.
Further investigation into the mechanism of insulin secretion was carried out 
using diazoxide. This drug inhibited the actions of glucose, arginine, leucine and 
glucagon on the B-cell, but not those of sulphonylureas. This lent support to the 
general concept of diversity of insulin secretion mechanisms. However the non­
specificity of diazoxide action prevented a precise interpretation of data.
A radioimmunoassay for neurotensin was developed in order to evaluate its 
plasma levels and hence its role in glucose homeostasis and insulin secretion. 
When applied to the study of fasting and fat-stimulated plasma neurotensin levels 
of healthy individuals, the assay could not measure any significant changes. Since 
the assay was specific only to the intact neurotensin molecule, these observations 
cast doubt on the importance of circulating NT (1-13) levels in post-meal 
physiology.
Infusion studies with synthetic neurotensin were carried out in rats. Results 
confirmed the hyperglycaemic and hyperglucagonaemic effects of the peptide at 
the pharmacological doses used. Contrarily, no effect on plasma insulin or 
somatostatin was observed. Further study of the hyperglycaemic action showed 
that it was mediated by glucagon.
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CHAPTER 1 
INTRODUCTION
GLUCOSE IN THE BODY
The hexose sugar glucose is important for body function because it is a
readily available source of energy, the metabolism of which generates the high
energy molecule ATP. If glucose, labelled with ^ C , is given to a living 
14organism, C can be detected in almost all the carbon-containing compounds of 
the organism, with a few known exceptions. This reflects the fact that there is a 
complex network of enzyme-catalyzed chemical reactions which relates almost 
every biological compound to glucose. Man could, in principle, build up every 
organic compound in his body, with the exception of some of the amino acids, 
some unsaturated fatty acids and all the vitamins, from this single compound.
Glucose is also particularly important for the erythron and the^brain. The latter
in  th e  f a s t in g  s t a te  
alone accounts for 30-50% of the total glucose turnover, and althougn tne brain
seems to adapt to a chronic deficiency in glucose - mainly by its ability to utilize
ketone bodies - it does not tolerate an acute episode of the same nature.
Glucose in the body is virtually confined to the extracellular fluid and liver 
cells. These together comprise , a body pool of glucose to which glucose 
molecules may be either added or removed (Marks 1981). In the ordinary resting 
state, the glucose pool is about 83-110 mmol, and glucose turnover varies between 
0.66 - 1 mmol/L per minute which corresponds to about 170-260 g per day (Searle 
1976).
In the fed state, glucose is supplied to the body through the hydrolysis of
starch in the intestinal mucosa, a process which yields glucose as well as other
monosaccharides, eg, galactose and fructose. Some of these monosaccharides
are later transformed into glucose. Once absorbed, glucose travels to the liver
via the portal vein where it finds free access to the hepatocytes. Glucose also
permeates readily into the cells of the pancreatic islets, the intestinal mucosa, 
the kidneys, the brain and the erythrocytes. In tissues, like muscle, fat and
connective tissue, insulin is needed in order for glucose to enter the cells. 
Insulin is believed To Jower the. threshold of these tissues for glucose to enter. 
When the glucose level in the extracellular compartment is less than the 
threshold for these less readily permeable tissues, glucose only flows into the 
tissues which are readily permeable. Conversely, when glucose levels exceed 
that threshold, it starts permeating from the glucose pool into the less readily 
accessible compartments, aided by insulin.
Glucose in excess of the immediate needs is either stored as the highly 
branching homopolysaccharide, glycogen, mainly in the liver and to a lesser 
extent in the muscle, or transformed into fat.
In the fasting state glucose is produced by the processes of glycogen 
breakdown (glycogenolysis) and/or gluconeogenesis.
Glycogen is found in nearly all tissues of the body, eg, muscle, brain, heart, 
kidneys ., but the liver is by far the most significant store of
glycogen. Its possession of the enzyme glucose-6-phosphatase, which liberates 
glucose and inorganic phosphorus, makes it the most important organ as far as 
glycogenolysis is concerned. This is augmented by the fact that liver cells are 
freely accessible to glucose from the extracellular compartment.
Glycogen is formed from dietary glucose, although it has also been suggested 
that gluconeogenic glucose may be used for this purpose (Shapiro and Shapiro
1979). Glycogenesis is brought about by the enzyme glycogen synthase, while 
glycogenolysis is brought about mainly by phosphorylase. The former process is 
favoured by high glucose and insulin concentrations in the portal blood. The 
latter is favoured by the intracellular accumulation of cAMP brought about by B- 
adrenergic stimulation. It has also been suggested that phosphorylase can be 
activated through a-adrenergic stimulation (Exton 1979).
Gluconeogenesis implies the de novo synthesis of glucose from molecules of 
shorter carbon backbone, mainly lactate, pyruvate, some amino acids and 
glycerol. The liver and kidneys are almost the only organs which possess the 
enzymes that can bring about gluconeogenesis, namely fructose-1-6- 
diphosphatase, pyruvate carboxylase, phospho-enolpyruvate carboxylase and 
glucose-6-phosphatase. The liver is the major contributor to gluconeogenesis 
except in circumstances such as prolonged fasting.
It is important to keep glucose levels in the blood within the range of 4-9 
mmol/L. Levels much higher than normal will cause osmotic disturbances, while 
lowering the glucose concentration below normal limits can jeopardize the 
integrity of an organ of such importance as the brain. The endocrine system, the 
autonomic nervous system, the paracrine influence, renal tubular absorption as 
well as intracellular regulatory mechanisms, all operate to keep a very fine 
balance of glucose concentrations in the blood over a wide range of situations. 
In the instance of one or more of these regulatory mechanisms becomes 
defective, glucose homeostasis is perturbed.
2 THE PANCREATIC ISLET
(a) Microanatomy
Ever since Paul Langerhans discovered the pancreatic islets in 1869, a 
considerable amount of the details of their structure has been outlined. This was 
made possible by developments in microscopic and staining techniques.
Four types of cells have been identified so far: (a) B-cell secreting insulin,
(b) A -cell secreting glucagen, (c) D-cell secreting somatostatin and (d) PP-cell 
secreting pancreatic polypeptide. It has been shown by Orci (1980), that there is 
considerable variation in the amount and arrangement of these cells in the 
different pancreatic portions. In the rat, in the head region of the pancreas, 
islets have about 74% of their cell population as B-cells; PP-cells comprise 20%, 
while D- and A-cells represent 4.5 and 1.5% respectively. In the tail or splenic 
portion the percentages are as follows: 66% B-cells, 28% A-cells, 4% D-cells 
and 2% PP-cells.
In the rat, the mouse and in man the A, D and PP cells are situated 
peripherally surrounding a core of B-cells (Orci & Unger 1975, Orci 1980). Orci 
and Unger (1975) have noticed a close association between the A and D cells 
which, interestingly enough, are situated centrally in the horse"surrounded by B- 
cells. This finding has led Orci and his co-worker to suggest that the 
arrangement of the islet cells is important for their normal and pathological 
functioning, a fact which was supported by the finding of Halban et al (1979), 
that dispersed islet cells repsonded poorly to glucose stimulation while 
reaggregation restored their sensitivity to glucose.
In man, within the tail region of the pancrease, the periphery of the islet is 
predominated by A-cells, while in the head region, there is a predominance of 
PP-cells in the periphery of the islet (Orci 1980).
With the use of the. freeze-fracture.-technique,. .specializ£d„contact_.po]nts_ 
between plasma membranes of islet cells have been observed. These are the 
tight and gap junctions (Orci et al 1973, Orci and Unger 1975) which exist 
between both homogeneous and heterogeneous types of islet cells. Tight 
junctions are focal areas where the outer leaflets of two cell membranes are 
fused together. The function of these junctions is not yet clear but they may 
serve to control accessibility of substances from the extracellular compartment 
into the cell. There has been a report, however, that challenges the existence of 
tight junctions in normal situations. It suggests that tight junctions observed in 
histological preparations made from isolated islets "provide an adaptive 
mechanism intended to seal, and hence to protect, islet microdomains against 
sudden perturbations in local interstitial fluid" (int Veld et al 1984).’
Gap junctions, on the other hand, are points of direct contact between cells 
which allow the passage of electrical impulses, ions and small molecules up to 
1200 daltons (Orci et al 1973, Simpson et al 1977). In the resting B-cell, gap 
junctions are small and scarce, but the area occupied by them on the B-cell 
plasma membrane is increased following insulin secretion (Meda et al 1979). The 
possibility that these junctions play a role in islet cell responsiveness is 
supported by the finding that 6-carboxyfluorescein can rapidly pass from one cell 
to as many as eight cells and that this phenomenon can be modified by insulin 
stimulators and inhibitors (Kohen et al 1983).
Blood Supply
In the rabbit the endocrine pancreas receives 11-23% of the total pancreatic 
blood flow despite the fact that the islets occupy only 0.8% of the pancreas 
(Lifson et al 1980). The blood flow is increased even further when insulin 
secretion is stimulated (Jansson and Hellerstrom 1983).
The blood supply to the .islets, echoes the pattern of their embryological 
origin. Islets of the duodenal segment are supplied by the superior mesenteric 
artery, whilst those of the splenic segment are supplied by the gastroduodenal 
and splenic arteries. Different arterioles enter the islet through a gap in the 
non-mantle cells and break up into a glomerular network. In the rabbit, efferent 
islet blood flow passes into the acinar capillaries first before leaving the organ. 
This finding supports the possibility of an insuloacinar portal system (Lifson et al
1980). Such a possibility has however been challenged by Bonner-Weir and Orci 
(1982) who described two types of efferent islet blood flow in the rat pancreas: 
efferent capillaries from small islets which coalesce together either directly at 
the periphery of the islet or pass through the acinar tissue first; and capillaries 
from intermediate and large islets which pass directly to form venules at the 
periphery of the islet.
Innervation
Islets receive a cholinergic as well as an adrenergic nerve supply (Smith and 
Porte 1976) from the vagal and splanchnic trunks, respectively. A local 
presynaptic autonomic regulation has been proposed by Langer et al (1977). This 
view has been supported by Samols and Stranger (1981) in view of their 
observation that the isolated canine pancreas retained Tts ability to be 
autoregulated by adrenergic neurotransmission. According to Samols and 
Stranger (1981) the pancreatic B-cell is modulated by a pre(a2)- and postsynaptic 
a2 system. These findings may explain the contradictory reports of the effect of 
(a-agonism) on pancreatic islet cell secretion.
A third class of fibres containing large electron-dense storage granules has 
been labelled by Bloom and Polak (1978) as peptidergic. This is because they 
contain enkephalins, substance P, somatostatin and VIP (Larsson et al 1978).
3 HORMONES OF THE ISLET
(a) Insulin
(i) Biosynthesis
The first product in insulin biosynthesis, which has so far been identified, is 
preproinsulin. This has been identified by its sensitivity to glucose, its pattern of 
N ^-term ina l leucine residues, and the rapidity of its appearance and 
disappearance in islet cell tumor preparations. Preproinsulin has a molecular 
weight of 11,100 (Patzelt et al 1978). The ’pre1 region consists of 20- to 30- N ^ -  
terminal extension that contains a high proportion of hydrophobic amino acids. 
This region is believed to assist in the formation of the ribosome-membrane 
junction (Patzelt et al 1978).
Proteolytic activity, which removes the 'pre' region of preproinsulin, yields 
proinsulin. This process takes place in the rough endoplasmic reticulum of the B- 
cell. Thereafter, proinsulin is transferred via an energy-dependent process to 
the Golgi apparatus where proteolytic conversion to insulin begins (Tager and 
Steiner 1974).
and
The tow main end products of degradation of proinsulln are insuliny^C- 
peptide of J proinsulin. C-peptide, which is the connecting peptide linking the 
two chains of insulin, A and B, shows a wide variation between species (Tager 
and Steiner 1974). It accumulates with insulin in the secretory granules in 
equimolar quantities and is secreted along with it by emiocytosis.
The proportion of proinsulin which remains unaffected by proteolysis is 
approximately 3%. This is subsequently secreted with insulin and has been 
identified in the circulation of man and animals (Samols et al 1972).
(ii)Storage and Release
Once insulin is in.the Golgi apparatus, it.gets packaged in secretory granules, 
which involves crystallization with the zinc and calcium ions found in these 
granules (Pitts et al 1980). When the appropriate signal is provided, insulin is 
secreted by emiocytosis, a mechanism that is energy-dependent. Emiocytosis is 
triggered by the accumulation of calcium ions in the B-cell while insulin release 
is attended by an efflux of these ions from the B-cell (Malaisse 1973). 
Ultrastructural studies have revealed a system of microtubules in close vicinity 
to the secretory granules. These are believed to guide the granules in their trip 
to the cell surface during emiocytosis (Orci et al 1972). In addition to 
emiocytosis, some investigators have observed an intracytoplasmic breakdown of 
insulin-secretory granules and diffusion of the hormone through the plasma 
membrane of the B-cell (Smith 1973). This may have a role in insulin secretion.
Insulin is secreted in a biphasic pattern, with the first phase lasting 
approximately 10 minutes and the second, more prolonged phase, occuring over 
the next 30-60 minutes.
Glucose is the prime stimulator of insulin secretion under physiological 
conditions. Other sugars and certain amino acids (eg, leucine and arginine) and 
several lipid metabolites also stimulate insulin secretion under physiological 
conditions (Malaisse and Malaisse-Lagae 1968). Arginine, when given orally, 
stimulates insulin secretion more than when it is given intravenously (Dupre7 et al 
1968). Similarly, glucose-induced insulin secretion has been shown to be 
potentiated by the concomitant administration of an intestinal polypeptide in 
rats (Turner & Marks 1972). This is suggestive of a factor released by the 
gastrointestinal tract which plays a role in enhancing glucose-stimulated insulin 
secretion.
(iii)Actions . .......... .................................................................................
Insulin inhibits glucose release while at the same time promoting glucose 
uptake by the liver. The net result is a fall in circulating glucose levels. Insulin 
leads to the dephosphorylation of the phosphorylase kinase and glycogen 
synthase, thereby inhibiting glucose liberation from glycogen. At the same time 
the final step in glycogen synthesis is activated when UDP glucose glycogen 
synthase is dephosphorylated (Levine 1982). It is not known, as yet, how this is 
brought about, but work by Larner and co-worker (1979) has led to the detection 
of a factor produced by insulin in the tissues, a "mediator", which seems to 
activate the phosphatase that dephosphorylates glycogen synthase thereby 
activating it. This factor, which has been isolated from muscle after its 
exposure to insulin, has a molecular weight of about 1000 and has been called 
"factor II of Larner".
In diabetes there is intense destruction of tissue proteins leading to a 
negative nitrogen balance. This process is directed towards the formation of 
sugars from released amino acids. Insulin reverses this effect by assisting in the 
transport of amino acids into the cells and in their incorporation into peptides. 
Furthermore, in the absence of insulin a defect in the aggregation of ribosomes 
into polysomes leads to defective initiation of peptide formation from amino 
acids (Levine 1982).
Insulin favours the synthesis and storage of fat, an effect which is exerted by 
a combination of stimulation of synthetic steps and simultaneous inhibition of fat 
breakdown. Fat synthesis is promoted by insulin through the transformation of 
carbohydrates (or any other metabolites that yield acetyl-CoA) into 
triglycerides. Glucose is, however, the most favoured precursor. Insulin is 
believed to promote triglyceride formation in the same way as it does to 
glycogen synthesis (Levine 1982).
That is, insulin activates protein phosphatases, which then activate the
dephosphorylation of the enzymes that catalyse the formation of acetyl-CoA and 
malonyl-CoA (these enzymes are more active in their dephosphorylated forms).
Insulin Receptors
Hormones exert their actions by attaching to hormone receptors on the cell 
plasma membrane or the cytoplasm of the target organ cell. Receptors are 
specific molecules (proteins or glycoproteins) that have a high affinity for the 
hormone.
The insulin receptor is present on the plasma membrane of the target organ 
cell. It is believed to be composed of two a subunits and two $ subunits linked 
by sulphydryl groups with a molecular weight of approximately 350,000 
(Massague and Czech 1982). These receptors are present in abundance in the 
three major sites of insulin action, namely, the liver, adipose tissue and skeletal 
muscle. However, it has also been reported to be present in the brain 
parenchyma, myocardium, kidney tubules, glomeruli, pulmonary alveoli, 
pancreatic acini, monocytes, granulocytes, erythrocytes and fibroblasts (Kaplan 
1984).
Maximum effects of insulin in tissues are achieved when only part of the
total number of receptors is occupied. It  has been suggested, therefore, that two
classes of insulin receptors exist - the high affinity and the low affinity ones
(Kaplan 1984). This model has been proposed on the basis of both Scatchard
analysis and the finding that when 50% of the total number of receptors is
available, (a percentage theoretically in excess of that needed for insulin to
exert maximal effects), more insulin is in fact required to attain maximum
action. It is therefore the reduction in the number of the high affinity receptors 
which can have profound effects on insulin action.
Following occupancy of the receptor by insulin, the receptor-hormone 
complex is internalized by an endocytotic mechanism (Green and Olefsky 1982).
Once insulin is bound to its target in significant quantities, a diminution in 
insulin binding capacity is observed. This phenomenon is termed ’down 
regulation’. Down regulation increases with time and is related to the 
concentration of insulin. That is, the higher the concentration of insulin the 
greater the loss of cell surface binding potential. Down regulation is attenuated 
by substances like chloroquine and ammonium chloride, possibly through 
interference with the degradation of hormone-receptor complex (Green and 
Olefsky 1982).
In general, binding of a hormone to its receptor activates a nucleotide binding 
protein (N-protein) in the cell-plasma membrane, and this in turn activates the 
so called second messenger. The latter triggers off a series of reactions which 
bring about the cellular response. Two second messengers have so far been 
identified. First, cyclic AMP (cAMP) generated through the activation of the 
adenyl cyclase system and degraded by phosphodiestrase. Second, accumulation 
of intracellular calcium which activates calmodulin which in turn stimulates 
cellular response. There is also evidence that accumulation of intracellular 
calcium stimulates the generation of inositol triphosphate and diacylglycerol 
from inositol. These end products of inosital metabolism then stimulate cellular 
action. As far as insulin action is concerned, there is evidence that cAMP does 
not act as a second messenger. In fact, cAMP is inhibited after occupancy of 
insulin receptors (Kono and Barham 1973).
Metabolism
The liver and the kidney are the two major sites for degradation of insulin.
The liver accounts for 40-60% of the removal of biosynthetic insulin in humans 
(Bratusch-Marrian et al 1984).
There is evidence that more than one mechanism is involved in the 
degradation of insulin, including reductive cleavage of disulphide bonds catalysed 
by the enzyme glutathione reductase and proteolytic degradation of insulin (Izzo
1975). More recent evidence is suggestive of a receptor-mediated process 
involved in the removal of insulin. Eaton et al (1984) have reported a marked 
decrease in hepatic removal and metabolic clearance of insulin in a patient with 
blocked receptors due to endogenous anti-insulin-receptor antibodies.
Of all the insulin removed by the kidneys, only 5% is excreted in the urine. 
The rest is degraded by the processes described above.
Fasting and low insulin levels induced by alloxan treatment in rats have been 
shown to reduce "insulinase" activity. This is suggestive of an auto-regulatory 
system of insulin degradation in which the hormone itself is involved (Izzo 1975).
Glucagon
Glucagon is a 29-amino acid polypeptide synthesized by the pancreatic A-cell 
with a molecular weight of 3485 daltons. Mammalian glucagon, when compared 
with glucagon from avian species and angler fish, shows strong conservation of 
primary structure which may indicate that glucagon is more important than it 
appears to be (Bromer 1983).
The hormone is formed from a larger precursor called preproglucagon. In 
angler fish this is represented by a group of polypeptides whose molecular 
weights range between 12,000 to 16,000 daltons (Hellerstrom 1983). In mammals, 
the evidence for the presence of preproglucagon is less conclusive, but according 
to Tager (1981), the mammalian precursor of glucagon has a molecular weight of 
18,000 to 19,000 daltons. Tryptic activity in the rough endoplasmic reticulum
converts this large polypeptide to proglucagon, followed by stepwise conversion 
involving several intermediates to glucagon (Noe et al 1977 a, b). The glucagon 
molecule is stored in the pancreatic a-granule, together with another 
intermediate most probably identical with glicentin, before being secreted by 
exocytosis.
Plasma half-life of glucagon is approximately 5 mins. The liver and kidneys 
are the major sites of glucagon clearance, each organ contributing 30% of the 
overall clearance (Polonsky et al 1983).
In the liver, glucagon stimulates hepatic glycogenolysis by favouring the 
activation of glycogen phosphorylase (Sutherland and Cori 1951), and inhibits 
glycogen synthesis through the inactivation of glycogen synthase (Bishop and 
Larner 1967). The hormone also stimulates gluconeogenesis by increasing the 
rate of phosphoenolpyruvate production (ClaOs et al 1983) and decreasing the rate 
of its disposal by pyruvate kinase (Felin et al 1976). The result of these two 
processes, namely glycogenolysis and gluconeogenesis, is a net flow of glucose 
into the blood stream, a property with which the hormone has been identified 
since its discovery.
In adipose tissue, glucagon promotes lipolysis. In addition, it lowers the 
levels of malonyl CoA in the liver, switching hepatic metabolism from a non- 
ketogenic to a ketogenic mode (McGarry and Foster 1983). This leads to a net 
production of ketone bodies which provides the body with an alternative source 
of energy, and in conditions of stress, eg, prolonged starvation, assists in saving 
glucose for the more important function of cerebral metabolism.
Glucagon also increases the transport of amino acids into the hepatocytes, 
inhibits net protein synthesis and augments ureogenesis (Cahill et al 1983).
One of the most important findings, regarding intra-islet interrelationships 
has been the demonstration _by _Saraols- et_al. (1965), that .exogenous .glucagon 
stimulates insulin secretion in the presence of hyperglycaemia. Glucagon has 
also been shown to stimulate somatostatin secretion by the D-cell (Patton et al
1976).
Glucagon exerts its effects on different tissues by activating adenylate 
cyclase. When the hormone attaches to the cell membrane, this triggers off a 
series of reactions leading to the activation of the adenylate cyclase, which 
catalyses the conversion of ATP to cAMP - the internal cellular messenger. 
There is indication that, for the first step of adenylate cyclase activation, GTP 
as well as Mg and Mn cations and adenosine are needed (Rodbell 1972; 
Birnbaumer and Rodbell 1973; Birnbaumer and Pohl 1969). Desensitization or 
tachyphlaxis is probably brought about by the destruction of cAMP by 
phosphodiestrase or by uncoupling of the receptor (Rodbell 1983).
Glucose and insulin are physiological inhibitors of glucagon secretion. Amino 
acids, on the other hand, stimulate glucagon secretion. Catecholamines and 
their agonists increase glucagon secretion in vitro (Leclercq-Meyer et al 1971) 
and in vivo (Gerich et al 1973a) while cholinergic stimulation has an inhibitory 
effect on glucagon secretion (Bloom et al 1974).
Apart from the pancreas, true A-cells have been demonstrated in the dog 
gastric fundus (Larsson et al 1975). In addition, morphological studies have 
confirmed the presence of A-cells in the oxyntic glands of the stomach of the 
pig, the cat and the rat (Larsson et al (1975). The presence of extrapancreatic A- 
cells in human tissues has been difficult to identify and its exact physiological 
role is yet to be elucidated.
Recently, ileal glicentin-containing L-cells have been observed to be 
transformed into glucagon-containing cells by in vitro enzymatic digestion with 
trypsin and carboxypeptidase B (Ravazzola and Orci 1980).
Somatostatin
Somatostatin is a tetradecapeptide, originally isolated from hypothalamic 
extracts (Brazeau et al 1972) and later found to be widely distributed in the body. 
In the rat, it is present in both the central and peripheral nervous systems, the 
gastrointestinal tract and the pancreas (Patel and Reichlin, 1978). Somatostatin 
occurs in the body in both cyclic and linear forms.
The name, somatostatin, was coined in view of the ability of the peptide to 
inhibit growth hormone secretion. Further research revealed that it can inhibit 
the secretion and actions of many other hormones including most of the digestive 
hormonese (pancreozymin, secretin, motilin, VIP and GIP), gastric acid and 
pepsin secretion, as well as gut motility and absorption (Guillemin and Gerich 
1976; Gerich 1981).
Somatostatin is formed from a larger precursor, preprosomatostatin. This 
has a molecular weight of 18,000 to 19,000 and is broken down to give 
prosomatostatin (MWt 12,000 to 15,000) before somatostatin is finally produced 
(Shields 1980).
Another form of the peptide has been discovered, called somatostatin-28. 
This was originally isolated from porcine intestine and procine and bovine 
hypothalami. Recently, somatostatin-28 has been reported to be present in the 
human gut and the plasma of the dog and the rat (Ito et al 1982, Shoelson et al 
1982). There is some evidence that somatostatin-28 is the real hormone and that
somatostatin-14 is a mere degradation product. This evidence is based on the 
fact that somatostatin-.28_Js_10.times..more potent.than somatostatin-14, binds 
more avidly to somatostatin receptors and has, perhaps, the same if not longer 
duration of action than somatostatin-14 in vivo (Gerich 1981).
Among the other actions of somatostatin is its ability to block acetylcholine 
and noradrenaline release (Guillemin & Gerich 1976). Infusion of somatostatin 
has been shown to reduce splanchinic blood flow, thus cutting hepatic blood flow 
by 50% in dogs (Jaspan et al 1979).
The role of somatostatin in glucose homeostasis is not yet fully understood 
and it is difficult to extrapolate conclusions drawn from experiments performed 
with pharmacological doses of the peptide to explain its physiology. However, 
some of the findings may be of significance. Incubation of isolated islets with 
anti-somatostatin serum increases both insulin and glucagon release (loth et al 
1980; Barden et al 1977). Infusion of somatostatin into normal subjects or 
patients with insulin-dependant diabetes, on the other hand, leads to a decrease 
in plasma glucose concentration. In normal subjects this is accompanied by a 
decrease in plasma insulin levels (Gerich 1981). Another finding, which may be of 
physiological importance, is the ability of somatostatin to reduce blood flow to 
the liver thus reducing its glucose uptake and release (Marks 1981).
Pancreatic Polypeptide (PP)
This is a 36-amino acid polypeptide which was discovered in 1968 by Kimmel 
and co-worker in chicken pancreas. It has an average molecular weight of 
42,000. Bovine, ovine, porcine and human PP differ in only one to four of the 36 
positions of amino acids.
Pancreatic polypeptide is secreted by the PP cells of the islet which, in 
contrast to other islet, cells, are found both in the islets and scattered in the 
exocrine parenchyma. PP cells are more numerous at the duodenal end of the 
pancreas as compared to the splenic end and become more numerous with 
advancing age (Orci 1980). Paulin and Dubois (1978) have reported rare PP-cells 
in the foetal antrum and duodenum but numerous PP cells in the foetal jejunum 
in man. The pancreas, however, seems to be the major source of PP since, after 
total pancreatectomy, basal plasma levels of PP become undetectable and do not 
rise after ingestion of a mixed meal (Adrian et al 1976 and 1977).
Pancreatic polypeptide secretion is stimulated in response to almost all 
ingested nutrients even those of low calorific value, but the most potent nutrient 
in this respect is ingested protein (Floyd et al 1978); fat and carbohydrates are 
less effective than protein although late after the ingestion of glucose, if plasma 
glucose falls to below basal levels, there may be a substantial increase of human 
PP release.
It seems that nutrients do not act directly on the pancreas to stimulate PP 
secretion. Intravenous administration of amino acids, glucose and fat does not 
bring about a rise in circulating levels of human PP. Rather, PP release induced 
by food is mediated by vagal stimulation (Schwartz et al 1976). These workers 
have found that the plasma human PP response to food is biphasic and that soon 
after truncal vagotomy the early rise in PP is eliminated and the secondary, 
prolonged response is reduced. More recently, Glaser et al (1983) have shown 
that atropine, a muscurinic cholinergic blocking agent, inhibits both phases of 
human PP secretion. They suggested that the portion of the late phase response, 
which persists after truncal vagotomy, must be mediated by an extravagal 
cholinergic mechanism. Conversely, Gingerich and Kramer (1983) believe that 
the second phase of PP release is mediated by a vagal cholinergic-dependant
pathway in concert with a humoral factor of gut origin. These workers have 
shown that the. duodenal mucosa of dogs contains two thermostable Agents with 
molecular weights slightly larger than insulin, which have stimulatory effects on 
PP. The role of adrenergic stimulation of PP secretion is less established (Floyd 
1979).
In an attempt to elucidate the physiology of PP, Kimmel and Pollock (1981) 
investigated the target organs for PP. They found that in the chicken, these are 
the pancreas, the duodenum, the ileum, the spleen and the bone marrow and 
probably the liver and the proventriculus. They also found that the C-terminal 
region of PP is involved in receptor binding.
In the chicken, PP infusion decreases liver glycogen, plasma glycerol, free 
fatty acids and amino acids but increases plasma triglycerides (Floyd 1979). In 
the dog, PP administration increases basal production of gastric acid and gut 
motility and decreases fluid, enzyme and bicarbonate output by the pancreas 
(Floyd 1979).
The effect of the administration of PP on islet function has been equivocal 
and such experiments have been beset by the problems of impure hormone 
preparations. However, the availability of synthetic PP has made it possible to 
arrive at some findings, so far as its influence on islet function is concerned. 
Arimura et al (1979) have shown that intravenous administration of PP at a high 
dose brings about an acute suppression of portal plasma somatostatin levels in 
the rat. Conversely, somatostatin has been shown to exert an inhibitory effect 
on PP in mammals, in contrast to insulin and glucagon which show no apparent 
effect on PP secretion (Floyd 1979).
4 MODULATION OF ISLET FUNCTION
(a) Modulation by Intrinsic Factors
(i) Autonomic 
Sympathetic
8-adrenergic agonism has been shown to stimulate somatostatin, insulin and 
glucagon secretion. This effect is more profound with regard to insulin and 
glucagon as compared to somatostatin (Samols & Weir 1979) and is abolished by 
8-adrenergic blockers, a-adrenergic agonism and electrical stimulation of the 
splanchnic nerves have been shown by the same workers to suppress B- and D- 
cell function and mildly stimulate A-cell function. Marre et al (1982), although 
in agreement with most of these findings, have challenged the proposed 
suppression on D-cell by electrical stimulation of the splanchnic nerve. In their 
study this produced a sharp rise in somatostatin like immunoreactivity (5LI).
The physiological significance of sympathetic stimulation of glucagon 
secretion has been doubted by some authors. According to Marks (1981), this is 
unlikely to be physiologically significant except during severe muscular exercise 
or in response to stress when the dual effects of stimulating glucagon and 
inhibiting insulin secretion encourage hepatic glucose release. This argument is 
based upon the fact that catecholamines increase blood ^glucose by both 
stimulating glycogenolysis and decreasing glucose outflow into the tissues. The 
latter effect is quantitatively the more important and is largely due to inhibition 
of insulin secretion by an a-adrenergic mechanism.
Parasympathetic
Acetylcholine profoundly stimulates pancreatic polypeptide secretion and 
strongly stimulates insulin and glucagon secretion (Samols et al 1983). This is in 
keeping with the findings of Marre et al (1982) that vagal stimulation induces 
insulin and glucagon secretion in rats.
Reports on the ef fee ts-of-cholinergic~ agonism-and vagal-stimulation-on-D-cell—  
function are conflicting, with some workers reporting inhibition (Samols et al 
1977) while others reporting no effect (Hermansen 1980). Marre et al (1982), on 
the other hand, have reported different effects of vagal stimulation on 
somatostatin secretion according to the experimental conditions. Thus, vagal 
stimulation in rats was not followed by a rise in portal somatostatin levels 
except when the rats were stressed. Conversely, in fed animals, with initial 
somatostatin values higher than in fasted state, vagal stimulation inhibited 
somatostatin secretion.
Peptidergic
A peptidergic class of fibres has been described by Bloom & Polak (1978). 
Many peptides have been shown to be present in these nerve endings. Thus, VIP 
and Tetrin, the C-terminal tetrapeptide of CCK/gastrin, have been shown to 
innervate islets and VIP to innervate acini and blood vessels.
Porcine Tetrin and VIP have been shown to stimulate the release of the four 
pancreatic hormones in homologous species (Holst et al 1981).
The islets have also been shown to contain a number of putative peptides with 
potential role in the regulation of islet function. GIP, cholecystokinin, secretin, 
8-endorphin, corticotrophin and glicentin have all been reported to be present in 
the islets (Samols et al 1983). However, according to Holst et al (1981), the 
possibility cannot be excluded that many of the peptidergic nerves merely serve 
the function of interneurones.
Paracrine
The role of the interactions between islet cells in modulating islet function is 
reviewed in the next section.
(iii)Enteropancreatic
The possibility of a peptide secreted by the gastrointestinal mucosa that 
augments insulin secretion was realised as far back as 1932 when Barre proposed 
the existence of a pancreatic endocrine regulator, which he called ’incretin1 
(Sarson and Bloom 1981). A long time ensued before this incretin concept was 
revived by McIntyre et al (1964). In 1969 Unger and Eisentraut introduced the 
term ’enteroinsular axis’ to describe the influence exerted by the intestine on the 
release of the pancreatic hormones. Many studies have since substantiated this 
concept (Dupre et al 1968; Turner and Marks 1972; Turner et al 1973).
Several peptides have been nominated to be candidates for. the role of 
incretin. Among these are gastrin, secretin, cholecystokinin, glicentin, GIP and 
vasoactive intestinal polypeptide (Creutzfeldt 1979). GIP remains, by far, the 
strongest candidate.
According to Brown and Otte (1978), in order for a peptide to qualify for the 
role of incretin it must fulfil the following requirements: (1) It must stimulate 
insulin. (2) This stimulation must take place at physiological concentrations of 
the peptide. (3) The peptide preparation must be pure. (4) The peptide should 
show a rise in the blood stream during the physiological events under 
consideration.
Several peptides have fallen out of favour as incretin factors either because 
they had not met these criteria or because their pattern of insulin secretion had 
not mimicked the biphasic pattern of insulin secretion by glucose. For example, 
secretion of insulin in response to gastrin is monophasic, transitory and remains 
the same in the euglycaemic and hyperglycaemic states (Brown and Otte 1978). 
Gastrin had remained a serious contender for ’incretin’ because, unlike the other 
candidates, only it and GIP are released in response to glucose ingestion. The
other peptides are released in response to either protein or fat ingestion or both
(Creutzfeldt 1979). Vasoactive intestinal polypeptide, remains a potential
modulator of islet function in its capacity as a neurocrine agent present in the 
peptidergic fibres of the islets.
GIP is a 42 amino acid polypeptide secreted by the upper gastrointestinal 
mucosa in response to carbohydrate and fat ingestion, with fat being the more 
potent stimulant in the basal states. It seems that it is the absorption of these 
nutrients rather than their mere presence in the gut, which provides the proper 
stimulus for GIP secretion. Until recently, GIP was thought to be composed of 
43 amino acids, but revision of its structure has shown that it contains 42 amino 
acids only (Brown 1982a). This might influence previously obtained findings with 
43-amino acid synthetic GIP.
GIP has an enterogastrone effect. It  is a powerful releaser of somatostatin 
like immunoreactivity in the isolated perfused rat stomach and this leads to the 
inhibition of gastric acid secretion (Brown et al 1981). Among its other effects 
are stimulation of insulin, glucagon and small intestine secretions and 
stimulation of mesenteric blood flow and lipoprotein lipase activity (Anderson 
1981). However, of all the GIP effects, none seems to be as physiologically 
significant as its stimulation of insulin secretion. The fact that GIP stimulates 
insulin secretion only in the presence of hyperglycaemia suggests that this acts 
as a safeguard against hypoglycaemia induced by the insulinotropic action of the 
peptide (Sarson and Bloom 1981).
More recently Sarson et al (1984) have cast doubt on the observation that GIP
augments insulin secretion under physiological conditions. In their study of
healthy individuals, they concluded that the concentrations of GIP and glucose
required to produce potentiation of insulin release appear to be in the 
pharmacological rather than physiological range.
Endocrine .
Several endocrine hormones have been shown to affect insulin release. Thus, 
growth hormone in acromegaly, and corticoid hormones in Cushing’s syndrome 
lead to enhanced insulin secretion despite the fact that peripheral utilization of 
glucose is impaired. The net result is increased blood glucose levels and reduced 
sensitivity to insulin. Placental lactogen, prolactin, progesterone and oestrogen, 
such as present in pregnancy, all enhance insulin secretion. It is not clear, 
however, whether these hormones promote insulin secretion, by acting directly 
on B-cells or indirectly by producing insulin resistance.
Modulation by Extrinsic Factors: Sulphonylureas
The compounds most commonly used in clinical practice to ameliorate 
glucose intolerance are the sulphonylureas. These will be briefly reviewed in this 
section. Diazoxide, which is the other compound used to a lesser extent in 
clinical practice to modulate islet function in some cases of hypoglycaemia, is 
reviewed in Chapter IV.
Sulphonylureas, which are closely related to the sulphonamide antibiotics and, 
to a lesser degree, to the thiazide diuretics, have been first introduced as oral 
hypoglycaemic agents in the late 1950's.
Mechanism of action
Although sulphonylureas have been used for over twenty years, their mode of 
action is not fully understood. However, they have been noticed to have two 
effects on glucose homeostasis: pancreatic and extrapancreatic. Which of these 
two mechanisms is more important in the long term amelioration of non-insulin 
dependant diabetes remains to be elucidated.
Pancreatic Effects
One possible e ffec t on pancreatic B-cells by sulphonylureas. isjthe .stimulation 
of adenylate cyclase and inhibition of phosphodiesterase. The former decreases 
mitochondrial uptake of calcium ions leading to their accumulation in the 
cytosol. Glucose further increases cytosolic calcium by inhibiting its efflux 
across the cell membrane. Accumulation of calcium in the cells then stimulates 
exocytosis and insulin release (Jackson and Bressler 1981; Ostenson et al 1983). 
This model has been challenged by Henquin (1980) who argued that the 
observation that sulphonylureas do not increase cyclic-AMP levels in the islet 
cells when extracellular calcium has been omitted, raises the possibility that the 
increase in cellular c-AMP follows rather than precedes changes in calcium 
influx. Instead, Henquin suggested that binding of the drug to the membrane 
depolarizes B-cells by reducing potassium permeability, which then activates 
voltage-dependent calcium channels. This assumption was supported by Heilman 
(1982) who further proposed that the sulphonylurea binding to the B-cell is 
essentially the result of hydrophobic interactions between the drug, which at 
physiological levels carries a net negative charge, counteracted by electrostatic 
repulsion from fixed negative charges at the cell surface. One interesting 
finding by Heilman has been that glibenclamide is exceptional among 
sulphonylureas in being progressively taken up by B-cells. This is thought to be 
due to slow permeation of glibenclamide through anion channels in the plasma 
membrane (Heilman 1982, 1984). There was no correlation, however, between 
this progressive binding of the sulphonylurea tothejslets and the stimulation of 
insulin release.
Reports on the effects of sulphonylureas on A-cells have been conflicting. 
Samols et al (1969) reported suppression of pancreatic glucagon secretion and 
concluded that this effect is as important as stimulation of insulin release in 
determining the blood glucose response to sulphonylureas. This finding was
supported by the study of Laube et al (1971) in rats. However, P.ek et al (1972) 
reported failure of sulphorylureas to suppress plasma glucagon levels in man. 
These findings were further supported by the study of Kajinuma et al (1974). 
Conversely, Aguilar-Parade et al (1969) reported stimulation of glucagon release 
following sulphonylurea administration in anaesthetized dogs. On the other hand, 
Unger et al (1970) have differentiated between diabetics and non-diabetics. They 
reported higher levels of glucagon in diabetics in response to arginine and 
sulphonylureas as compared to non-diabetics. They concluded that A-cell 
function is inappropriately increased in diabetes mellitus.
Stimulation by sulphonylureas of D-cell function in isolated perfused rat 
pancreas has been reported by Ostenson et al (1983); c-AMP has been implicated 
in this effect.
Extrapancreatic
The possibility of an extrapancreatic action of sulphonylureas has been raised 
because of the observation that with long a duration of treatment, these agents 
exert less influence on pancreatic islet cells.
Dunbar and Foa (1974) have shown that in islet preparations, following long 
term administration of sulphonylureas, the B-cells synthesized and released less 
insulin and oxidized less glucose than did insulin- and saline-treated controls. It 
has also been noticed that after administration of sulphonylureas to non-insulin 
dependent diabetics, there was no correlation between the increase in plasma 
insulin levels and the fall in glucose levels.
Many extrapancreatic mechanisms of action have been proposed. Inhibition 
of glucagon-stimulated glucose production by the liver has been suggested by 
Blumenthal (1977). This is thought to be brought about by augmentation of the 
action of insulin in the liver. Alternatively, Davies et al (1980) have shown that 
sulphonylureas inhibit transglutaminase. This is an enzyme associated with the 
inner surface of the cell membrane and appears to play an essential role in the 
internalization of hormone-receptor complexes. This assumption of 
transglutaminase action has, however, been challenged by Nowak et al (1983) on 
the basis of non-specificity. On the other hand, Salhnick et al (1983) have 
suggested a post-binding mechanism augmenting insulin action. More recently 
sulphonylureas have been shown to potentiate insulin action on carbohydrate 
metabolism by the cultured rat hepatocytes (Wolfgang et al 1984). This 
potentiation was not due to modulation of insulin binding to the hepatocytes, 
which supports a post-receptor mechanism of action.
Pharmacokinetics
Sulphonylureas are completely absorbed from the bowel after oral 
administration. They are moderately to highly protein-bound, mainly to albumin 
and, to a lesser extent, fibrinogen and a- and 8-globulins, with variations 
between individual drugs (Judis 1972). The fact that they are bound to albumin 
makes them vulnerable to translocation by other highly protein-bound drugs, 
which has a potentiating effect on insulin secretion.
Metabolism takes place in the liver giving rise to compounds with varying 
degrees of hypoglycaemic activity. However, active metabolites probably do not 
contribute much to the overall clinical activity in normal situations. These 
metabolites are ultimately excreted in the urine mainly by tubular secretion.
5 INTRAISLETINTERREL ATIONSHIRS:E ANTASYOR REALITY _________ -
Insulin has dominated the scene for a considerable length of time as the 
prime hormone in glucose homeostasis. Although it still remains the most 
important factor in the control of blood glucose levels, the extensive elaboration 
of the mechanisms which precede and culminate in the release of insulin has 
added clarity as well as complexity to the picture. Thus, new islet hormones, gut 
hormones, neural and peptidergic fibres, the arrangement of cells in the islet, to 
mention but a few, have all been shown to influence glucose levels in the blood.
In the debate on whether islet cells interact with each other, the balance has 
tipped considerably to the side of the proponents of interaction to such an extent 
that it is now the opponents who have to prove that interactions do not exist.
(a) Basic Plan
Exogenous glucagon stimulates insulin (Samols et al 1965) and somatostatin 
secretion (Patton et al 1977).
Somatostatin potently inhibits insulin (Alberti et al 1973) and glucagon 
secretion (Koerker et al 1974).
Insulin suppresses glucagon secretion (Samols et al 1972) while its effect on 
D-cells is still unclear (Samols and Harrison 1976; Honey and Weir 1979).
Pancreatic polypeptide has been reported to inhibit somatostatin (Arimura et 
al 1979) and insulin release (Lundquist et al 1979).
Models of Interrelationships : Pros and Cons
The task of weaving together a plausible theory out of the individual facts 
mentioned in the basic plan has been beset not only by the complex and, to some 
extent, contradictory nature of these facts, but also by the difficulty of
distinguishing between their physiological and pharmacological significance.
did
Nevertheless, some research workers propose models of interrelationships.A
The pancreatic islet of many species has two histologically distinct zones: an 
outer heterocellular zone comprised of D-cells and either PP- or A-calls and an 
inner core of B-cells. This has led Orci (1975) to hypothesize that there is 
functional significance attached to this heterogeneity of cellular arrangement . 
Thus, the heterocellular part could be the acutely responsive component which 
deals with the rapid moment-to-moment changes in insulin - the first phase of 
insulin release which is rapidly quenched by somatostatin. The other 
homocellular region could be the less dynamic, but steadier site of insulin 
production.
Alternatively, Marks (1970) proposed that glucagon secretion must, of 
necessity, stimulate insulin secretion in normal situations, thereby augmenting 
the insulinotropic properties of glucose and some amino acids. This 
insulinotropic effect of glucagon is blocked by increased sympathetic activity in 
stressful situations, eg, prolonged fasting or starvation. Conversely, glucagon 
secretion is checked by insulin release.
While agreeing with Marks that insulin secretion is stimulated by endogenous 
glucagon secretion, Fujita et al (1976) draw the attention to another anatomical 
finding which could be of significance in intraislet interrelationships, namely, 
that the blood coming into the islet first supplies the A- and D-cell region and 
later the B-cell mantle, thus, hormones from A- and D-cells are carried down 
stream to modulate B-cell function.
Schatz and Kullek (1980) were in support of the above model and added the 
finding that endogenous—glucagon stimulated both -insulin release and 
biosynthesis, but only somatostatin release. On the other hand somatostatin 
reduced the release but not the biosynthesis of insulin.
Using an uncharacterized antiglucagon serum in monolayer culture of rat 
pancreas Fujimoto et al (1983) demonstated a rise in both somatostatin and 
insulin secretion. The authors then proposed that the effect of endogenously 
secreted glucagon on B-cell is a restraining one and may be mediated through 
somatostatin release. In order to reconcile this with the fact that exogenous 
glucagon stimulates rather than inhibits insulin secretion, Fujimoto and his co- 
worker concluded that exogenous glucagon, unlike endogenous glucagon, has a 
net stimulatory effect upon insulin secretion.
The mainstay of the argument against intraislet interactions is summed up by 
Unger’s thesis (1983) that somatostatin, administered at low doses, potently 
inhibits insulin secretion. Had the theory of intraislet interactions been true, 
very high doses of somatostatin would have been needed to mimic, 
concentrations in the interstitium. The peptides released locally, Unger 
maintains, may not be in contact with their receptors in neighbouring cells, a 
mechanism in which tight junctions may be instrumental. Finally, administration 
of antisomatostatin promptly enhances insulin secretion before the former 
actually penetrates the interstitium of the islet.
As an alternative to intraislet interactions, a bihormonal model was proposed 
by Unger (1983) and Unger and Orci (1981). In this model, in normal situations, a 
fall in glucose levels instantly reduces insulin levels, thereby releasing the 
restraining effect on A-cell. Glucagon, thus released, restores the glycaemia, 
whereupon insulin and glucose levels return to their original levels. In such
situations, the direct stimulatory effect of glucagon upon insulin becomes 
ineffectual because cataglycaemia renders B-cells unresponsive to all non­
glucose stimuli. In addition, Raskin (1981) suggested that diabetes is essentially a 
failure on the part of this bihormonal model to regulate glucose homeostasis. In 
diabetes the A-cell loses its ability to sense changes in plasma glucose levels, 
which explains the hyperglucagonaemia found in diabetics despite their high 
blood glucose levels.
CHAPTER H
IMMUNE NEUTRALISATION OF ENDOGENOUS GLUCAGON 
AS A MEANS OF STUDYING GLUCAGON PHYSIOLOGY: 
CHARACTERIZATION OF A MODEL
INTRODUCTION
Moloney and Coval (1955) have been first to use insulin antibodies to produce 
hyperglycaemia in mice. Since then, immune neutralization has bcome a popular 
method in studying the physiology of peptide hormones. Anti-GIP (Ebert et al 
1979), Antimotilin (Borody et al 1981) and antisecretin (Chey et al 1979) have all 
been used to study the role of the respective gut hormones in regulating gut 
function. More recently, immune sera have been used to occupy specific 
hormone receptors either to mimick or to block the actions of the respective 
hormones (Nicholas and Topper 1983; Feil 1983); but in no other field was the 
technique of immune neutralization more extensively used than in the study of 
paracrine interactions between islet hormones. So much so, that it is the 
development in this latter field of study that has helped to explore the 
potentials and demarcate the limitations of the technique.
Barling and Beloff-Chain (1973) have been first to carry out a detailed study 
on immune neutralization with glucagon antibodies. They showed that whereas 
insulin antibodies produced transitory hyperglycaemia, glucagon antibodies had 
no effect on basal blood glucose levels. This is in keeping with observations by 
Holst et al (1978). Failure of glucagon antibodies to affect basal blood glucose 
levels has been consistently reported by other workers (Epand and Douglas 1973). 
Lowering of basal blood glucose levels by glucagon antibodies has, nevertheless, 
been reported by Grey et al (1970) in fasted adrenalectomized rats. Insulin 
levels, on the other hand, have been shown to be significantly lowered in rabbits 
actively immunized against glucagon (Epand and Douglas 1973), but this effect 
could not be reproduced by Seino and co-workers (1982) who used an isolated 
perfused rat pancreas system.
Antisomatostatin antibodies have been used extensively in the study of 
intraislet interactions, but results have been conflicting. This is probably due to 
the inhibitory action of somatostatin. Thus, using somatostatin antibodies is in 
effect relieving a tissue of an inhibition rather than negating a positive 
stimulation. Schusdziarra et al (1980) reported a rise in plasma insulin levels 
following somatostatin antibodies administration, indicating a tonic suppression 
of insulin secretion by somatostatin. Similar findings were reported by Fujimoto 
and co-workers (1983) who, in addition, reported a rise in plasma glucagon levels. 
Schatz and Kullek (1980) used antisera against the three islet hormones but 
obtained conflicting data about intraislet interactions.
Many of the differences in results reported by various workers can be 
attributed to differences in the experimental models, but more importantly to 
variations in the qualities of the antisera used. The criteria for a good 
experimental model utilizing immune neutralization are as follows:-
Specificity; Antibodies must be very specific to the hormone to be neutralized. 
This specificity must be demonstrated in comparison to hormones of similar 
structure. In addition, the antiserum must be reactive to the biologically active 
form of the hormone.
Purity: Contaminants, such as native peptides from the animal in which the
antiserum was raised, can be minimized by ammonium sulphate precipitation of 
immunoglobulins. Better still, is to use immunoadsorption.
Titre: The higher the titre of the antiserum, the more hormone it can bind and 
consequently the less antiserum will be needed.
Avidity: An antiserum with high titre but low avidity will not bind endogenous 
hormone adequately. The reverse is more likely to be true provided that the 
titre is not very low.
It has been suggested that more often than not, antisera used in immune 
neutralization experiments are already partially bound to native hormone from 
the animals in which they were raised (Holst et al 1978). Despite the fact that in 
the latter study, the antiserum whose binding sites had been freed of bound 
hormone was not superior to the crude one, it remains a possibility that in some 
of the immune neutralization studies reported the antisera used were only 
partially effective despite their high titres.
Acessibility of the cell to be blocked to the administered antiserum is of 
particular importance in studies addressing the question of paracrine 
interactions. It has been demonstrated that the pancreas as a whole is poorly 
accessible to 8 -globulins (Schusdziarra et al 1980). This does not necessarily 
mean that the endocrine pancreas is not suitable for immune neutralization 
experiments; the islets are richly vascularized, receiving 15% of the total 
pancreatic blood flow despite their occupying only 0.8% of the total pancreas. It 
is, therefore, important to decide whether in vivo or in vitro experiments are to 
be used. In the latter, the blood supply is cut off and the distribution of the 
antibodies in the interstitium is less efficient.
One of the most important factors is the behaviour of the antiserum under the 
experimental conditions employed. The standard means of assessing this is to 
demonstrate the abolition by the antibodies of the effects of the exogenously 
administered hormone. More difficult, but perhaps more important, is to 
demonstrate the ability of the antiserum to neutralize endogenously released 
hormone. Sometimes, despite the high quality of . the antiserum, the desired 
neutralization of hormone is not achieved under experimental conditions.
Several factors can. account for this. For instance, the avidity of the tissue 
receptor for a particular hormone may be greater than that of the antiserum. 
The net result would be more binding to the receptor than to the antiserum.
In the following study the qualities of a glucagon antiserum and its suitability 
for immune neutralization experiments has been assessed.
2 MATERIALS AND METHODS
(a) Characterization of Antiglucagon Serum
A C-terminally directed antiglucagon serum was obtained from Guildhay
Antisera (Guildford, UK). The antiserum was raised in half-lob rabbits which
the
were immunized using glucagon conjugated to egg albumen by gluteraldehyde
A
method. The titre of the antiserum was 1:30,000.
(i) Specificity
Cross-reaction studies were carried out with the following peptides:- 
Insulin: (Novo Research Institute, Copenhagen)
Gastrin: (MRC, National Institute for Biological Standards and Controls, London) 
Vasoactive intestinal polypeptide: (Karolinska Institute, Stockholm) 1 
Gastric inhibitory polypeptide: (Dr John Brown, University of British Columbia, 
Vancouver)
In addition, cross-reactivity with glucagon-like immunoreactivity (GLI) was 
assessed by Professor Buchanan’s group, Queen’s University, Belfast.
Various quantities of these peptides were added to a glucagon assay and their
123 -ability to displace I-glucagon bound to the glucagon antiserum was observed.
Furthermore, the glucagon antiserum and an insulin antiserum (GP4) were
125
incubated with I-insulin and their binding was observed. This was carried out 
to detect any insulin antibodies contaminating glucagon antiserum (MF/Y6).
(ii) Binding affinity
Scatchard (1949) analysis was followed in determining the binding affinity and 
equilibrium constant of the antiserum.
(iii) The effect of antiglucagon serum on insulin recovery in'plasma •
This was studied by ..assaying  ^insulin-spiked plasma_samples containing an 
immunoglobulin fraction of the glucagon antiserum (1:20).
(b) Preparation of Antiqlucagon Immunoglobulins (AGI)
Saturated ammonium sulphate (BDH Chemicals, Poole, Dorset, UK) solution 
was added, with continuous stirring, to a volume of the antiglucagon serum to a 
final concentration of 43%. This mixture was then centrifuged at 1000 rpm for 
20 minutes and the pellet reconstituted with the initial volume of saline. This 
was dialysed against isotonic saline at 4°C, at least 5 times before being stored 
at -20°C in 1 ml aliquots.
Recovery of glucagon antibodies in the immunoglobulin fraction, thus 
obtained, was assessed by comparing two antisera dilution curves constructed 
using the antiglucagon serum and its immunoglobulin fraction.
#
(c) Preparation of Non-Immune Rabbit Immunoglobulins (NRI)
Non-immune rabbit serum (Guildhay Antisera, Guildford, UK), was treated in 
the same way as glucagon antiserum in order to prepare non-immune rabbit 
immunoglobulins. Aliquots of 1 ml were then stored at -20°C.
(d) Insulin Radioimmunoassay
The rat insulin radioimmunoassay used in the present study was a 
modification of the assay by Tan (1982). It  was an equilibrium assay that could 
measure 20pl plasma and had a detection limit of 0.125 ng/ml.
Insulin antiserum (GP9) was obtained from Guildhay Antisera and had a titre  
of 1:30,000.
ay
The assay buffer was 0.04 M phosphate pH7.4 containing 0.25% bovine serum 
albumin (Sigma Chemicals, Poole, Dorset, UK).
Insulin standards were prepared by dissolving rat insulin (Novo Research 
Institute, Copenhagen) in the assay buffer to give 20 ng/ml. This was then 
lyophilized and kept at -20°C.
125I-insulin was obtained from Amersham International (Amersham, Bucks,
UK). It had a shelf life of 10 weeks; 50 pi of a 1:20 initial dilution was added so
125that each assay tube contained 26 pg I-insulin.
Dextran-coated charcoal, at an initial concentration of 2.5%, was used in the 
separation step.
The intra- and inter-assay reproducibility, expressed as a coefficient of 
variation for the quality control pool was 5.9% (n=14) and 6.6% (n=14) 
respectively.
(e) Glucose Estimation
Plasma glucose levels were assayed using Beckman Glucose Analyser and 
glucose oxidase reagent, both obtained from Beckman Ltd (Glenrothes, UK).
(f) Time Course Study of Plasma Uptake of Antiglucagon 
Immunoglobulins Following their Intraperitoneal Administration
Six male Wistar albino rats weighing around 250 g, which had been allowed 
free access to food, were injected with antiglucagon immunoglobulins (0.5 ml 
each) intraperitoneally and subsequently kept in Tan-Bishop rat restrainers. 
They were bled, via the tail vein, immediately before the injection of antibodies 
and at different time intervals up to 48 hours. Blood was collected in 
heparinized blood tubes (500 U/ml) and plasma was separated by centrifugation.
The uptake of antiglucagon immunoglobulins by plasma was assessed by
1 oc
incubating samples (diluted 1:10) with - I-glucagon. -Separation was effected 
after 24 hours and binding calculated.
Inhibition of Some of the Actions of Exogenous Glucagon by Antiglucagon 
I immunoglobulins
Twelve male Wistar albino rats weighing around 250 g were divided into two 
equal groups.
A dose-response curve of glucagon (Novo Industri, Copenhagen) had 
previously been carried out and the dose of 20 pg/kg was chosen for the 
experiment on the basis of its ability to elicit, at a submaximal level, two of the 
known body responses to glucagon, namely, hyperglycaemia and 
hyperinsulinaemia.
The experiment was performed in conscious animals which had been allowed 
free access to food. The test group received antiglucagon immunoglobulins (0.5 
ml per rat), while the control group received non-immune rabbit immunoglobulins 
(0.5 ml per rat), both intraperitoneally between 40 to 60 minutes before glucagon 
administration. Glucagon was given i.p. and rats were kept in their restrainers. 
Rats were bled immediately before glucagon injection and at 5, 10, 20 and 45 
minutes. Blood was collected in heparinized (500 U/ml) blood tubes and plasma 
was separated by centrifugation. Samples were later assayed for insulin and 
glucose.
Statistical Analysis
Data were analysed using student’s t-test.
3 RESULTS
(a) Properties of the antiglucagon serum
(i) Specificity
No cross-reactivity could be demonstrated with vasoactive intestinal 
polypeptide, gastric inhibitory polypeptide, gastrin, secretin and insulin over the 
concentration range tested (Fig. 1:1). Cross-reactivity with GLI was determined 
to be 6%.
No binding between the antiserum and insulin label could be detected (Fig. 
1:2) indicating that there were no insulin antibodies contaminating glucagon 
antiserum (MF/Y6).
(ii) Binding affinity
The non-linearity of the scatchard plot (Fig. 1:3) suggests that two classes of
antibodies exist - a higher affinity and a lower affinity class. The former had a
10 9binding affinity value of 2.9 x 10 litre/mole, the latter had a value of 3.7 x 10
litre/mole.
(iii)Non-interference by the antiglucagon serum with insulin RIA
As shown in Fig. 1:4 the recovered values of insulin were more or less equal to 
the values of exogenous insulin added to hormone-free plasma. Thus, insulin 
radioimmunoassay used in this study was not affected by the presence of the 
antiglucagon serum.
(b) Recovery of the antiglucaqon immunoglobulin fraction by ammonium sulphate 
precipitation
Fig. 1:5 shows the two antisera dilution curves of antiglucagon serum (MF/Y6) 
and its immunoglobulin fraction precipitated by ammonium sulphate. There was 
almost complete recovery of antiglucagon immunoglobulins in the 
immunoglobulin fraction.
(c) Plasma uptake of the antiqlucaqon immunoglobulins
Antiglucagon immunoglobulins start-reachingtheir_jmaximum. level-in plasma.  _
in 30 to 60 minutes after i.p. injection (Fig. 1:6); thereafter, they are present in 
the plasma for up to 48 hours, which was the last time point studied.
(d) Insulin Radioimmunoassay Standard Curve
Fig. 1:7 shows an example of the standard curves obtained from insulin
radioimmunoassay.
(e) Inhibition of the Actions of Exogenous Glucagon by Antiglucagon
Immunoglobulins
Insulin secretion by exogenous glucagon was completely inhibited by
antiglucagon antibodies (P<0.0005, Fig. 1:8). Hyperglycaemia, on the other hand, 
was inhibited at 10 (P<0.05) and 20 (P<0.0005) minutes; at 5 minutes it was 
slightly reduced but not significantly (Fig. 1:9).
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DISCUSSION
The purpose of the present study was to work out a reliable experimental 
model for immuno neutralization of glucagon. This involved: (a) deciding on 
which system of experiments to be used, ie, in vivo or in vitro, (b) rigorous 
characterization of the glucagon antiserum, (c) demonstrating inhibition by the 
glucagon antibodies of the actions of exogenously administered glucagon.
From the very outset, the decision was in favour of in vivo experiments. This 
was because some studies carried out with labelled IgG antibodies have shown 
that vascularly infused antibodies enter interstitial spaces poorly in the pancreas 
as a whole (Schusdziarra et al 1980). This study did not address what happens in 
the endocrine pancreas, which is much more vascularized than its exocrine
counterpart. In an in vitro system the problem  ^ of_ distribution of
exaggerated1'
immunoglobulins in interstitial spaces is more likely to be , since the
blood supply will be cut off. In addition, in isolated islet preparations, tight 
junctions have been observed to form between islet cells. These probably 
provide an adaptive mechanism intended to seal and hence to protect, islet 
microdomains against sudden perturbations in local interstitial fluid (in’t Veld et 
al 1984), a phenomenon which might further interfere with the circulation of 
immunoglobulins and other substances. In an in vivo system on the other hand, 
the adequate blood supply to the endocrine pancreas ensures adequate circulation 
of substances in interstitial spaces. Moreover, islets retain their physiological 
and anatomical status, which in in vitro preparations is disturbed either by 
removal of the pancreas from the animal thereby depriving it from its 
innervation and blood supply, or by subjecting the islets to the trauma of 
collagenase digestion. The conclusions drawn from in vivo experiments are 
therefore more relevant to normal physiology.
Characterization of the antiglucagon serum which had a high titre (1:30,000), 
showed that it possessed high avidity as well. The total binding capacity (13nmol) 
of both classes of immunoglobulins administered (0.3 ml per rat) is estimated to 
bind up to 13 times the total content of glucagon in the rat pancreas estimated 
by Barling and Beloff-Chain (1973) as 1.0 nmol. The low capacity, high affinity 
class of immunoglobulins alone, with a binding capacity of 3 nmol, will bind three 
times as much the glucagon content of the rat pancreas. Furthermore, the total 
binding capacity of the immunoglobulins is over 300 times the total amount of 
glucagon secreted by the rat pancreas during 60 minutes of moderate 
stimulation, estimated by Luyckx (1974) to be between 0.032-0.052 nmol per 
hour. On the other hand the average binding affinity for glucagon of the two 
classes of immunoglobulins is much greater (60 times) than that of the hepatic
p
glucagon receptor of the rat, reported by Rodbell et al (1971) to be 2.5 x 10 litre 
per mol.
Cross-reactivity studies revealed a highly specific antiserum for glucagon. 
Most important among the cross-reactants studied was glucagon-like 
immunoreactivity (GLI). This often plagued antisera used for immune 
neutralization of glucagon, some of which their cross-reactivity was not reported 
at all (Grey et al 1970; Fujimoto et al 1983).
Incubation of the antiserum with plasma samples assayed for insulin did not 
interfere with the assay. In addition, when samples containing antiglucagon 
serum were incubated with insulin label, there was no binding demonstrated. 
These findings show that the antiglucagon serum was not contaminated with 
insulin antibodies which might interfere with insulin assay or bind endogenously 
secreted insulin. Further purification was effected by ammonium sulphate 
precipitation.
These findings demonstrated that a high titre antiglucagon serum was 
available, which was capable, because of its high avidity for glucagon, to 
effectively neutralize the endogenously secreted hormone. In addition, this 
antiserum was found to be highly specific for glucagon and did not have 
contaminating insulin antibodies which might interfere with insulin 
radioimmunoassay or modify the role of endogenously secreted insulin.
When antiglucagon immunoglobulins were injected intraperitoneally, they 
reached maximum concentrations in the circulation in 40-60 minutes. 
Substances from the peritoneum reach the main circulation by any of the 
following routes: (a) capillaries draining first into the portal veins to reach the 
liver parenchyma and finally Teaching the inferior vena cava, (b) capillaries from 
the parietal peritoneum draining directly into the inferior vena cava, (c) drainage 
by abdominal lymphatics into the thoracic duct and the main circulation. This 
third route is an effective way of absorption, albeit slow. It has been estimated 
that lymphatics remove 20 ml/Kg of whole blood within 24 hours and 20 ml/Kg of 
homologous plasma within 3-4 hours from the peritoneum of the rat (Schade and 
Eaton 1980). Molecules smaller than plasma proteins, eg, insulin tend to be 
absorbed by abdominal lymphatics more quickly, in a few minutes (Schade et al 
1980). In the present study, immunoglobulins reached a peak level in 40-60 
minutes. This is in favour of lymphatic absorption, although absorption by other 
routes can not be ruled out. Experiments were performed when immunoglobulins 
were present at maximum concentrations in the circulation - that is 40-60 
minutes after IgG administration. As time progressed more and more 
immunoglobulins became neutralized with endogenously secreted glucagon and 
the system became less suitable for immune neutralization experiments.
The next step was to demonstrate the effect of neutralization of endogenous 
glucagon on basal plasma insulin and glucose levels. Holst and associates (1978) 
who used a glucagon antiserum of similar properties to the one reported in the 
present study, have demonstrated that administration of glucagon antibodies to 
exercised rats effectively neutralized endogenously secreted glucagon. This had 
no effect on basal glucose and insulin levels, which is in keeping with results 
reported here. Similar findings were reported by Barling and Beloff-Chain (1973) 
and Epand and Douglas (1973).
It was not possible that the failure of glucagon antibodies to produce 
hypoglycaemia was due to a concomitant fall in insulin levels. The latter were 
not significantly lowered by antiglucagon immunoglobulins. Instead, adrenergic 
mechanisms which participate in the control of hepatic glucose production might 
have compensated for the lack of glucagon-mediated glucose production. Indeed, 
Grey et al (1970) have reported a fall in basal glucose levels of fasted 
adrenalectomized rats injected with glucagon antibodies. Such a possibility has, 
however, been disputed by Holst et al (1978) who reported failure of glucagon 
antibodies to affect basal glucose levels of adrenalectomized rats. The findings 
of Holst and co-workers are more credible since, unlike the antiserum used by 
Grey and associates, theirs was of high quality and was properly characterized. 
Another possible explanation for the lack of an effect of glucagon antibodies on 
blood glucose concentrations would be that the affinity of glucagon for receptors 
in the liver is greater than its affinity for its antibody, so that even when the 
latter is in excess, the antibody-antigen complex would dissociate at the site of 
hormone action. This however, is unlikely since, as has been shown earlier, the 
avidity for glucagon of the antibodies used in the present study is much greater 
than that of liver receptors. These findings, taken together with the observation 
that exogenous glucagon! ■ causes no permanent changes in blood glucose 
concentration when maintained for several days (Felig et al 1976), throw doubt on 
the essentiality of glucagon for the regulation of basal blood glucose levels.
Failure of glucagon antibodies to affect basal insulin levels is in keeping with
observations reported by Seino et al (1981).   -Patel et.a l (1979) and Epand ..and
Douglas (1973) have reported the reverse, that is, a fall in basal insulin levels in 
response to glucagon antibodies. The latter workers have concluded that since 
glucagon is insulinotropic, lowering its concentration would be expected to lower 
insulin levels. This implies that glucagon has a role in the regulation of basal 
insulin levels. In the study carried out by Patel and co-workers neonatal rat 
pancreas was used. Neonatal islets have their pecularities with regard to insulin 
secretion, which could account for the difference with our findings. It is not 
clear however, why the observations reported by Epand and Douglas were 
different from the ones reported here. A possible explanation would have been 
that the bovine glucagon they used to immunize rabbit was contaminated with 
insulin leading to production of insulin antibodies, but these had not been 
demonstrated in plasma of the animals they used. A more plausible explanation 
would be therefore that the prolonged period of active immunization (more than 
4 weeks) used in their study was responsible for a fall in the glucose 
requirements and consequently insulin secretion. Indeed, they have reported that 
in the presence of glucagon antibodies normal blood sugar levels could be 
maintained with a reduced supply of insulin. Likewise, in the present study 
insulin levels started to fall by 24 hours although not significantly. Had the 
glucagon antibodies been given over a longer period, a significant fall in insulin 
levels might have been noticed. The present findings do not support the 
assumption that endogenous glucagon is important for the regulation of basal 
insulin levels.
Exogenous glucagon at the dose of 20 pg/Kg produced a marked increase in 
both insulin and glucose levels. It was estimated that at this dose, plasma 
glucagon levels would be about 1000 times the basal levels of 150 pg/ml. Prior 
administration of antiglucagon immunoglobulins potently and completely 
inhibited the insulin response (P<0.0005). Plasma glucose response was also
inhibited but not to the same extent as insulin response. Similar findings have 
been reported by Frohman et al (1970) and Holst et al (1978). The relative 
difference in inhibition by glucagon antibodies of insulin and glucose responses 
can be explained as follows: As has been explained earlier, substances injected 
intraperitoneally reach the main circulation either directly via the lymphatic 
system and capillaries, draining the parietal peritoneum, or reach the liver first 
via capillaries, draining the visceral peritoneum. Thus, some of the glucagon 
injected intraperitoneally will have reached the liver parenchyma first. This 
fraction of glucagon escaped neutralization by antibodies and thus produced the 
hyperglycaemic response. As soon as all the glucagon was absorbed and passed 
the liver it was neutralized and any further effect on the latter was prevented. 
Glucagon reaching the pancreas, on the other hand, first reached the main 
circulation where it was inactivated.
This study has made available a reliable model for studying intraislet 
interactions by immune neutralization of glucagon using a high quality 
antiserum. By selectively blocking A-cell secretion, the mechanism of action of 
various insulin secretagogues in relation to glucagon secretion will be studied.
CHAPTER HI
A STUDY ON THE EFFECT OF ANTIGLUCAGON IMMUNOGLOBULINS 
ON INSULIN SECRETION BY DIFFERENT SECRETAGOGUES IN  RATS
INTRODUCTION
There is no agreement as to how insulin secretagogues work. One theory 
purports that glucose, which is the prime stimulator of insulin secretion, does 
not, as the intact molecule, stimulate insulin release; rather, a metabolite of 
glucose, or a co-factor generated during glucose catabolism, provides the trigger 
for insulin secretion (Grodsky et al 1963). Alternatively, it has been proposed 
that it is the direct effect of glucose on a membrane or a cytosolic receptor, 
which provides the stimulus for B-cell secretion (Matschinsky et al 1972; 
Robertson and Metz 1979).
The first theory, which is called the substrate-site or metabolic theory, was 
based on the following findings (Zawalich 1979): (a) increased glucose catabolism 
is parallelled by increased rate of insulin secretion, (b) poorly metabolized sugars 
are weak stimulators of insulin secretion, (c) metabolic inhibitors, eg, 
mannoheptulose, reduce glucose-stimulated insulin secretion, (d) triose 
glyceraldehyde, which presumably enters glycolysis, mimicks glucose-stimulated 
insulin secretion. However, some findings can not be reconciled with this theory. 
First, Coore and Randle (1964) have shown that some substances that are poor 
substrates for glycolysis possess the ability to alter insulin secretion 
dramatically. Second, studies with some metabolites of glucose failed to 
demonstrate stimulation of insulin secretion (Zawalich 1979).
The glucoreceptor theory has never been vindicated by actually identifying 
and isolating a receptor to glucose located in the B-cell membrane or cytoplasm. 
However, some workers find it a plausible theory to account for certain 
observations. Robertson and Metz (1979) argue that despite the lack of an acute 
insulin response to glucose challenge in diabetics, such a response does occur
with a variety of other secretagogues, eg, isoproterenol and glucagon. On the 
other hand, it has been shown that sodium salicylate augments glucose-induced 
insulin secretion and inhibits prostaglandin synthesis in man. Thus, according to 
these workers it can be argued that excess prostaglandins in diabetic patients 
compete for the glucoreceptors, a process which can be reversed if prostaglandin 
synthesis were to be inhibited. Accordingly, sodium salicylate and possibly 
other substances eg, glucagon and isoproterenol, produce their effect of 
stimulating insulin secretion in diabetic patients by inhibiting prostaglandin 
synthesis.
Apart from glucose, amino acids have been shown to stimulate insulin 
secretion in different species when administered at physiological doses (Assan et 
al 1983). The most potent amino acids in this respect are arginine, leucine and 
ornithine.The mechanism by which these amino acids operate is not fully 
understood. They have been shown to be potent stimulators of glucagon 
secretion, an effect which can be mediated by ionic influxes (Campillo et al, 
1977), metabolism of amino acids within the A-cell (Malaisse et al 1981), or 
transport of amino acids into the A-cell (Akpan et al 1981). Glucagon is a potent 
stimulator of insulin release and therefore a possible mediator of amino acid- 
stimulated insulin secretion. Glucagon brings about its effect on the B-cell by 
activating the adenyl cyclase system leading to the generation of cAMP (Turtle 
and Kipnis 1967). This reaction is inhibited by phosphodiesterase, and substances 
which inhibit it, eg, caffeine and theophylline, would potentiate the effect of 
glucagon on insulin secretion (Malaisse and Malaisse-Lagae 1969). Samols (1983) 
suggested that cAMP amplifies rather than initiates insulin release. He further 
added that during circumstances in which the effects of glucose itself are 
relatively weak as an insulin stimulant, in diabetes or premature infants, the 
administration of agents (glucagon, phosphodiesterase inhibitors, cAMP) known 
to increase intracellular cAMP will greatly potentiate insulin secretion. Thus, if
local intraislet extracellular glucagon is available to the B-cell, this paracrine 
glucagon would be the logical major regulator of B-cell cAMP, and thus of the 
amplification of insulin secretion.
Probably not all amino acids stimulate insulin release by the same 
mechanism; leucine for instance seems to stimulate insulin secretion by a 
mechanism more akin to that of glucose. Milner (1969a) has shown that while 
pyruvate and lactate can substitute for glucose as the metabolizable substrate in 
the stimulation of insulin secretion, L-leucine alone has this capacity among all 
the other amino acids.
GIP stimulates insulin secretion only in the presence of hyperglycaemia
(Dupre et al 1973). Apart from this dependence on glucose, little  is known about
its mechanism of action. Stimulation of glucagon by GIP has been equivocal with
-*ing
some studies reporting stimulation (Taminato et al 1977) while others report no 
effect (Sirinek et al 1980). More recently, it has been shown that GIP also 
potentiates amino acid-induced insulin secretion independently of glucose levels 
(Mazzaferri et al 1983).
The purpose of this study is to evaluate the role of glucagon in mediating 
insulin secretion by several secretagogues. The experimental model described in 
Chapter II will be used to immuno neutralize glucagon secreted by the A-cell and 
the effect this will have on insulin secretion will be observed.
2 METHODOLOGY
(a) Experimental Protocol
(i) Animals
Male Wistar albino rats weighing around 250 g and fed on normal laboratory 
diet were used in this study. Unless otherwise stated, animals were kept 
conscious throughout the experimental procedure.
(ii) Administration of immunoglobulins
In each experiment, twelve rats were divided into two equal groups 
designated control and test. Control rats were each injected with 0.5 ml non- 
immune rabbit immunoglobulins intraperitoneally, 40-60 minutes before the 
administration of insulin secretagogues. The same procedure was repeated with 
the test animals except that antiglucagon immunoglobulins were used.
(iii)Administration of insulin secretagogues
All secretagogues were dissolved in isotonic saline. Where conscious animals 
were used, secretagogues were given either orally by trocar, or by 
intraperitoneal injection, 40-60 minutes after immunoglobulins administration, 
the following insulinotropes were studied:
Nutrients: D-glucose (BDH Chemicals, Poole, England) was given orally at a
dose of 5 g/Kg and intraperitoneally at a dose of 2 g/Kg. Arginine HCL (Sigma 
London, Poole, England) was given orally at a dose of 2 g/Kg and 
intraperitoneally at a dose of 1.5 g/Kg. At the latter dose, arginine was also 
given 24 hours and 7 days after immunoglobulins administration in two different 
sets of experiments. Tryptophan (Sigma London, Poole, England) was dissolved, 
after alkalinization to a pH of 10.2 and given orally at a dose of 0.5 g/Kg.
Sulphonylureas: Tolbutamide (Hoechst UK Ltd, Hounslow, Middlesex, England) 
was given orally and intraperitoneally in both instances at a dose of 100 mg/Kg. 
Glibenclamide (Boehringer Mannheim, West Germany), was given 
intraperitoneally at a dose of 0.3 mg/Kg.
(iv) Experiments in anaesthetized rats
In these experiments immunoglobulins were administered as described above. 
Thereafter, anaesthesia was effected by intraperitoneal injection of sodium 
pentobarbitone (Sagatal, May and Baker Ltd, England) at a dose of 50 mg/Kg, 20- 
30 minutes before the administration of leucine or GIP, intravenously into the 
femoral vein. Leucine was given at a dose of 0.33 g/Kg. In the GIP experiment 
3 groups of rats (6 rats each) were used instead of 2 groups. Two groups received 
non-immune rabbit immunoglobulins and one group received antiglucagon 
immunoglobulins as described previously. The latter group was given glucose (0.5 
g/Kg) plus GIP (1 pg/Kg, Dr 3 Brown, University of British Columbia, 
Vancouver). Of the former two groups, one received glucose alone (0.5 g/Kg) and 
the other received glucose (0.5 g/Kg) plus GIP (1 pg/Kg).
(v) Bleeding
Blood was collected by tail bleeding in heparinized (500 U/ml) chilled tubes. 
Plasma was then separated by centrifugation and samples for glucose estimation 
and insulin assay were aliquotted.
(b) Assays
(i) Rat insulin radioimmunoassay
Plasma insulin levels were measured by the method described in Chapter II
(ii)Glucagon radioimmunoassay
Plasma glucagon levels were measured by the method of Tan (1982) using a 
porcine standard and a C-terminally reactive antiserum. The detection limit of 
the assay was 100 pg/ml, the intra-assay coefficient of variation 7.3 (n=12) and 
the inter-assay coefficient of variation 10.3 (n=9).
(iii)GIP radioimmunoassay
Plasma GIP levels were measured by a double antibody radioimmunoassay 
(Morgan et al 1978). The assay sensitivity was 110 ng/Litre and the inter-assay 
coefficient of variation was 4.1% at 2677 ng/Litre and 22.5% at 138 ng/Litre.
(iv) Glucose estimation
Plasma glucose levels were measured by the glucose oxidase method 
described in Chapter II.
(c) Statistical analysis
Students t-test for unpaired data was used to analyse the results.
3 RESULTS
The effects of antiglucagon immunoglobulins on insulin secretion by different 
secretagogues in rats, were as follows:
(a) Nutrients
Insulin response to glucose administration was not inhibited by the injection 
of antiglucagon immunoglobulins, either when glucose was given orally (Fig. 2:1) 
or intraperitoneally (Fig. 2:2). Insulin response to intraperitoneal arginine, on 
the other hand, was significantly inhibited in the test rats, which received 
antiglucagon immunoglobulins, as compared to the control rats, which received 
non-immuno rabbit immunoglobulins (P<0.0005, Fig. 2:5). Plasma glucose levels 
showed a small insignificant rise in response to i.p. arginine in the control group 
(Fig. 2:5). There was a significant rise in plasma glucagon levels in the same 
group (P<0.0005, Fig. 2:6).
Suppression of insulin response to arginine could only be demonstrated when 
the latter was given 40-60 minutes after antiglucagon immunoglobulin (AGI) 
injection; when arginine was given 24 hours and 7 days after AGI, its stimulation 
of insulin secretion was not inhibited (Figs. 2:7 and 2:8).
As shown in Fig. 2:3, arginine did not elicit any rise in insulin secretion when 
given orally at the present dose (2 g/Kg). In fact higher doses were given which 
failed to stimulate insulin secretion. Fig. 2:4 shows plasma antiglucagon 
immunoglobulins levels in the test rats during oral arginine stimulation.
Intravenous injection of leucine (0.33 g/Kg) produced a marked increase in 
insulin secretion. This response was not significantly different from the control 
group (Fig. 2:9). There was no significant rise in plasma glucose levels following 
leucine administration.
Tryptophan, given at different concentrations, failed to stimulate insulin 
secretion. Tryptophan was difficult to dissolve and had to be alkalinized to a pH 
of 10.2 which rendered it unsuitable for i.p. administration. Fig. 2:10shows one of 
the trials at stimulating insulin secretion by oral tryptophan administration.
(b) Gut Hormones
Gastric inhibitory polypeptide (GIP) was initially given intraperitoneally, but 
failed to reach the circulation and stimulate insulin secretion. However, when 
given intravenously in the presence of hyperglycaemia, GIP produced a potent 
stimulation of insulin secretion, which was significantly higher than when glucose 
was given alone (P<0.0005, Fig. 2:11). There were no significant differences in 
insulin response between the control group (receiving non-immune rabbit 
immunoglobulins and GIP plus glucose) and the test group (receiving antiglucagon 
immunoglobulins and GIP plus glucose). Also shown in Fig. 2:11 are the plasma 
glucose levels in the three groups of rats studied in this experiment. There were 
no marked differences between them.
Plasma GIP levels rose to 1500 pg/ml from a basal level of about 400 pg/ml in 
the groups which received GIP.
(c) Antidiabetic Drugs
Tolbutamide produced a potent insulin response, both when given orally and 
intraperitoneally. In both instances, this response was strongly inhibited in the 
groups which received antiglucagon immunoglobulins (P<0.001 and P<0.005 
respectively. Figs. 2:12 and 2:13).
In the oral tolbutamide experiment, glucose levels in the test group were 
significantly lower at 60 minutes as compared to zero time (P<0.05), despite the 
suppression of insulin secretion (Fig. 2:12). In the same experiment, plasma 
glucose levels at 30 minutes were significantly lower in the control group than in 
the test group (P<0.05. Fig. 2:12). Likewise, in the i.p. tolbutamide experiment, 
plasma glucose levels in the test group were significantly lower at 30 and 60 
minutes than at zero time (P<0.001. Fig. 2:13) and in the same experiment, 
plasma glucose levels at 15, 30 and 60 minutes were significantly lower in the 
control group than in the test group (P<0.001. Fig. 2:13).
Glibenclamide (0.3 mg/Kg) given i.p. produced a marked increase in plasma 
insulin levels in the control rats receiving non-immune rabbit immunoglobulins. 
It  also produced a smaller rise in the test group receiving antiglucagon 
immunoglobulins (Fig. 2:14). The difference between the two responses was 
statistically significant (P<0.0005) at 15, 30 and 60 minutes. However, the insulin 
response to glibenclamide in the test group was not completely inhibited and was 
significantly different from basal levels (P<0.001 at 15, 30 and 60 minutes, Fig. 
2:14). The stimulation of insulin secretion was accompanied by a fall in blood 
glucose from basal levels. This hypoglycaemic effect was identical in the two 
groups (Fig. 2:14).
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Fig. 2:3 Plasia insulin levels Following oral arginine stiaulation 
in rats.Control and test groips were given noniwuune rabbit inmino- 
globulins(NRI) and antiglucagon iwnunoglobulins respectively. 
Arginine (2g/Kg) was given orally 40 nin later .Points are «ean(+/-/ 
SB1 (n=6).
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Fig. 2:1 Plasia onliglucagon immunoglobulins levels during arginine 
stimulation in rats.Rats vere given antiglucagon imswoglobulins 
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Fig. 2:6 Plasma glucagon levels following i.p. arginine adminstration 
in rats .Rais were given nonimmune rabbit immunoglobulins (NRI) 
i.p. and 40 min later arginine (t.5g/Kg) i.p..Points are mean (+/-) 
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Fig. 2:7 Arginine-stimulated insulin secretion 21 hr aPter the ad- 
■instration oP antiglucagon immunoglobulins(AGI).Control and test 
groups were given nonimmune rabbit i»munoglobulins(NRI) and AGI i.p., 
respectively.Arginine (1.5g/Kg) was given i.p. 21 hr later .Points 
are mean (*/-) SEfl (n=G).
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Fig. 2^ 8 Arginie-stiaulated insulin secretion 7 days aPter anti­
glucagon iwunoglobulins(AGI) adainstration in rats.Control and 
test groups were given noniaaune rabbit iwunoglobulins(NRI) and 
AGI i.p.,respectively.Arginine (l.5g/Kg) was given i.p. 7 days 
later .Points are *ean(+/-) SEtl (n=G).
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Fig. 2:10 Plasaa insulin levels following oral tryptophan stiiula- 
tion in rats .Control and test groups were given noniwune rabbit 
iw&unoglobulins(NRI) and antiglucagon iw#unoglobulins(AGI).Trypto“ 
phan(.5g/Kg) was given orally 10 *in later.Points are lean (+/-)
SEfl (n=B).
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DISCUSSION
It has been shown in the previous Chapter that a high titre, high avidity 
antiglucagon immunoglobulin fraction capable of specifically blocking A-cell 
secretion has been made available. Intraperitoneal injection of this 
immunoglobulin fraction was able to potently inhibit the actions of exogenous 
glucagon administered at a dose estimated to be one thousand times the basal 
glucagon levels. In the present study experiments were preformed at the time 
when antiglucagon immunoglobulins were at their highest concentrations in the 
circulation before being progressively neutralized by endogenous glucagon. It 
can be reasonably assumed from these observations that the immunoglobulin 
fraction used in this study was capable of effectively neutralizing endogenously 
secreted glucagon.
Minutes after their intraperitoneal administration, the insulin secretagogues 
started to exert their effects. This is consistent with rapid uptake by the 
lymphatic system and probably also by capillaries leading to the portal vein 
(Schade et al 1980). However, GIP and leucine failed to reach the main 
circulation when given intraperitoneally. It has been shown in previous studies 
(Schade et al 1980) and in the previous chapter that peptide hormones like insulin 
and glucagon were effectively absorbed via the intraperitoneal route. GIP was 
expected to behave similarly. It is possible, however, that GIP is more labile 
than the former peptide hormones and that it is degraded in the peritoneal space 
and does not reach the main blood stream as the intact molecule. On the other 
hand, failure of leucine to be absorbed via the intraperitoneal route may have 
been a result of the high pH (10.2) at which it had to be dissolved. This might 
have produced a degree of peritonitis which interfered with the absorption of 
leucine.
When administered orally the insulin secretagogues produced maximal effects 
in 15-30 minutes. However, oral administration of arginine, leucine and 
tryptophan failed to elicit any response. One possible explanation for this is the 
fact that tryptophan and leucine which had to be dissolved at high pH (10.2) 
precipitated whenever the pH fell from this value. It is possible therefore that 
once these alkaline solutions reached the acidic environment of the stomach they 
precipitated and could not be absorbed. Although this may have contributed to 
the failure of oral tryptophan and leucine to elicit an insulin response, it can not 
explain the failure of arginine to do so, since the latter was given at an acidic pH 
(6.5). It is more likely therefore that following i.p. administration of 
immunoglobulins, some degree of paralytic ileus was produced, which interfered 
with the absorption of orally administered substances. This explains why high 
concentrations of oral glucose and tolbutamide (5 g/Kg and 100 mg/Kg, 
respectively) were needed for an insulin response to be elicited. Probably amino 
acid doses used in this study, although comparable to those reported elsewhere 
(Ohneda et al 1968; Rocha et al 1972), were not adequately abosrbed because of 
sluggish bowel movement.
Glucose administration produced a marked insulin response both when given 
i.p. (2 g/Kg) and orally (5 g/Kg). Plasma glucose levels were higher after i.p. 
administration than after oral administration. However, insulin levels in 
response to these two modes of administration were not significantly different. 
This is at variance with previous observations that the same dose of glucose 
produced higher insulin levels when administered intrajejunally than when given 
intravenously, indicating that the bowel secretes an incretin factor in response 
to orally administered substances (McIntyre et al 1964). Apart from differences 
in species and modes of administration this discrepancy can be explained in view
of the following facts. First, interference with bowel movements mentioned 
earlier may have hindered bowel emptying and consequent absorption of glucose. 
Second, in the study by McIntyre and co-workers, potentiation of insulin 
secretion was observed in the first few minutes after administration of 
intrajejunal glucose. In the present study, the first insulin sample was measured 
15 minutes after glucose administration. It  is possible, therefore, that 
potentiation of insulin secretion by oral glucose would have been observed if 
insulin levels had been assayed in the first few minutes after glucose 
administration. Third, the fact that at 15 minutes oral and i.p. glucose produced 
comparable insulin levels (7.3 and 8 ng/ml, respectively) despite markedly 
different plasma glucose levels (8 and 14 mmol/L, respectively) is itself a further 
evidence in favour of the incretin concept.
Intraperitoneal administration of arginine elicited marked insulin and 
glucagon responses. These insulinotropic and glucagonotropic effects of arginine 
are consistent with those reported in previous studies (Ohneda et al 1968; Rocha 
et al 1972; Gerich et al 1974; Assan et al 1983). Glucose levels in response to 
arginine were raised but not significantly.
Intravenous leucine produced a potent insulin response. Glucose levels, on 
the other hand, showed a small but insignificant rise. These results are similar 
to those obtained by Pek et al (1978).
Following infusion of GIP plus glucose, plasma GIP rose to 1.5 ng/ml from a 
basal level of about 0.4 ng/ml. Glucose levels rose from 5 to 7 mmol/L. GIP plus 
glucose produced over 50% higher insulin response than did glucose alone. This is 
in agreement with results reported by Dupre et al (1973) and Brown (1982), but 
the degree of potentiation by GIP of glucose-induced insulin secretion reported 
by these workers is higher than the one reported here. It has been shown that for 
GIP to potentiate insulin secretion, glucose levels in the blood have to rise above
the threshold of 5.5 mmol/L and that this potentiation becomes more apparent at 
8.0 mmol/L (Brown. 1982b). In the pre_senl_ study plasma ..glucose..levels did.not 
surpass 8.0 mmol/L, which might explain why only moderate potentiation of 
insulin secretion by GIP was observed.
Recently, it has been shown by Sarson et al (1984) that the glucose levels 
needed in order for GIP to exert its action are supraphysiological (10.6 mmol/L). 
They have therefore cast doubt on the role of GIP as an insulinotropic hormone. 
This is obviously in conflict with data reported here. In the present study, 
plasma GIP levels following exogenous GIP infusion (1.5 ng/ml) were within 
physiologically attainable limits. Similarly, plasma glucose levels mimicked 
those observed postprandially. These results therefore indicate that GIP is 
capable of potentiating insulin secretion under physiological conditions and 
substantiate the possibility that GIP is the incretin factor secreted by the small 
intestine in response to ingested nutrients.
Tolbutamide and glibenclamide produced marked insulin responses, similar to 
those reported in previous studies (Samols et al 1970; Laube et al 1971; Kajinuma 
et al 1974). There was no difference between insulin responses to oral and 
intraperitoneal tolbutamide. As has been mentioned previously, in the present 
experimental model, intraperitoneal administration of immunoglobulins prior to 
the administration of insulin secretagogues may have interfered with bowel 
movements and hence absorption. Under these circumstances the present model 
is not suitable for comparing insulin secretion in response to oral and parenteral 
administration, and it is therefore difficult to conclude whether oral 
administration is superior to intraperitoneal administration of tolbutamide in 
eliciting an insulin response.
The secretagogues investigated in this study can be divided into two groups 
on the basis of their mechanisms of action. Group (A) includes secretagogues 
which are known to act on the B-cell directly, eg, glucose and leucine. GIP is 
also included in this group because of its dependence on glucose levels in its 
insulinotropic action. Group (B) includes secretagogues whose exact mechanisms 
of action are not well understood, but which are known to, (i) stimulate insulin as 
well as glucagon secretion, eg, arginine or (ii) stimulate insulin secretion but 
their effect on glucagon secretion is uncertain, eg, sulphonylureas.
If such categorization was true, one could predict that antiglucagon 
immunoglobulins would not modify the actions of the first group but might 
modify the actions of the second. Indeed, neither glucose nor leucine or GIP- 
induced insulin secretion was inhibited by antiglucagon immunoglobulins. This is 
further evidence in favour of the fact that glucose acts directly on the B-cell. In 
previous studies glucose-induced insulin secretion could only be inhibited when 
the direct action of glucose on the B-cell was suppressed. This was effected 
either by interfering with glycolysis by iodoacetate (George et al 1971), by 
supposedly occupying the glucoreceptors on the B-cell by prostaglandins 
(Robertson 1979) or by inhibiting calcium channels on the B-cell membrane by 
diazoxide (Henquin et al 1982). This however, does not rule out the importance 
of other islet cells for glucose-induced insulin secretion. Gorus et al (1984) have 
shown that glucose releases 30-fold more insulin from islets than from single B- 
cells. This marked difference has been shown not to be associated with 
difference in glucose handling. The rate of glucose oxidation was virtually 
identical in single B-cells and intact islets. Thus, although glucose acts directly 
on the B- cell, this action seems to be dependent on the integrity of the islet 
cells being maintained. However, the importance of the other islet cells for 
glucose action on the B-cell is not fully understood and is yet to be elucidated.
Leucine seems to act_on_ the_B-cell .yja a. mechanism different. _from_-Other_ 
amino acids (Pek et al 1978). This may involve metabolism of leucine in the 13- 
cell (Milner 1969a; Gylfe and Sehlin 1976) or promotion of calcium permeability 
through the B-cell membrane (Henquin et al 1982). These two mechanisms entail 
leucine having a direct action on the B-cell of similar nature to that of glucose. 
On the other hand leucine has been shown to have glucagonotropic activity, 
although its potency in this respect does not match that of arginine. In the 
present study, effective neutralization of endogenously secreted glucagon could 
not inhibit stimulation of insulin secretion by leucine. It is therefore concluded 
that glucagon is not instrumental in leucine action.
The dependence of GIP on glucose in its stimulation of insulin secretion is 
well documented (Dupre et al 1973; Anderson 1981). However, the exact 
mechanism of this action is yet to be clarified. The logical assumption would be 
that GIP has got a receptor on the B-cell, but this has so far not been reported. 
A recent report has demonstrated GIP receptors in the pancreas as a whole 
(Whitcomb et al 1984). The method used in this study was described as new, and 
its details were not mentioned. Moreover, the fact that GIP receptors are 
present in the pancreas as a whole does not necessarily mean that they are 
located in the B-cell. Therefore, the presence of specific GIP receptors on B- 
cells have yet to be demonstrated.
Alternative to a direct mechanism of action, Ebert et al (1979) have 
suggested that GIP may be acting on the B-cell indirectly through glucagon 
release. In addition, Anderson (1981) has proposed that GIP and arginine 
stimulate insulin secretion by a common mediator which in this case might be 
glucagon. However, the effect of GIP on glucagon secretion is equivocal, with 
some workers reporting stimulation (Taminato et al 1977) and others reporting no
effect (Sirinek et al 1980). These discrepancies can be explained by differences 
in experimental models and species as well as blood glucose levels achieved 
during the administration of GIP. In the present study the administratin of 
glucagon antibodies failed to affect the potentiation of insulin secretion by GIP. 
This clearly shows that GIP-induced insulin secretion is not mediated by 
glucagon. The present results are also consistent with the fact that GIP is only 
insulinotropic in the presence of hyperglycaemia. Since glucose acts directly on 
the B-cell it is suggested that GIP too has a direct action on the B-cell, the 
nature of which is not yet clear.
Arginine-stimulated insulin secretion was strongly inhibited by the 
administration of antiglucagon immunoglobulins. Similar results have been 
reported in the isolated rat islets by Tan and Marks (1981) who concluded that 
glucagon must be instrumental in mediating arginine-stimulated insulin release. 
However, failure of glucagon antibodies to inhibit insulin secretion by arginine 
has been reported by Grey et al (1970) and Seino et al (1982). In the study by 
Grey and associates, adrenalectomized rats were used. More importantly, they 
used a poorly characterized glucagon antiserum. In fact, none of the properties 
of the antiserum they used had been reported, and their findings did not only 
conflict with ours, but with other workers’ as well (Holst et al 1978). Seino and 
co-workers, on the other hand, have conducted their study in the perfused rat 
pancreas. Like the antiserum used by Grey et al, their antiserum had not been 
properly characterized. The disagreement with the present findings can be 
explained by inadequate neutralization of glucagon, a possibility to which the 
authors themselves have admitted. Apart from that, the inadequacy of 
neutralization of glucagon can be explained by the short duration of perfusion (15 
minutes) and the fact that in the perfused pancreas - unlike in in vivo studies - 
the circulation becomes less effective in delivering substances to the interstitial 
space. Furthermore, if the data reported by Seino et al is carefully examined, it
can be seen that the arginine-induced insulin levels following perfusion with 
glucagon antiserum, were lower than after perfusion with normal rabbit serum, 
however, the degree of scatter in these values made the difference statistically 
insignificant.
If it is true that glucagon is the mediator of insulin secretion by arginine 
(Milner 1969b; Tan and Marks 1981; Flatt et al 1982) then it might be expected 
that in some cases of diabetes a malfunction of A-cell in response to arginine 
could be demonstrated. Indeed, Poussier et al (1983) have reported less arginine- 
mediated glucagon response in BB diabetic rats as compared to normal, although 
basal glucagon levels were higher in the former group. This was attributed to a 
possible increase in somatostatin secretion or loss of A-cells. Earlier to that, A- 
cell antibodies with subnormal glucagon response to arginine have been reported 
(Del Prete et al 1978).
The mechanism of action of sulphonylureas on the B-cell is not yet fully 
understood. Henquin (1980) suggested that they create voltage-dependent 
calcium channels by decreasing potassium permeability. Heilman (1982) added 
that sulphonylureas bring about the above effect by binding directly to the B- 
cells. Ostenson et al (1983), on the other hand, showed that B-cell secretion is 
modulated by cAMP which is in agreement with observations reported by Grill 
and Cerasi (1978). These facts - namely, insulin secretion by increased calcium 
permeability or intracellular cAMP - are not necessarily contradictory, since 
cAMP itself leads to an increase in cytosolic calcium by decreasing 
mitochondrial uptake (Jackson and Bressler 1981). However, the present 
observation of inhibition of tolbutamide-induced insulin secretion by glucagon 
antibodies is not in favour of a direct action of the drug on the B-cell membrane 
leading to increased calcium permeability (Heilman 1982). Rather, it suggests 
that tolbutamide acts by promoting the release of glucagon, which in turn binds
to the B-cell and activates the adenyl cyclase system. The problem with such an 
assumption is that the data relating to the effect of tolbutamide on the A-cell is 
conflicting. Tolbutamide has been reported to inhibit glucagon secretion in the 
duck but not in the dog (Kajinuma et al 1974). It has also been reported to inhibit 
A-cell secretion in streptozotocin-treated rats which rules out the possibility of 
inhibition by insulin (Laube et al 1971). Conversely, Loubatieres and associates 
(1974) have observed stimulation of glucagon secretion by tolbutamide in the 
perfused rat pancreas. A variety of reasons have been proposed to account for 
these discrepancies. Thus, variations in glucose levels under the experimental 
conditions employed (Hermansen et al 1982; Kadawaki et al 1983; Pfeiffer et al 
1982) and presences or absence of diabetes (Bohannon et al 1982) have been shown 
to influence the effect of sulphonylureas on A-cell secretion. One important 
finding has been that glibenclamide administration stimulates glucagon secretion 
for the first 3 minutes then inhibits it in the perfused rat pancreas (Efendic et al 
1979). Similar oscillation between inhibition and stimulation of glucagon 
secretion in response to tolbutamide has been reported by Samols et al (1970). 
Bearing in mind that glucagon is a potent stimulator of insulin and somatostatin 
release, which themselves are inhibitors of glucagon secretion, it could be argued 
that sulphonylureas actually stimulate glucagon secretion, an effect which is 
rapidly and potently reversed by paracrine release of somatostatin, or insulin, or 
both. Inhibition of tolbutamide-stimulated insulin secretion presently reported 
suggests that tolbutamide acts indirectly via glucagon secretion. The other 
explanation would be that glucagon antibodies interfered with the direct 
mechanism by which sulphonylureas increase calcium permeability, either by 
preventing their binding to the B-cell membrane, or by blocking the calcium 
channels they created. It is beyond the scope of the present study to verify such 
assumptions but it is difficult to see how antiglucagon immunoglobulins can 
affect calcium permeability.
Unlike tolbutamide, glibenclamide-induced insulin secretion was only 
partially inhibited-by -the administrationof. glucagon antibodies.- The ..effect, of 
glibenclamide on glucagon secretion is less well-documented than that of 
tolbutamide, and in many studies it exerted neither stimulation nor inhibition on 
A-cell function (Kajinuma et al 1974). In addition, glibenclamide appears to be 
special among other sulphonylureas with regard to promotion of calcium 
permeability. Of six sulphonylureas tested only glibenclamide was progressively 
taken up by the B-cell; uptake of the other sulphonylureas soon attained 
equilibrium. The uptake of glibenclamide was accompanied by a progressive 
influx of calcium ions (Heilman 1982). This suggests either that glibenclamide is 
very potent in stimulating calcium permeability or that it promotes calcium 
influx by an insaturable mechanism different from that of other sulphonylureas. 
In the present study, inhibition of glibenclamide action by glucagon antibodies 
suggests that glucagon may be one of the mediators of such action; nevertheless, 
failure to completely abolish glibenclamide-induced insulin release is in keeping 
with a second mechanism of action, probably involving stimulation of calcium 
permeability by directly binding to the B-cell membrane.
Despite suppression of tolbutamide-induced insulin secretion by glucagon 
antibodies, plasma glucose levels were lowered. This is in favour of an 
extrapancreatic mechanism of action by sulphonylureas. Several such 
mechanisms have been proposed, including augmentation of insulin activity in the 
liver (Blumenthal 1977), inhibition of transglutaminase - an enzyme responsible 
for internalization of hormone-receptor complexes (Davies et al 1980) - and 
increasing the number of insulin receptors in the tissues (Mark and Harold 1978). 
It is beyond the scope of the present study to decide which of these actions was 
responsible for the extrapancreatic action of tolbutamide. It  was not possible, 
on the other hand, to demonstrate an extrapancreatic action of glibenclamide, 
since glibenclamide-induced insulin secretion was not completely inhibited by 
glucagon antibodies.
The importance of the present study lies in the fact that it underlines the 
complexity and diversity of the mechanism of insulin secretion. Glucagon has 
been viewed for a Jong time as an antagonist to insulin, a view which has been 
seriously shaken by the demonstration that glucagon is insulinotropic (Samols et 
al 1965). Several other anatomical and physiological discoveries have played a 
part in putting the role of glucagon into perspective. Ever since the 
insulinotropic properties of glucagon were demonstrated, several studies have 
suggested that glucagon is the mediator of insulin secretion with regard to some 
secretagogues (Milner 1969b; Tan and Marks 1981; Flatt et al 1982). Samols and 
Marks (1972) have suggested that glucagon plays a major role in regulating insulin 
secretion in response to the ingestion of food, without the necessity for 
comparatively large changes in substate concentrations in the blood. The 
present study gives evidence in support of the above hypothesis and clearly shows 
that A-cell function is essential for the insulinotropic action of some 
secretagogues - at least the insulinotropic actions of arginine and tolbutamide. 
If such were the case, it could be speculated that A-cell dysfunction may be an 
additional factor in the pathogenesis of diabetes mellitus. A-cell antibodies 
have, indeed, been reported in some cases of diabetes (Villalpando et al 1979; Del 
Prete et al 1978). In addition, abnormal A-cell function has been reported in 
some diabetic patients (Bolli et al 1982; Gerich et al 197^. The fact that 
glucagon is instrumental in sulphonylurea-induced insulin secretion may explain 
the failure of some cases of type II diabetes to respond to treatment with these 
agents.
CHAPTER IV
USE OF DIAZOXIDE IN  STUDYING THE MECHANISM OF INSULIN SECRETION
INTRODUCTION
Diazoxide is a nondiuretic, antihypertensive drug of the benzothidiazine 
group of compounds. It is also a hyperglycaemic agent, a property made use of 
in the treatment of leucine-sensitive hypoglycaemia, (Drash and Wolff 1964; 
Bower et al 1967) and drug-induced hypoglycaemia (Jeffery and Graham 1983).
Diazoxide-induced hyperglycaemia is brought about mainly by inhibition of 
insulin secretion. However, extra-pancreatic mechanisms are also thought to 
play a role. Diazoxide has been shown to induce a further elevation of blood 
sugar in depancreatized dogs (Tabacknick et al 1964). One possible mechanism 
for extrapancreatic action is through elevation of catecholamines in the general 
circulation (Walfish et al 1968; Henquin et al 1982).
The mechanism of action of diazoxide on B cells is not fully understood. Its* 
selective inhibition of insulin secretion in response to different secretagogues 
(Henquin et al 1982; Fajans et al 1967; Urdanivia et al 1979) points to the fact 
that it may have more than one mechanism of action. The prevention of 
diazoxide action on B cells by theo<-adrenergic blocker phentolamine has led to 
the suggestion that it might act via anoc-adrenergic mechanism (Burr et al 1971). 
This has been disputed by Henquin and associates (1982) for being irreconcilable 
with the smooth muscle relaxing effect which diazoxide produces; moreover, not 
all oc-adrenergic blocking agents could prevent diazoxide inhibition of insulin 
secretion, eg, dihydroxyergotamine and yohimbine.
There is now a good body of evidence which suggests that diazoxide exerts its 
action on B cells by modifying their calcium permeability. By increasing 
potassium efflux from the B cell, diazoxide hyperpolarizes the B cell membrane, 
thereby preventing influx of calcium ions and insulin secretion that ensues
(Henquin et al 1982; Henquin and Meissner 1982). De Bruno and coworkers (1982) 
have noted that this inhibition of calcium permeability is restricted to 
extracellular calcium. Permeability of intracellular calcium, eg, from 
mitochondria into the cytoplasm is not affected by diazoxide. Another 
observation reported by these workers was the inhibition of pancreatic tubulin 
polymerization by diazoxide.
Other pancreatic actions of diazoxide include suppression of somatostatin 
(Hillaire-Buys et al, unpublished observations) and glucagon secretion. 
Stimulation of glucagon secretion in the duck has been reported by Samols et al 
(1970), however, other reports have concurred that diazoxide actually inhibits 
rather than stimulates glucagon secretion in vivo and in vitro (Hillaire-buys et al 
unpublished observations ; Urdanivia et al 1979; Samols and Harrison 1975).
Diazoxide has been used to further elucidate the mechanism of insulin 
secretion by different secretagogues. The study was carried out in anaesthetized 
rats, with two important actions of diazoxide borne in consideration, namely, 
inhibition of insulin secretion and calcium permeability. The following report 
describes the methods and results.
-2 METHODOLOGY
(a) Experimental Protocol
Male Wistar rats weighing around 200 g each and fed on a normal laboratory 
diet were used in this study. In each experiment, 12 animals divided into two 
equal groups were studied. The test group received diazoxide plus an insulin 
secretagogues, while the control group received the insulin secretagogue alone.
Anaesthesia was effected by sodium pentobarbitone (Sagatal, May and Baker 
Ltd, England) given intraperitoneally at a dose of 50 mg/Kg, about 20-30 minutes 
before diazoxide injection. As soon as deep anaesthesia was established, an 
incision was made on the medial aspect of the thigh to expose the femoral 
vessels. Deep anaesthesia was maintained throughout the experiment and 
animals were sacrificed before regaining consciousness.
Diazoxide (Allen & Hanburys Ltd, Bethnal Green, London) was given 
intravenously in the femoral vein at a dose of 30 mg/Kg.
Insulin secretagogues were dissolved in isotonic saline. They were injected 
into the femoral vein about 5 minutes after the administration of diazoxide. The 
following secretagogues were studied:-
Glucose (BDH Chemicals, Poole, England) at a dose of 0.5 g/Kg 
Arginine (Sigma London, Poole, England) at a dose of 0.25 g/Kg 
Leucine (Sigma London, Poole, England) at a dose of 0.33 g/Kg 
Glucagon (Novo Industri, Copenhagen, Denmark) at a dose of 20 pg/Kg 
Tolbutamide (Hoechst UK Ltd, Hounslow, England) at a dose of 50 mg/Kg 
Glibenclamide (Boehringer, Mannheim, West Germany) at a dose of 0.3 mg/Kg
Dose/response curves were iirst carried out and the doses, which produced 
submaximal stimulation of insulin were adopted.
Blood was collected from the tail in heparinized tubes (500 U/ml). Plasma 
was separated by centrifugation and samples were assayed for insulin and 
glucose.
Assays
(i) Rat insulin radioimmunoassay
The method described in Chapter II was used to assay plasma insulin levels.
(ii) Plasma glucose estimation
A hexokinase enzyme method was used to determine plasma glucose levels. 
Samples were assayed in an automatic glucose analyser (Cobas-bio, Roche 
Diagnostica, Basle, Switzerland). Hexokinase enzyme was obtained from 
Hoffman-Roche (Basle, Switzerland).
Statistical Analysis
Results were analysed using students t-test for unpaired data.
3 RESULTS
Administration of diazoxide alone produced hyperglycaemia in the test group 
which was significantly different from the control group at 15 minutes (P<0.005) 
and became marked at 30 minutes (P<0.0005). Plasma insulin levels fell and 
were significantly lower in the test group at 5, 15 and 30 minutes (P<0.0025, 
P<0.0005 and P<0.0025 respectively, Fig. 3:1).
The effects of diazoxide on insulin secretion by different secretagogues were 
as follows:
(a) Nutrients
(i) Glucose
There was a strong inhibition of insulin secretion in response to i.v glucose in 
the test group receiving diazoxide (P<0.0005, P<.0005, P<0.025 at 5, 15 and 30 
minutes respectively. Fig. 3:2). By 5 minutes, plasma glucose levels were higher 
in the test group as compared to the control group (P<0.025) and continued to 
rise steadily at 15 and 30 minutes (P<.0005. Fig. 3:2).
(ii) Arginine
Arginine-stimulated insulin secretion was potently inhibited in the test group 
(P<0.0005 and P<0.025 at 5 and 15 minutes respectively. Fig. 3:3). Glucose 
levels in plasma started to shoot up at 15 and 30 minutes (P<0.0025 and P<0.0005 
respectively. Fig. 3:3).
(iii)Leucine
There was a strong inhibition of insulin secretion in response to i.v. leucine at 
5, 15 and 30 minutes (P<0.0005, P<0.0005 and P<0.0025 respectively. Fig. 3:4). 
Plasma glucose levels, on the other hand, rose steadily in the test group from 15 
minutes onward (P<0.0005 at 15 and 30 minutes, Fig. 3:4).
Glucagon
Administration ofLglucagom at. the.present .dose (20gg/Kg) produced a.potent 
repsonse of insulin secretion. The administration of diazoxide in the test group 
strongly inhibited this response (P<0.0005 at 5 and 15 minutes, Fig. 3:5). 
However, by 30 minutes plasma insulin levels in the test group were starting to 
rise again and were significantly different from basal levels (P<.005/  Fig. 3:5).
Diazoxide had an additive effect on glucagon-induced hyperglycaemia and at 
15 and 30 minutes, plasma glucose reached very high levels (Fig. 3:5).
Antidiabetic Drugs 
Tolbutamide
Tolbutamide-stimulated insulin secretion was reduced but not completely 
inhibited by diazoxide (Fig. 3:6). At 5 minutes there was a significant difference 
between the control and test groups (P<0.0005), but at the same time point, 
tolbutamide, in the presence of diazoxide (test group), produced a rise in insulin 
secretion which was significantly different from basal levels (P<0.0005, Fig. 
3:6).
In the control group (receiving tolbutamide only) plasma glucose levels fell 
sharply at 15 and 30 minutes (Fig. 3:6). In the test group the fall in glucose levels 
was less sharp, but became significant at 30 minutes (P<0005/ Fig. 2:6). 
However, even at 30 minutes plasma glucose levels were lower in the control 
group (P<0.0005) as compared to test group.
Glibenclamide
Insulin levels in the test group (receiving glibenclamide and diazoxide) were 
slightly lower than in the control group. This difference was not statistically 
significant (Fig. 3:7). Plasma glucose levels at 30 minutes in the test group were 
significantly lower than basal (P<0.0005, Fig. 3:7). However, the fall in glucose
levels in the control group was sharper and at 
significantly lower than in the test (P<0.005, Fig. 3:7). 
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DISCUSSION
In the previous chapter it was possible by the use of glucagon antibodies to 
specifically block A-cell secretion. This facilitated the evaluation of the role of 
endogenously secreted glucagon in mediating insulin secretion. It was deemed 
necessary to further examine the mechanism of insulin secretion using another 
model. Diazoxide which was frequently used in the past to study islet physiology 
was chosen for this purpose.
Anaesthesia administered intraperitoneally was used in all experiments. 
Diazoxide and insulin secretagogues were given intravenously about 30 minutes 
aftr the administration of anaesthesia. This procedure alone did not influence 
plasma insulin and glucose levels. These remained virtually unaltered in rats 
receiving pentobarbitone plus isotonic saline (Fig. 3:1). It can thus be assumed 
that the administration of anaesthesia did not interfere with the mechanism of 
insulin secretion. When, on the other hand, diazoxide alone was injected it 
markedly lowered basal insulin levels, and glucose concentration began to rise by 
25-30 minutes. This is in keeping with results reported elsewhere (Loubatieres et 
al 1968). Several mechanisms, pancreatic and extrapancreatic, have been shown 
to account for the hyperglycaemic action of diazoxide. These include elevation 
of catecholamine levels in the blood (Walfish et al 1968; Loubatieres et al 1968; 
Henquin et al 1982), inhibition of peripheral uptake of glucose (Barnet and 
Whitney 1966), increasing cAMP through inhibition of phosphodiesterase in the 
liver (Moore 1968), as well as inhibition of B-cell secretion with which diazoxide 
is well identified. It is not possible to decide here which of the above 
mechanisms was repsonsible for diazoxide hyperglycaemia. However, there was 
a time lag of 20-30 minutes before hyperglycaemia was manifest. An exception 
to this was when other hyperglycaemic secretagogues, namely glucose and 
glucagon, were administered in addition to diazoxide. In such case 
hyperglycaemia took a few minutes to develop. This delay is suggestive of an 
indirect action of diazoxide in the production of hyperglycaemia .
Diazoxide potently inhibited insulin secretion in response to glucose, leucine, 
arginine and glucagon. Several previous studies have concurred in reporting 
inhibition of glucose and leucine-induced insulin secretion by diazoxide (Fajans et 
al 1967; Basabe et al 1971a; Urdanivia et al 1979; de Bruno et al 1982; Henquin et 
al 1982). Inhibition of arginine-induced secretion by diazoxide, on the other hand, 
has been inconsistently reported. Urdanivia et al (1979) and de Bruno et al (1982) 
have reported inhibition, whereas Fajans et al (1967) and Henquin et al (1982) 
have reported failure of inhibition. Basabe and associates (1971a), on the other 
hand, have reported suppression of arginine-stimulated insulin secretion in the 
perfused rat pancreas at a diazoxide concentration of 25mg%, yet failure of such 
suppression at a diazoxide concentration of 10mg%.
Suppression of glucagon-stimulated insulin secretion is in agreement with 
that reported, in a patient with a functioning islet tumour, by Fajans et al (1968). 
Contrarily, these workers have reported only partial inhibition by diazoxide of 
glucagon-induced insulin secretion in healthy individuals.
Tolbutamide-induced insulin secretion was partially inhibited by diazoxide 
while that in response to glibenclamide was not affected. Similar tolbutamide 
data have been reported before (Loubatieres et al 1967; Basabe et al 1971a; 
Henquin and Meissner 1982). Conversely, failure to inhibit toibutamide-induced 
insulin secretion has been reported by Fajans et al (1968). To our knowledge, 
there has been no reported data concerning the effect of diazoxide on 
glibenclamide-induced insulin secretion.
One problem inherent in experiments with diazoxide is the multiple ways in 
which the latter can influence insulin secretion. Firstly, diazoxide elevates 
circulating catecholamine levels (Walfish et al 1968; Loubatieres et al 1968). 
Secondly, it inhibits calcium permeability into the B-cell (Henquin et al 1982; de
Bruno et al 1982). Thirdly, diazoxide inhibits glucagon secretion by certain 
glucagonotropic agents, eg, arginine (Urdanivia et al l979f Samols and-Harrison -  
1975). Any one of these actions can lead to inhibition of insulin secretion, which 
complicates the interpretation of results obtained from diazoxide experiments.
Another problem encountered here relates to the adjustment of diazoxide 
dose. As has been mentioned above, work by Basabe and co-workers (1971a) has 
shown that inhibition of arginine-stimulated insulin secretion by diazoxide is 
dose-dependent. Similarly, in the same study, inhibition of tolbutamide-induced 
insulin secretion has been shown to be the result of a mole-to-mole interaction 
between the sulphonylurea and diazoxide; thus the higher the concentration of 
diazoxide, the more the inhibition of tolbutamide was effective.
Despite all the shortcomings of the diazoxide model a general conclusion, 
underlining the diversity of the mechanism of insulin secretion, can be drawn 
from the present study. Thus, the mechanism by which glucose and leucine- 
induce insulin secretion seem to be readily suppressible by diazoxide. There are 
two possible mechanisms of action by glucose and leucine. First, through their 
metabolism. Glucose (Ashcroft et al 1970) and leucine (Gylfe and Sehlin 1976) are 
readily metabolized by the B-cell. Second, glucose and leucine may promote 
insulin secretion by decreasing potassium permeability of the B-cell leading to 
calcium influx (Henquin et al 1982). The first mechanism is unlikely to be the 
one affected by diazoxide, which has been shown not to interfere with B-cell 
metabolism even when administered at high doses (Ashcroft et al 1970). It has 
been shown, on the other hand, that diazoxide can inhibit calcium permeability 
by increasing efflux of potassium ions from the B-cell (Henquin et al 1982; de 
Bruno et al 1982). These findings lend support to the notion that glucose and 
leucine act directly on the B-cell, possibly through promotion of calcium 
permeability.
Several mechanisms have been proposed for the action of arginine on B-cells. 
These include direct action by promotion of calcium influx into the B-cell 
(Henquin et al 1982; de Bruno et al 1982) and an indirect one through glucagon 
secretion (Milner 1969b; Tan and Marks 1981; Flatt et al 1982). However, the 
former action can not account for the failure of diazoxide to inhibit arginine- 
induced insulin secretion reported in some studies (Fajans et al 1967; Henquin et 
al 1982). These workers have proposed that promotion of calcium permeability 
by arginine is mediated through a mechanism different from that of glucose and 
leucine. Supposedly, the glucose and leucine mechanism is sensitive to 
diazoxide, whereas that of arginine is not, which would account for the 
difference in inhibition. However, the existence of two mechanisms by which 
calcium influx into the B-cell is promoted is highly hypothetical and not 
supported by previous data. The other proposed action of arginine - namely, 
through glucagon - seems to be more fitting with data presented here. This  
possibility is further supported by the observation that diazoxide is an inhibitor 
of arginine-stimulated glucagon secretion (Urdaniviia et al 1979; Samols and 
Harrison 1975). Data reporting failure of diazoxide to inhibit arginine-induced 
insulin secretion can be accounted for by the low doses used. In the study by 
Fajans et al (1967), only 5 mg diazoxide per Kg was used. This compares with 30 
mg/Kg used in the present study. Indeed, inhibition of arginine-induced insulin 
secretion by diazoxide has been shown to be dose-dependent (Basabe et al 1971a).
Reports on the effect of diazoxide on glucagon-induced insulin secretion are 
conflicting. In the present study the latter was potently inhibited. This is in 
keeping with data reported by Fajans et al (1968) in a patient with pancreatic 
islet tumour. However, the same workers reported failure of inhibition in 
healthy individuals. Similar results have been reported by Basabe et al (1971b). 
In the latter study, diazoxide was given at a dose similar to the one reported 
here. Discrepant results were, therefore, not due to different diazoxide doses. 
They may have resulted, however, from different glucagon doses. In the present
study, glucagon is estimated to have attained a plasma concentration of about
0.16 pg/ml. Basabe and. co-workers have used three times the above dose (5 
pg/ml) in the perfused rat pancreas. It can be assumed therefore that diazoxide 
inhibition of glucagon-induced insulin secretion is dose-dependent.
Tolbutamide has been reported to stimulate insulin secretion by promoting 
calcium permeability into the B-cell (Henquin et al 1982). Conversely, we have 
shown in the previous chapter that glucagon is probably the main mediator of 
tolbutamide-induced insulin secretion. Results obtained with regard to 
tolbutamide in the present study are difficult to reconcile with both these 
mechanisms. First, if it was the case that tolbutamide-induced insulin secretion 
by increasing B-cell permeability to calcium, the immediate question would be 
why did diazoxide fail to block this mechanism with regard to tolbutamide, but 
succeeded with regard to glucose and leucine. The answer might be that the 
mechanism by which tolbutamide enhances calcium permeability is different 
from that of glucose and leucine. This, however, is highly hypothetical and not 
supported by previous data. Alternatively, it could be argued that tolbutamide 
promotes calcium permeability so potently that this effect is not inhibited by 
diazoxide. Verification of such possibility is beyond the scope of the present 
study. Secondly, if tolbutamide action was mediated by glucagon why did 
diazoxide fail to inhibit it? A possible answer is provided "by the study of 
Urdanivia et al (1979), who have shown that whereas diazoxide potently inhibited 
glucagon secretion by arginine and leucine, it failed to do so when substances 
like prostaglandins, growth hormone and theophylline were used. It  could thus be 
argued that, the glucagonotropic action of tolbutamide, similar to these 
substances, is not inhibited by diazoxide. However, the next task would be to 
reconcile this assumption with an observation that glucagon-mediated insulin 
secretion is itself inhibited by diazoxide. As has been discussed previously, the 
latter effect seems to be dependent on the doses of both diazoxide and glucagon,
and for tolbutamide to counteract the effect of diazoxide it has to induce very 
potent glucagon secretion in the paracrine space of the islet. This effect has to 
be even stronger than that of arginine. In the previous chapter it has been 
clearly shown that tolbutamide-induced insulin secretion is mediated by 
glucagon, the latter presumably attaining very high concentrations in the 
paracrine space. Whether this effect is more potent than that of arginine is yet 
to be seen.
Data reported previously (Chapter III) have suggested that although glucagon 
appears to mediate glibenclamide-induced insulin secretion, it is not the sole 
agent in this respect. On the other hand, glibenclamide has been shown to be 
special in producing a state of sustained influx of calcium ions in the B-cells 
(Heilman et al 1984), a process which normally ceases soon after it starts when 
other sulphonylureas are tested. This is in keeping with earlier studies 
demonstrating that unlike glucose, glibenclamide produced a constant 
depolarization of the B-cell membrane, a phenomenon which correlated with 
insulin secretion (Meissner and Atwalar 1976). These findings support the 
possibility that glibenclamide-induced insulin secretion may be, at least partly, 
mediated by its ability to enhance calcium permeability. Moreover 
glibenclamide seems to be more potent than glucose and other sulphonylureas in 
this respect. This may explain the presently reported resistance of 
glibenclamide action to diazoxide.
In conclusion, data reported here lent support to the notion that different 
insulin secretagogues act differently. It is not possible, due to the multiplicity 
of actions of diazoxide, to elucidate the specific nature of these mechanisms. 
The present study does, however, provide indirect evidence suggesting that 
glucose, leucine and glibenclamide induce insulin secretion by promoting calcium 
permeability and that in this respect glibenclamide is more potent and less
sensitive to diazoxide than the other two agents. This, however, does not 
contradict the fact-that _glibencl,annide_.aciion_is^partly, mediated via glucagon. 
Inhibition by diazoxide of arginine-stimulated insulin secretion was probably 
mediated by inhibition of glucagon secretion. Failure of diazoxide to inhibit 
tolbutamide-induced insulin secretion, on the other hand, was probably due to the 
immense glucagonotropic action of the latter, an effect which might have 
surmounted the inhibitory action of diazoxide. Taken alone, the present findings 
appear to be inconclusive; however, when they are viewed in conjunction with 
data reported in the previous chapter, they lend support to the general concept 
of diversity of insulin secretion mechanisms.
CHAPTER V
DEVELOPMENT OF A RADIOIMMUNOASSAY FOR NEUROTENSIN
INTRODUCTION
Neurotensin is a tridecapeptide originally isolated from bovine hypothalamic 
extracts (Carraway and Leeman 1973). It has the following sequence of amino 
acids:-
<Glu-Leu-T yr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-T yr-Ileu-Leu-OH
Neurotensin is widely distributed in the body with maximum concentrations in 
the gastrointestinal tract and hypothalamus (Leeman and Carraway 1982). 
Neurotensin immunoreactivity of tissue extracts from the gastrointestinal tract 
of man have been shown to increase as the ileum is reached (Polak et al 1977). 
Similarly, neurotensin secreting cells - N-cells - are more abundant in the 
terminal ileum as compared to the jejunum and duodenum (Hammer and Leeman
1981). These are oval cells, present in the upper two thirds of the villi, which 
have their secretory granules located mainly in the basal parts and which 
communicate with the intestinal lumen by means of microvilli. These features 
are suggestive of an endocrine role; that is, direct secretion of hormone into the 
circulation in response to stimuli in the intestinal lumen (Polak et al 1977).
Neurotensin is present in different parts of the central nervous system where 
it may be acting as a neurotransmitter; highest concentrations of 
radioimmunoassayable neurotensin have been demonstrated in the hypothalamus, 
thalamus, amygadaloid nucleus and the substantia gelatinosa of the spinal cord 
(Leeman and Carraway 1982).
A variety of pharmacological actions have been demonstrated with infusion 
experiments with neurotensin. These include hypotension, vasodilatation, 
hypothermia, inhibition of gastric motility, hyperglycaemia and
hyperglucagonaemia (Leeman and Carraway 1982). It is not clear, however,
whether any of these actions has a role in mammalian physiology. Nevertheless,
plasma neurotensin levels have been shown to increase in response to ingested
food (Blackburn and Bloom 1979). Further work showed fat to be the most
important nutrient in eliciting such a response (Ferris et al 1981). Interestingly,
Hammer and associates (1982) have demonstrated that essentially all the
postprandial elevation in plasma neurotensin-like immunoreactivity was due to
increases in NT (1-8) and NT (1-11). This has led to the suggestion that the
hormone might act locally in a paracrine fashion after its release from the N-
•en t er o g as trn e
cells; for instance, since the effect of neurotensin requires the
presence of the COOH-terminal, it can not be mediated by the circulating N ^ -  
terminal metabolites; possibly the locally released hormone acts on the enteric 
nervous system or induces the release of other substances that circulate to 
affect the stomach (Leeman and Carraway 1982).
In search of a physiological role for neurotensin, several research workers
have developed specific radioimmunoassays in order to estimate its circulating
levels. Synthetic bovine neurotensin - identical in structure to human
neurotensin - was conjugated to a variety of carrier proteins by carbodiimide
(Carraway and Leeman 1976; Iwasaki et al 1980; Rokaeus 1981; Shulkes et al 1982;
Kronheim et al 1981; Shaw and Buchanan 1984); alternatively, Blackburn and
Bloom (1979) have used bisdiazotozide benzidine for conjugation. Different
immunization and boosting regimens were employed in the administration of
these conjugates. Both chloramine-T and lactoperoxidase methods were used to 
125*prepare I-neurotensin. Detection limits of the resultant assays ranged from 
less than 1 pg per ml (Rokaeus 1981) to about 100 pg per ml (Iwasaki et al 1980). In 
none of these assays was neurotensin shown to cross-react with the putative 
hormones. In fact, the amino acid sequence of neurotensin appears to be unique 
among peptide hormones; only xenopsin, thyrotropin-releasing hormone and
;l\Tteinisinq-hormone-releasing hormone bear some resemblance to the structure 
of neurotensin in having an Nh^-terminal <Glu residue (Leeman-and Carraway.
1982). Neurotensin is very unstable if left in plasma for a long time. Addition of 
aprotinin and freezing of samples at -20°C confers considerable stability on the 
hormone (Blackburn and Bloom 1979). Different fasting and stimulated plasma 
neurotensin levels have been reported: fasting level of 48 pg per ml rising to 95 
pg per ml post-prandially (Blackburn and Bloom 1979);. 48 pg per ml rising to 90 
pg per ml (Shulkes et al 1982); and 110 pg per ml rising to 400 pg per ml (Rokaeus 
1981).
For the development of a sensitive radioimmunoassay three conditions must 
be fulfilled: (a) A good antiserum - with high avidity and specificity to the 
antigen - must be available, (b) Pure label with high specific activity must be 
produced, (c) Adequate optimization of assay conditions must be carried out.
Binding avidity of an antiserum is a funciton of many factors, including 
immunogenicity of the antigen with which the animal is immunized, injection 
procedure and the immune responses of the individual animals. In general, 
proteins whose molecular weights are higher than 10,000 daltons are 
immunogenic by themselves. Peptides of less than 10,000 daltons (haptens), on 
the other hand, would have to be conjugated to other proteins (carriers) to 
become immunogenic. The most commonly used carrier proteins in 
t ib o d y  p ro d u c tio n ' are bovine serum albumin, ovalbumin, bovine thyroglobulin 
and Keyhole limpet haemocyanin. Conjugation is usually effected by one of 
three agents:
1. Gluteraldehyde conjugates the primary amino groups (eg, at the end terminus 
or lysyl residues) of both the protein and hapten
2. Carbodimides conjugate free COOH and Nb^ groups, whether C- or N- 
terminal or side-chain. Since such conjugation can take place at different 
points, it is difficult to forcast which amino acids will determine the antigenic 
response. Nevertheless, attempts have been made to produce C-terminally 
directed antisera using the following method: COOH-groups were concealed by 
esterification prior to conjugation by carbodiimide; following conjugation, the 
COOH-groups were de-esterified and the resultant conjugate was used for 
immunization of animals (Carraway and Leeman 1976).
3. Bis-diazonium salts bridge tyrosyl and histidyl residues between hapten and 
carrier. Although limited in coupling points, bis-diazonium salts produce a 
spacer arm holding the hapten away from the carrier, which eliminates steric 
hinderance and usually results in a good immunogenic response.
It is important to add the hapten in excess of the carrier protein to achieve a 
high 'degree of derivitization'. This ensures efficient cross-linking between the 
hapten and the carrier and hence better immunogenicity. Hapten-protein ratios 
ranging from 4:1 to 40:1 have been reported (O'Shaughnessy 1982).
Two things should be considered in the immunization procedure. First, the 
antigen dose should not be too high to produce 'high dose tolerance' nor too low 
to produce 'low dose tolerance'. The final decision may be reached through trial 
and error, but a literature review of similar radioimmunoassays is invaluable in 
this respect. Second, the route of administration is important. Routes affecting 
the lymph nodes increase the effectiveness of immunization (Hurn and Landon 
1971). In addition, a better immunogenic response can be achieved by emulsifying 
the conjugate with an adjuvant, eg, mineral oil. This acts in two ways: slow 
release of the immunogen and production of ulcers. Injection of BCG and 
Pertussis vaccines can also enhance antibody production.
An antiserum may-show-high -avidity,-but prove._to--.be-nonrSpecifiC-Jto_.the__. 
hormone in question. The binding sites of an antibody can accommodate no more 
than approximately six amino acids (Carraway 1982), which means a limited 
power of identification. Thus, precursors and metabolites of the hormone as well 
as other peptides of similar amino acid sequence may bind the antiserum 
unspecifically, leading to factitiously high measurements in assay systems. The 
ability of such prospective cross-reactants to interfere with the assay should 
therefore be investigated.
Apart from a good antiserum, the most important factor in determining the
sensitivity of an assay is the quality of the label. This must be pure and of high
specific activity. Radioactive labelling can be effected either by incorporating
or 14C into the primary structure of the peptide during synthesis, or by
substituting an "^1  atom in a susceptible amino acid (eg, tyrosine). and ^4C
are beta emitters whose radioactivity counting necessitates the use of
scintillation liquids. Iodine, on the other hand, is a gamma emitter with high
disintegration rate - albeit a short half life - and is more commonly used in
radioimmunoassay. Iodination can be effected by chloramine-T (generates
123 123 4*nascent iodine) or lactoperoxidase (oxidizes I” to I ) method. The former 
method is more commonly used. Iodination products should be purified from 
impurities, such as diiodo-products, free iodine, denatured and unlabelled 
peptides. Initial filtration by gel permeation chromatography followed by ion 
exchange chromatography, affinity chromatography or immunoadsorption are the 
most commonly used procedures.
Once the antiserum is characterized and a good label produced, optimization 
of assay conditions can be undertaken. Assay volume is governed by factors such 
as volume of samples to be assayed and cost of reagents. For the assay of
paediatric samples and samples from small mammals, eg, rats and mice, the final 
volume would have to be scaled down. Generally, the plasma sample contributes 
to about 25% of the final assay volume, but can be reduced to half this volume if 
high circulating hormone levels are expected (eg, in plasma insulin 
radioimmunoassay). The incubation intervals should be adjusted so as to allow 
the antigen-antibody reaction to reach its equilibrium. Sometimes in order to 
improve sensitivity, unlabelled antigen is preincubated with the antiserum for 
various periods and the label added thereafter. Incubation is normally carried 
out at 4°C which ensures maximum antigen-antibody binding and reduces 
degradation of hormone by proteolytic enzymes and bacterial action.
Proteins and other non-specific plasma constituents (eg, urea) may interfere 
with the assay. This ’plasma effect* can be minimized either by reducing the 
volume of plasma added per tube or by extracting the hormone to be measured 
from each plasma sample.
Peptide hormones are variably susceptible to enzymatic degradation in 
plasma. Some, eg, pancreatic polypeptide and secretin are quite stable, whereas 
others, eg. somatostatin and neurotensin are very unstable. Addition of aprotinin 
to the assay buffer effectively minimizes enzymatic degradation of hormones. 
In addition, if the assay is incubated for a long time, the addition of sodium 
azide (0.1%) or thiomersal (0.1%) to the assay buffer can prevent bacterial 
degradation. Moreover, degradation during storage can be minimized by deep 
freezing of plasma samples at -20°C immediately after venepuncture.
Finally, continual assessment of the validity of the assay is of prime 
importance. A variety of measures can be applied to achieve this. Setting up 
tubes in duplicate (to check accidental pipetting errors), inclusion of non-specific
binding tubes for the standard curve as well as for each sample tested, inclusion 
of zero hormone standard tubes between each set of .unknown.-saraples (to datect- 
any drift in assay measurement) and periodical monitoring of the specific 
activity of the lavel, are all simple quality control measures. In addition, after 
each iodination the new and old label should be compared. The most important 
measure, though, is the measurement, in each assay, of quality control tubes 
containing known amounts of the hormone. Such quality control samples can be 
prepared by spiking hormone-free plasma with different amounts of hormone 
within the values measured by the standard curve. Better still, is to prepare 
fasting and post-meal plasma pools whose hormone levels can be measured and 
recorded and compared with values obtained in future assays.
4
A radioimmunoassay for neurotensin has been developed using synthetic 
neurotensin (1-13). Reported here are the steps associated with the development 
and validation of the assay. In addition, attempts have been made to measure 
fasting and stimulated plasma neurotensin levels in healthy individuals, with a 
view to assessing the role of neurotensin in glucose homeostasis.
METHODOLOGY
Production of Antiserum
(i) Preparation of immunogen
Synthetic neurotensin was obtained from Universal Biologicals (Cambridge, 
UK). Two methods were used to prepare immunogen.
Gluteraldehyde method: The following solutions were mixed together:-
200 pg Neurotensin/500 pi distilled water
400 pg egg albumin (BDH Chemicals, Poole, England)/500 pi distilled water 
50 pi of 0.25 M gluteraldehyde solution (TAAB Laboratories, Reading, England)
This conjugate was prepared fresh each time animals were immunized or 
boosted.
Carbodiimide method: The following procedure was employed:- 
1 mg Neurotensin was dissolved in 3 ml distilled water.
9.3 mg Keyhole limpet haemocyanin (Sigma Chemical Company, Poole, England) 
was dissolved in 200 pi distilled water.
76.5 mg Carbodiimide (Sigma Chemical Company, Poole, England) was dissolved 
in 800 pi distilled water.
These three solutions were added together giving a reaction mixture of 4 ml. 
This was allowed to mix at room temperature for one hour before being dialysed 
against isotonic saline. Dialysis was carried out for two hours and was repeated 
at least three times. Finally the dialysate was made up to 5 ml with distilled 
water, giving a conjugate concentration of 200 pg neurotensin per ml. This was 
aliquotted into 1 ml aliguots and stored at -20°C.
(ii) Immunization and boosting procedures
Four animals were immunized - two rabbits and two sheep* Gluteraldehyde- 
conjugated neurotensin was used in immunizing the two rabbits and one of the 
sheep. The other sheep was immunized using carbodiimide-conjugated 
neurotensin.
The immunization procedure was as follows:-
To 200 pg neurotensin was added 0.1 ml BCG vaccine (DIFCO Laboratories, 
West Molesey, England). The resultant solution was mixed vigorously with 2 ml 
marcol (Esso Petroleum Company, England) until a stable emulsion was formed 
and injected intradermally over multiple sites in the animal's back.
Animals were boosted whenever titre fell. The same procedure described for 
immunization was used in boosting, except that 100 pg neurotensin was used 
instead of 200 pg.
The antiserum currently used in the assay was obtained from one of the sheep 
(immunized using gluteraldehyde-conjugated neurotensin) nine weeks after 
primary immunization (batch No MF/S3/9). This bleed was found to be superior 
to all other bleeds which were tentatively assessed for titre and avidity.
(iii) Assessment of antiserum 
Specificity.
Cross-reaction studies were carried out with the following peptide 
hormones:-
Rat insulin (Novo Research Institute, Denmark)
Glucagon (WHO First International Standard 69/1194),
Somatostatin-14 (Bachem Inc, California, USA)
In order to determine the antigenic determinants of the antiserum a number 
of neurotensin fragments were tested for cross-reactivity. These were as 
follows:
N-Terminal fragments (1-11) and (1-8) : (Univrsal Biologicals Company,
Cambridge, UK)
N-Terminal fragment (1-6) : (Cambridge Research Biochemicals Ltd, Harston, 
Cambridgeshire, England)
C-Terminal fragment (8-13) : (Peninsula Laboratories, Belmont, California, USA).
Fragments kindly donated by Professor R Carraway, North Worcester, USA:- 
N-Terminal fragments (1-8), (1-12), (5-8)
C-Terminal fragments (12-13), (11-13), (10-13), (9-13), (8-13) and (6-13)
Fragments kindly donated by Dr St Pierre (Sherbrooke, Canada)
N-terminal fragments (1-8) and (1-12)
C-terminal fragments (7-13), (8-13) and (3-13)
Binding Capacity
The binding capacity was determined using Scatchard analysis (1949). The 
amount of label added to each tube was calculated by the method of Walker 
(1977).
Production of Labelled Neurotensin
(i) Iodination procedure
A modification of the method of Hunter and Greenwood (1962) was used. The
125method uses chloramine-T to generate nascent I, which is then incorporated 
in the body of the peptide by reacting with the tyrosyl residue. The reaction is 
allowed to proceed for 10-20 seconds before it is stopped by adding sodium 
metabisulphite. Potassium iodide is then added to remove any unreacted iodine.
The iodination was carried out in a fume cupboard. All substances were 
prepared fresh except neurotensin which had been deep-frozen at -20°C. The 
additions were made in a small V-shaped vial with continuous stirring, in the 
order shown in the protocol.
Iodination Procotol
Step No Material
Quantity Volume 
Ml
1 Neurotensin (in 0.05M PO^ buffer, 5 pg 50
pH 7.4)
2 Phosphate buffer (0.5M, pH 7.4) 50
3 Na125I 0.5 mCi 5
4 Chloramine-T (in 0.05M PO^ buffer, 20 pg 5
pH 7.4)
5 15 seconds interval
6 Na2S20^ (in 0.05 PO^ buffer, 50 pg 200
pH 7.4)
7 KI (in 0.05 PC>4 buffer, pH 7.4) 100 pg 50
125(ii) Purification of I-neurotensin
Sephadex gel G-15 (Pharmacia Company, Sweden) was used for purification.
A 20 X 1.1 cm column was equilibrated with 0.05 M sodium phosphate buffer pH
7.4 containing 0.1% human serum albumen(Lister Institute, Elstree, England).
The iodination mixture was then applied to the column. For elution, 0.05 M 
sodium phosphate buffer pH 7.4 containing 0.1% human serum albumen was used.
125(iii) Assessment of I-neurotensin 
Specific activity
This was determined by the method of Sarson (1982).
Immunoreactivity check
Eluted fractions of iodinated neurotensin which had the highest radioactive 
counts were assessed for immunoreactivity by being incubated with antiserum in 
antisera dilution curves.
Displacement curves
Binding of iodinated neurotensin to the antiserum in the presence of 
unlabelled neurotensin was assessed by constructing diplacement curves. This 
was carried out in order to determine roughly the avidity of antisera from 
different bleeds.
Effect of varying the dilution of label
Antisera dilution curves were constructed using both half and twice as much 
label per tube as was used in the assay.
(c) Optimization and Valildation of Assay
(i) Assay protocol
The diluent buffer used in the assay was 0.05 M sodium phosphate buffer pH 
7A  containing 0.1% human serum albumen.
Standard curves were constructed as follows:- 100 pi of antiserum was added 
to each tube to a final dilution of 1:36,000. 100 pi of neurotensin standard, which 
ranged between 15 to 1000 pg/ml was added to each tube. 100 pi of hormone-free 
plasma was also added and assay buffer was used to make the volume to 500 pi
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per tube. Tubes were vortexed and left at 4°C for 48 hours. Label (100 pi per
The1,
tube) was added thereafter.^ association time curve had shown that 24 hours 
were needed for the label to bind maximally to the antiserum, so after adding 
label tubes were left for 24 hours at 4°C. Separation was effected using 
dextran-coated charcoal (Norit GSX, Hopkin and Williams, Chadwell Heath, 
Essex, England) added to a final concentration of 1%. Tubes were vortexed and 
immediately spun at 2,500 rpm for 15 minutes. Supernatant was aspirated and 
pellet counted.
Non-specific binding tubes,which had no antiserum added, and zero tubes, 
which had no standard neurotensin added,were also included in the assay. All 
tubes were set up in duplicate. When plasma samples were assayed, each had its 
non-specific binding tubes.
Tubes were counted in a multigama counter which plotted standard curves by 
constructing B/T (bound radioactivity divided by total radioactivity) against 
concentration.
(ii) Preparation of neurotensin standard
Neurotensin (freshly obtained from Universal Biologicals Company, 
Cambridge, England) was added to 0.05 phosphate buffer pH 7.4 containing 0.25% 
bovine serum albumen to give 1 ng neurotensin per ml. This was subsequently 
aliqotted in one ml aliquots, freeze-dried and stored at -20°C. This standard was 
used throughout the present study.
In the assay, each vial was reconstituted with assay buffer giving a top 
standard of 1000 pg/ml. This was then double diluted to give a range of 
concentrations from 1000 to 15 pg/ml.
(iii)Preparation of hormone-free plasma
A pool of plasma was prepared from a group of healthy individuals bled after 
an overnight fast. Plasma was allowed to mix with 10% (W/V) charcoal at 4°C  
overnight. Charcoal was removed by centrifugation at 2,500 rpm for 30 minutes, 
followed by filtration through 6 cm Zeitz filtre. It was then aliquotted and stored 
at -20°C.
(iv) Effect of varying the incubation intervals
Standard curves were set up with label either’ added simultaneously with 
other additions, or sequentially after various periods of preincubation with 
unlabelled neurotensin.
(v) Effect of Plasma on the Assay
Standard curves were constructed with and without hormone-free plasma 
added to the tubes. A 100 pi plasma per tube was used (See protocol).
(vi) Assay sensitivity and intra-assay variation
A standard curve was constructed with each point represented by twelve 
tubes in the assay. Detection limit of the assay was determined according to the 
definition of Feldman and Rodbard (1971), ie, two standard deviations from the 
zero standard.
Intra-assay variation was determined by the formula of Sarson (1982).
(vii)Quality control and inter-assay variation
Three batches of quality control (61, 125 and 250 pg/ml) were prepared by 
spiking hormone-free plasma with synthetic neurotensin. Quality control tubes 
were included in all assays in which plasma samples were measured.
Inter-assay coefficient of variation was calculated according to the method 
of Sarson (1982)
(viii)Recoveries
jNeurotensin was added to hormone-free plasma1 to give 1000 
pg/ml. This was then diluted to give 500, 250, 125 and 62 pg/ml. These were 
subsequently assayed.
(d) Measurement of Fasting and Stimulated Plasma Neurotensin Levels
Nine healthy volunteers (6 males and 3 females) were investigated. Following 
an overnight fast, all the volunteers were given oral fat in the form of 200 ml 
double cream (96 g fat). Blood samples were drawn immediately before the oral 
fat and then at 15, 30, 90, 120, 150, 180 and 210 minutes. Blood was collected in 
heparinized blood tubes (500 U/ml) containing aprotinin (200 K.I.E/ml, Novo 
Research Institute,Novo Alle, Bagsvaerd, Denmark). Plasma was separated 
immediately and frozen at -20°C. These samples were later assayed for 
endogenous neurotensin.
3 RESULTS
(a) Properties of the Antiserum
i
(i) Specificity
Cross-reactivity with neurotensin 1-13 was 98%. No cross-reactivity could be 
demonstrated with either insulin, glucagon or somatostatin (Fig.4:l). There was 
negligible cross-reactivity with some of the fragments obtained by courtesy of 
Dr St Pierre (Canada), as follows: fragment 1-12 had 0.2% cross-reactivity;
fragment 7-13 had 0.03% cross-reactivity; fragment 8-13 had 0.2% cross- 
reactivity; and fragment 3-13 had 0.1% cross-reactivity (Fig.4:3).
This data suggest that the antiserum tended to recognize the molecule as a 
whole and not any of its fragments.
(ii) Binding capacity
The binding capacity of the antiserum was found to be 1.3 x 10^ Litre/mol. 
Scatchard plot is shown in Fig.4:4.
(iii)Immunocytochemical localization of neurotensin in the gastrointestinal tract
When rat intestinal segments were immunocytochemically stained with the
neurotensin antiserum, using a peroxidase antiperoxidase (PAP) method 
(Sternburger 1974), N-cells, oval in shape and restricted to the tips of the villi, 
were found in the small intestine with maximum concentrations in the ileum 
(C.Powell, personal communications). These observations are in keeping with 
those of Polak et al (1977) and Sundler et al (1982).
123(b) Production and Assessment o f  I-Neurotensin
(i) Elution pattern
Fig.4:5 shows the elution pattern of the products of neurotensin iodination on
123 125Sephadex gel G-15. I-neurotensin eluted before free I.
(ii) Specific activity
On average, specific activity was found to be 40 Bq/fmol neurotensin.
(iii)Antisera dilution and displacement curves
Fig, 4:6 shows one of the antisera dilution curves which were used to assess 
immunoreactivity of the eluted fractions. Maximum binding was found to be 
80% which-means that 20% of the label constituted damaged products.
125Displacement of unlabelled neurotensin by I-neurotensin is also shown.
(iv) Effect of varying the dilution of label on binding
The effect of varying the dilution of label on binding is shown in Fig. 4:7. 
There was no appreciable difference between these dilutions. In the assay, label 
was diluted to give 5,000 cpm per 100 pi.
Label was aliquotted and deep-frozen at -20°C. It remained stable for 5 
weeks under these storage conditions
(c) Optimization and Validation of Incubation Intervals
(i) Effect of varying incubation intervals
The most sensitive standard curve was obtained when the antiserum was 
preincubated with unlabelled neurotensin for 48 hours followed by incubation 
with label for 24 hours (Fig. 4:8).
(ii) Effect of plasma
Addition of hormone-free plasma caused a fall in binding of about 15%. 
However the shape of the curve was not changed nor was its sensitivity affected 
(Fig.4:9).
(iii)Detection limit and intra- and inter-assay variations
The detection limit of the assay was 20 pg/ml (n=12). Intra-assay coefficient 
of variation was 4.5% (n=12). Inter-assay coefficient of variation at quality 
control concentration of 125 pg/ml was 13% (n=6).
(iv) Recoveries
The mean recovery of exogenous neurotensin was 90% (Fig. 4:10).
(d) Measurement of Fasting and Stimulated Plasma Levels
The mean fasting plasma level of neurotensin was found to be 21 pg/ml + 4 
(mean + SEM). No rise in plasma neurotensin levels was detectable following the 
administration of oral fat. Results are shown in Fig.4:ll.
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DISCUSSION---------------------
The antiserum used in this study was raised in sheep. Almost all previous 
studies have raised neurotensin antisera in rabbits. However, in this study rabbits 
gave poor quality antisera. Recently, Shaw and Buchanan (1984) have reported that 
guinea pigs gave consistently better quality neurotensin antisera when compared 
with rabbits. If this finding proves to be true, it would have important 
implications on future neurotension radioimmunoassays. Hitherto rabbits have 
been used for reasons of practicability rather than for their superiority in 
producing neurotensin antisera.
Synthetic neurotensin was conjugated to ovalbumin by gluteraldehyde. Solid
phase synthesis has allowed the production of purer peptide preparations. 
/
Nevertheless, synthetic products can still be contaminated with peptide 
fragments, denatured peptides, etc, produced during synthesis. Ideally, the purity 
of a synthetic peptide should be assessed by HPLC before conjugation is carried 
out. Although this was not done here, cross-reactivity and immunocytochemistry 
results gave indirect evidence for the purity of the peptide used.
Gluteraldehyde is believed to form bridges between the primary amino groups 
(at the N-terminus or lysyl residues) on both the protein and hapten. Such linkage 
would allow free rotation of the hapten and reduce steric hinderance. 
Neurotensin has a lysyl residue at position six. It is difficult, from the data 
available, to establish which primary amino group of neurotensin (ie, at position 
six or the N-terminus) was involved in the conjugation. It is possible, however, to 
conjecture that whichever amino group was involved in the linkage, the rest of the 
neurotensin molecule was freely floating on the surface of the carrier protein and 
thus the whole of its amino acid sequence was available for recognition by 
lymphocytes. Cross-reactivity data showed that the antiserum recognized only
NT (1-13) and none of its C- or N-terminal fragments or fragment 5-8 representing 
the middle of the molecule. Moreover, no cross-reactivity could be demonstrated 
with insulin, glucagon and somatostatin, which is consistent with the fact that the 
amino acid sequence of neurotensin is shared by no known peptide hormone. Since 
the binding sites of an antibody can accommodate approximately six amino acids 
(Carraway 1982), the neurotensin molecule had to have a special three dimensional 
configuration allowing only a limited number of the thirteen amino acids in 
contact with the antibody binding sites.
Gluteraldehyde conjugation of neurotensin to ovalbumin has been reported by 
Shaw and Buchanan (1984). This gave intact neurotensin and C-terminal specific 
antisera in rabbits, whereas in guinea pigs it resulted in an antiserum specific only 
to the intact molecule, similar to the one reported here. Almost all other 
radioimmunoassays have used carbodiimide for conjugation, which resulted in a 
variety of antisera with different region-specificity, none of which was specific 
only to the intact molecule (Carraway and Leeman 1976; Kronheim et al 1981; 
Shulkes et al 1982; Rokaeus 1981).
The finding of a highly specific antibody was further substantiated by 
immunocytochemical results. In man, neurotensin N-cells have been shown to be 
sparse in the duodenum and to increase in number as the ileum is approached; they 
are oval and are situated in the upper two thirds of the villi (Polak 1977; Hammer 
and Leeman 1981). Similar observations have been reported here. However, the 
absence of N-cells from the bases of the villi is not well understood. One 
possibility is that these cells differentiate as they travel upwards and become 
fully developed only when they reach the upper two thirds of the villi. On the 
other hand, species variation in the distribution of N-cells has been reported: 
Sundler et al (1982) have reported the presence of N-cells in the bases as well as in 
the tips of the villi, in the chicken.
Iodine is relatively easy to introduce into the tyrosyl or histidyl residues of a
peptide. Since neurotensin has two tyrosine residues at positions-three-.and —
125eleven, the substitution of an I atom into the molecule is relatively straight" 
forward. However, two problems are associated with radioactive labelling: 
iodination of impurities and loss of the immunoreactivity of the labelled products. 
The immunoreactivity of the label used in this study, expressed as the percentage 
bound label of the total radioactivity added, was 80%. Thus, 20% of the label 
represented damaged products, iodinated impurities and probably also diiodinated 
neurotensin. In addition, the label had high specific acitvity (40 Bq per fmol) and, 
in general, the reproducibility of the labelling method was good. Another 
indicator to the quality of a label is the false or non-specific binding to the 
antibody. This averaged about 6% in this study. The use of gel permeation 
chromatography alone in purification seemed satisfactory, although a more 
discriminating method, eg, ion exchange chromatography, would have increased 
the shelf life of the label and probably also the sensitivity of the assay.
The antiserum had a high binding affinity (1.9 x 10^ litre/mol). In addition 
unlabelled hormone could effectively displace bound label, which confirms the 
high avidity of the antiserum. Preincubating the unlabelled hormone with the 
antiserum further enhanced displacement and increased the sensitivity of the 
assay.
The mean recovery of exogenous neurotensin added to plasma was 90%. In 
addition, the sensitivity of the assay was not affected by the presence of plasma, 
even though binding had fallen. Thus the assay was suitable for the measurement 
of plasma samples without the need for extraction.
The sensitivity of the assay, calculated as the smallest standard curve value 
measured which is two standard deviations from the zero standard, was 20 pg per
ml. This is well below fasting neurotensin levels mentioned below. Less sensitive 
assays have been reported by Iwasaki et al (1980) with a detection limit of 100 pg 
per ml and Kronheim et al (1982), 40 pg per ml. Rokaeus (1981) and Carraway and 
Leeman (1976) on the other hand, have reported assays capable of measuring less 
than one picogram neurotensin per ml.
Fasting neurotensin levels in normal subjects were 21 pg per ml and showed no 
rise, over a period of two and a half hours, in response to a fat load. Blackburn 
and Bloom (1979), Shulkes et al (1982) and Rokaeus (1981) have reported fasting 
neurotensin levels of 48, 48 and 110 pg per ml respectively. Following the 
ingestion of food these levels rose up to 95, 90 and 400 pg per ml,respectively. It  
has been suggested that discrepancies in values reported might be due to 
interference with the assay by plasma proteins. To ascertain this, Shulkes et al 
(1982) have compared extracted and non-extracted plasma samples and found 
markedly lower levels of neurotensin in the latter. On the other hand, the above 
radioimmunoassays have used antisera capable of identifying intact neurotensin as 
well as C- and N-terminal fragments. Thus, factitiously high levels might have 
resulted from the inability of these antisera to discriminate between neurotensin 
(1-13) and its breakdown products and probably also its precursors. An antiserum 
capable of identifying only the intact neurotensin molecule has been reported by 
Shaw and Buchanan (1984). These workers have demonstrated no rise in 
postprandial neurotensin levels (Shaw et al 1984), which is in keeping with results 
reported here. Unfortunately, the fasting neurotensin levels were not reported in 
the above study and therefore can not be compared with the present data. In 
addition, Hammer et al (1982) have chromatographically characterized the 
neurotensin-like immunoreactivity in post meal plasma and found it to be 
essentially due to NT (1-8) and NT (1-11). C-terminal fragments and NT (1-13) on 
the other hand, showed no such rise. The authors concluded that although 
neurotensin (1-13) is secreted in response to ingested food, its peripheral plasma
levels are not consequently elevated. None of the N-terminal fragments of 
neurotensin has been shown to have biological activity and as such their biological 
significance is doubtful. Conversely, the major participants in the hypotensive, 
hyperglycaemic and gut-contracting effects of neurotensin have been shown to 
reside within its COOH-terminal five to six residues. These findings together 
support the possibility that neurotensin may be acting locally in a paracrine 
fashion and therefore its peripheral levels bear no relation to its biological 
function (Leeman and Carraway 1982). The other possibility is that postprandial 
elevation of neurotensin levels occurs in the portal circulation, which means that 
the hepatocyte function may be influenced by neurotensin under physiological 
conditions. Such possibility has not been investigated in any of the studies 
reported so far.
In conclusion, a neurotensin radioimmunoassay has been developed with a view 
to assessing the role of neurotensin in glucose homeostasis. This assay was 
capable of measuring unextracted plasma samples and was specific only to NT (1- 
13). When plasma samples were assayed, there was no rise in NT (1-13) levels in 
response to the ingestion of fat. This lends support to the suggestion that 
neurotensin is a hormone, which acts in a paracrine fashion. It  is possible, 
however, that neurotensin levels are elevated in certain pathological states, such 
as the dumping syndrome (Blackburn et al 1978) and in post gastric surgery 
subjects (Shaw et al 1984).
CHAPTER VI
A STUDY ON THE ROLE OF NEUROTENSIN IN GLUCOSE HOMEOSTASIS
INTRODUCTION
Neurotensin is present mainly in the central nervous system and small 
intestine. There is a good body of evidence suggesting that neurotensin subserves 
a neurotransmitter role in the CNS. First, the hormone has been found in 
neuronal cell bodies and processes in the brain. Second, neurotensin - like 
immunoreactivity is released from hypothalamic fragments after depolarization 
by potassium. In the gastrointestinal tract, on the other hand, neurotensin has 
been located in a special type of cell (N-cells), present mainly in the villi of the 
ileum which respond to food stimuli by releasing the peptide from secretory 
granules in their basal parts. Apart from secretion by cells, neurotensin may also 
be present in synaptic spaces in the gastrointestinal tract, thus acting as a 
neurotransmitter (Brown and Miller 1982). Whether the hormone reaches the 
circulation and acts on distant target organs or whether it acts locally on adjacent 
structures in the bowel is not yet clear.
Specific binding sites for neurotensin have been demonstrated on neuronal 
elements in the CNS (Uhl and Synder 1977) and on longitudinal smooth muscle of 
the gastrointestinal tract (Kitabgi and Freychet 1979). The peptide binds to these 
sites with a high affinity. In addition, neurotensin binding sites have been found in 
rat kidneys, with maximum concentration in the cortex (Quirion et al 1982) and in 
rat mast cells (Lazarus et al 1977).
Neurotensin is readily metabolized in the circulation to NT(l-8). The half life 
of the peptide in plasma measured with a C-terminally directed antiserum was 1.4 
minutes. In contrast, plasma half life determined using an N-terminal antiserum 
was 6 minutes (Lee et al 1984). Hammer et al (1982) have shown that essentially, 
all the neurotensin-like immunoreactivity in post-meal plasma was due to NTQ-8) 
and NT(l-ll), which have no biological activity. Instead, the biological activity of 
neurotensin has been shown to reside within its C-terminal pentapeptide
(Carraway and Leeman 1975). Further studies have indicated that within the C-
9 10 12 13terminal five amino.acids, Arg , Pro , lie and Leu mainly contribute to the
binding properties of the molecule, whereas T y r^  appears to be responsible for
the activation of the neurotensin receptor (Jolicoeur et al 1982).
A variety of effects of neurotensin on different systems have been reported. 
It should be noted, however, that pharmacological doses of the peptide had to be 
used for these effects to be achieved. In the rat, centrally administered 
neurotensin caused hypothermia in a dose-related manner. It also increased 
somatostatin levels in hypophyseal portal blood and depressed growth hormone 
release from the pituitary. The latter effect might have been secondary to 
somatostatin release (Abe et al 1981). In contrast, peripheral administration of the 
peptide stimulated growth hormone and prolactin secretion (Rivier et al 1977).
Infusion of neurotensin causes vasodilatation and hypotension. These effects 
are not significantly altered by hypophysectomy, adrenalectomy, or previous 
administration of atropine, phenoxybenzamine or propanolol and are, therefore, 
likely to represent a direct effect of the peptide on the vasculature (Carraway 
and Leeman 1973).
Neurotensin relaxes the human lower oesophageal sphincter and rat and human 
duodenum, whereas it contracts the rat stomach fundus, guinea pig ileum and 
human colon. The predominant effect on the gastrointestinal tract is the 
inhibition of peristaltic activity. As such, neurotensin is a candidate for the role 
of the elusive ’enterogastrone’ which inhibits gastric emptying and secretion and 
relaxes the lower oesophageal sphincter (Brown and Miller 1982).
Among the other actions of the peptide are cyanosis and haemoconcentration 
(Carraway and Leeman 1973), inhibition of water and protein secretion by the 
exocrine pancreas (Demol et al 1979), production of hypercholesterolaemia (Peric-
Golia (1979) and interaction with mast-cells (Nagai and FrohmanJ.9J78)._.This latter 
affect may mediate some of the peripheral actions of neurotensin.
One of the most important actions of neurotensin is the production of 
hyperglycaemia. This has been consistently reported (Brown and Vale 1976; 
Carraway et al 1976; Nagai and Frohman 1976; Rosell et al 1976). In addition, 
neurotensin raises glucagon levels in the blood (Nagai and Frohman 1976; Brown 
and Vale 1976). Neurotensin-induced hyperglycaemia is due mainly to 
glycogenolysis since infusion of the peptide produces a fall in liver glycogen and 
an increase in liver glycogen phosphorylase a . Gluconeogenesis may also 
contribute to neurotensin-induced hyperglycaemia, since the latter persists - 
albeit to a much lesser degree - in glycogen-depleted animals (Wolfe et al 1978). 
Although neurotensin is a potent stimulator of glycogenolysis in the intact liver, it 
does not release glucose when applied to liver slices directly. This raises the 
possibility of a mediator of neurotensin action on the liver. Histamine has been 
shown to elevate blood glucose and glucagon levels in a fashion similar to that of 
neurotensin. In addition, Hj -  and H2 - receptor blockade have been shown to 
attenuate neurotensin-induced hyperglycaemia. On the other hand Hj histamine 
antagonists completely suppress, whereas H2 antagonists partially suppress 
neurotensin-induced hyperglucagonaemia (Nagai and Frohman 1978).
Unlike its effects on blood glucose and glucagon levels, the effect of 
neurotensin on insulin secretion has been equivocal. The peptide has been 
reported to have no effect (Carraway et al 1976; Nagai and Froham 1976), to 
decrease (Brown and Vale 1976) and to increase (Blackburn et al 1981) insulin levels 
in plasma. Stimulation of pancreatic somatostatin secretion, on the other hand, 
has been reported by Saito and Saito (1980).
The possibility that neurotensin has a role in physiology and/or pathophysiology 
has been raised by the demonstration of raised immunoreactive neurotensin levels 
in the pancreases of diabetic rats and mice (Fernstrom et al 1981; Berelowitz and 
Frohman 1983). Berelowitz and Frohman have observed, in addition, a reduction in 
hypothalamic neurotensin in these diabetic animals, which indicates that
decreased hypothalamic neurotensin activity may be partly responsible for 
abnormal pituitary hormone secretion seen in diabetes. Neurotensin has also been 
implicated in the pathogenesis of the dumping syndrome (Blackburn et al 1983). It 
has also been found in high circulating levels following jejunoileal bypass 
operations (Shaw et al 1984). Moreover, Shulkes et al (1984) have described a 
pancreatic tumour containing high concentrations of neurotensin.
Studies have been carried out on the effect of neurotensin on blood glucose 
levels. Anaesthetized rats were infused with neurotensin and the effect of this on 
islet hormone secretions was evaluated. The results of the experiments are 
discussed.
X L / V
2 METHODOLOGY
Experimental Protocol
Effect of intravenous neurotensin on plasma glucose levels and islet hormone 
secretion
Male Wistar albino rats weighing around 200 g each and fed on normal 
laboratory diet were divided into groups of six. Rats were anaesthetized by 
intraperitoneal injection of sodium pentobarbitone (50 mg/Kg, Sagatal, May and 
Baker Ltd, England). As soon as deep anaesthesia was established, an incision was 
made on the medial aspect of the thigh to expose the femoral vein, which was 
used for intravenous injection. Deep anaesthesia was maintained throughout the 
experiment and animals were sacrificed before regaining consciousness.
Neurotensin (Universal Biologicals, Cambridge, UK) and D-glucose (BDH 
Chemicals, Poole, England) were prepared fresh and given intravenously into the 
femoral vein, about 20 to 30 minutes after the administration of anaesthesia.
To study the effect of i.v. neurotensin on plasma glucose and insulin levels 
each of two groups of rats was injected with neurotensin either at the dose of 5 or 
10 pg per Kg. A control group was injected with isotonic saline.
To study the effect of i.v. neurotensin on plasma insulin in the presence of 
hyperglycaemia, each of three groups of rats was injected intravenously with 
either neurotensin (lOpg/Kg), glucose (0.5g/Kg), or neurotensin plus glucose (10 pg 
and 0.5g per Kg, respectively).
(a)
(i)
To study the effect of neurotensin on plasma glucagon and somatostatin levels, 
in the presence and absence of hyperglycaemia, each of three groups of rats was 
injected intravenously with either neurotensin (lOpg/Kg), saline (0.5ml) or 
neurotensin plus glucose (10 pg and 0.5g per Kg, respectively).
Rats were bled at 0, 5, 15, 30 and 45 minutes. Blood from the tail vein was 
collected in heparinized tubes (500 U/rpl) and plasma separated by centrifugation.
Effect of antiglucagon immunoglobulins on some of the actions of neurotensin
Male Wistar rats weighing around 200g each and fed on normal laboratory diet
-al
were divided into groups of six. The same experiment protocol described above 
was used in anaesthetizing rats and administering neurotensin and glucose. In 
addition, antiglucagon immunoglobulins were given to test groups, and non- 
immune rabbit immunoglobulins to control group. Both immunoglobulin fractions 
were given intraperitoneally, 40-60 minutes before the intravenous injection of 
neurotensin and/or glucose. Characterization of these immunoglobulin fractions 
is described in Chapter II.
Firstly, to investigate the effect of antiglucagon immunoglobulins on 
neurotensin-induced hyperglycaemia, a control group (receiving non-immune 
rabbit immunoglobulins) and a test group (receiving antiglucagon immunoglobulins) 
were both injected with neurotensin at a dose of 10pg per Kg.
Secondly, the effect of antiglucagon immunoglobulins on the potentiation by 
neurotensin of glucose-induced hyperglycaemia and insulinaemia was investigated. 
A test group (receiving antiglucagon immunoglobulins) was injected with 
neurotensin plus glucose (10 pg and 0.5g/Kg respectively). Each of two control 
groups (receiving non-immune rabbit antiserum) was injected with either glucose 
(0.5g/Kg) or neurotensin, plus glucose (lOpg and 0.5g/Kg respectively).
Rats were bled at 0, 5, 15, 30 and 45 minutes. Blood from the tail vein was 
collected in heparinized tubes (500U/ml) and plasma separated by-centrifugation.
(b) Assays
(i) Rat insulin radioimmunoassay
The method described in Chapter II was used to assay rat plasma insulin levels.
(ii) Glucagon radioimmunoassay
The glucagon radioimmunoassay described in Chapter III was used to determine 
plasma glucagon levels.
(iii) Somatostatin radioimmunoassay
Plasma somatostatin levels were measured using an antiserum raised against 
synthetic cyclic somatostatin-14 (Guildhay Antisera, Guildford, UK). The 
antiserum was specific for somatostatin with a 10% cross-reactivity for 
somatostatin-28. Synthetic cyclic-somatostatin-14 (Bachem Inc, California, USA) 
was used as standard, and for the preparation of the tracer, "^Tyr-somatostatin 
(Bachem Inc, California, USA) was used. The tracer was purified on ODS silica 
before use. Separation was achieved using dextran-coated charcoal. Assay 
sensitivity was 40pg/ml with intra- and inter-assay coefficients of variation of 7% 
(n=9) and 15% (n=10), respectively.
(iv) Neurotensin radioimmunoassay
The method described in Chapter V was used to determine plasma neurotensin 
levels.
(v) Glucose estimation
Plasma glucose levels were measured by the hexokinase method described in 
Chapter IV.
Statistical Analysis
Results were compared using student's t test for unpaired data.
3 RESULTS
(a) Effect of Intravenous Neurotensin on Plasma Insulin Levels
Neurotensin had no effect on plasma insulin levels at either of the doses used 
(ie, 3 and 10pg/Kg, Figs 5:1 and 3:2)
(b) Effect of Intravenous Neurotensin on Plasma Insulin Levels in the Presence of 
Hyperglycaemia
When glucose was administered in conjunction with neurotensin, plasma insulin 
levels continued to rise and reached a plateau at 15 and 30 minutes. This 
sustained insulinaemia was different from when glucose was given alone, in which 
case plasma insulin fell to basal levels at 15 minutes (P<0.0005, Fig 5:4).
(c) Effect of Intravenous Neurotensin on Plasma Glucose Levels
Intravenous neurotensin at the dose of lOpg/Kg raised plasma glucose from a 
basal level of 7 mmol/Litre to 10.5 mmol/Litre at 15 minutes. This 
hyperglycaemic effect was significantly different from the control group (P<0.01 
at 30 minutes and P<0.005 at 5, 15 and 45 minutes, Fig 5:2).
On the other hand, blood glucose levels in response to intravenous neurotensin 
at the dose of 5pg/Kg were not significantly different from basal; however, they 
were significantly different from glucose levels in the control group, which 
received only saline (P<0.0005, P<0.01, P<0.005 at 15, 30 and 45 minutes, 
respectively, Fig 5:1).
(d) Effect of Intravenous Neurotensin on Glucose-Induced Hyperglycaemia
When neurotensin was injected together with glucose, plasma glucose levels 
remained high at 15 and 30 minutes and finally fell to basal at 45 minutes. This 
was significantly different from when glucose was given alone, in which case 
blood glucose started to fall at 15 minutes and reached basal levels at 30 minutes 
(P<0.005, P<0.0005 at 15 and 30 minutes respectively, Fig 5:5).
(e) Effect of Intravenous Neurotensin-on-P-lasma Glucagon L e v e ls --------------  - ...
Plasma glucagon levels were significantly elevated in the test group, which 
received neurotensin, as compared to the control group, which received saline 
only (P<0.05 at 5 and 15 minutes, Fig 5:6). However, when glucose and neurotensin 
were injected together, there was no significant rise in plasma glucagon levels at 
5, 15 and 30 minutes, but at 45 minutes a sharp rise, equivalent to a ten-fold 
increase in glucagon levels was produced (P<0.0005, Fig 5:6). This was
accompanied by . a fall in plasma glucose levels in the same group (Fig 5:5).
(f) Effect of Intravenous Neurotensin on Plasma Somatostatin Levels
There was no significant rise in plasma somatostatin levels in either of the 
three groups which received saline, neurotensin or neurotensin plus glucose. 
Plasma somatostatin levels were maintained around a value of 500pg/ml (Fig 5:7).
(g) Effect of Antiglucagon Immunoglobulins on Neurotensin-Induced Hyperglycaemia
In the control group which received non-immune rabbit immunoglobulins,
intravenous neurotensin produced a significant rise in plasma glucose levels at 15, 
30 and 45 minutes. This hyperglycaemic effect was significantly suppressed in the 
test group which received antiglucagon immunoglobulins (P<0.0005 at 15, 30 and 
45 minutes, Fig 5:8).
(h) Effect of Antiglucagon Immunoglobulins on the Potentiation by Neurotensin of 
Glucose-Induced Hyperglycaemia and Insulinaemia
In the control group which received non-immune rabbit immunoglobulins, the 
administration of neurotensin plus glucose maintained higher levels of blood 
glucose at 15 and 30 minutes than did glucose alone. This potentiating effect of 
neurotensin on glucose-induced hyperglycaemia was inhibited in the test group 
which received antiglucagon immunoglobulins (P<0.0025, P<0.05 at 15 and 30 
minutes, Fig 5:10).
Similarly, in the control group which-received-glucose plus-neurotensin,-plasma 
insulin levels returned to basal more slowly than in the other control group which 
received glucose alone. Again, this potentiating effect of neurotensin on glucose- 
induced insulin secretion was significantly suppressed in the test group which 
received antiglucagon immunoglobulins (P<0.0005 at 15 and 30 minutes, Fig 5:9).
Plasma Neurotensin Levels After Injection of Synthetic Neurotensin
In the rats which received neurotensin at the dose of lOpg/Kg, the circulating 
levels of the peptide reached a peak of 2ng/ml at 5 minutes and then started to 
fall, but were still high (1.5 ng/ml) at 45 minutes (Fig 5:3).
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DISCUSSION
The present findings have confirmed the reported dose-related 
hyperglycaemic effects of neurotensin (Carraway et al 1976; Brown and Vale 
1976; Nagai and Frohman 1976). At the dose of 5 pg/Kg, neurotensin produced 
relative hyperglycaemia; ie, glucose levels were not significantly elevated from 
basal, but were significantly higher than those of the control group. However, at 
the dose of 10 pg/Kg the peptide significantly raised blood glucose, relative to 
both basal and control levels. This hyperglycaemic effect was prolonged and was 
present until the end of the experiment (45 minutes), an observation which has 
been reported by all of the above mentioned studies.
Following its intravenous injection, neurotensin reached high circulating 
levels (2 ng/ml) at 5 minutes. Interestingly, however, these levels did not fall 
appreciably thereafter and at 45 minutes were about 1.5 ng/ml, which is 
inconsistent with the short half life of the peptide, reported by Blackburn et al 
(1981) and Lee et al (1984) to be 1.4 minutes. These workers have reported, in 
addition, that infused NT (1-13) is readily metabolized to NT (1-8). The antiserum 
used in the present study recognized only NT (1-13), and the possibility of high 
peptide levels reported here being the result of interference in the assay by N- 
terminal fragments is therefore excluded. It is proposed, instead, that some 
factor(s) must have caused this delay in the degradation of circulating hormone. 
Firstly, the role of the liver in neurotensin metabolism has so far not been 
ascertained (Lee et al 1984). On the other hand, neurotensin has a multiplicity of 
pharmacological actions in different parts of the body, and it is possible that the 
peptide has an inhibitory effect on liver enzymes involved in the degradation of 
peptide hormones. If this is true and if the liver is involved in the metabolism of 
neurotensin, then a high dose of the peptide such as the one used here, would be 
cleared from the circulation in longer than the normal time. Secondly,
neurotensin is known to produce hypotension and vasodilatation in the splanchnic 
area leading to stasis of-circulation-and hence a decrease in the amount of blood 
passing through the liver. Again this might slow down the degradation process. 
These mechanisms are, however, speculative and await confirmation by other 
studies.
The prolonged hyperglycaemic effect of neurotensin may have been the result 
of the continuous action of the high circulating levels of the peptide on the liver. 
However, two observations militate against the possibility of a direct action on 
the liver by neurotensin. First, in the study of Blackburn et al (1981) the peptide 
was infused for 15 minutes only, and its circulating levels fell exponentially soon 
after it was stopped; yet the hyperglycaemia which ensued lasted for 60 minutes, 
suggesting that a mediator was involved in the action of the hormone on the 
liver. Second, the mediator theory was first proposed when neurotensin was 
observed to stimulate liver glycogenolysis in intact animals but not directly in 
liver slice preparations (Carraway et al 1976).
Several mechanisms have been proposed to be instrumental in neurotensin- 
induced hyperglycaemia, including hypotension, hypophyseal hormone secretion, 
adrenal gland secretion, glucagon secretion and histamine release. Hypotension 
has, however been ruled out since the administration of other hypotensive 
substances (substance P and bradykinin) in equimolar quantities to neurotensin 
did not produce a similar rise in blood glucose levels (Carraway et al 1976). 
Similarly in hypophysectomized and adrenalectomized rats, the rise in blood 
glucose levels in response to neurotensin was not significantly affected, although 
it was slightly diminished in the former group of animals; this might have been a 
consequence of their depleted liver glucogen stores (Carraway et al 1976). In 
view of the hyperglucagonaemic effect of neurotensin, Nagai and Frohman (1976) 
and Brown and Vale (1976) suggested that glucagon may be the mediator of
neurotensin action on the liver. Furthermore, Nagai and Frohman (1978) 
demonstrated that -both TLe-hyperglycaemic and hyperglucagonaemic—effect-s- 
were mediated by histamine: firstly, histamine evoked hyperglycaemic and 
hyperglucagonaemic responses similar to those of neurotensin; secondly, these 
effects were blocked by and h^-histamine receptor blocking agents. In 
addition, Selebekk et al (1980) demonstrated degranulation of human intestinal 
mast cells in response to neurotensin. It was however, suggested by these 
workers that this might be an non-specific effect on the mast cell, since Johnson 
and Erdos (1973) had shown that the histamine-releasing properties of several 
peptide hormones were dependent on the number of basic amino acids in their 
sequences rather than on a true interaction between these peptides and their 
specific receptors on mast cells. Neurotensin has several basic amino acids in its 
structure, which may suggest that its histamine-releasing activity is a non­
specific one. However, this is unlikely, since Lazarus et al (1977) have 
demonstrated receptors for neurotensin in rat intestinal mast cells.
In the present study, intravenous neurotensin significantly raised blood 
glucagon levels at 5 and 15 minutes (Fig 5:6). It was not possible, however, from 
the present findings to establish whether glucagon secretion was the result of a 
direct action by neurotensin on the A-cell, or whether it was mediated via 
histamine release. In order to further investigate the role of glucagon in 
mediating neurotensin-induced hyperglycaemia, the peptide was administered to 
rats that were previously given antiglucagon antibodies. This effectively blocked 
the hyperglycaemic effect (P<0.0005, Fig 5:8). It is concluded from these data 
that neurotensin, at the present pharmacological dose, released glucagon either 
by a direct action on the A-cell or via histamine release from mast cells, and 
that glucagon consequently acted on the liver to stimulate glycogenolysis.
Intravenous neurotensin-atboth doses (5 and 10. pg/Kg) had no effect -on— 
plasma insulin levels. This is in agreement with data reported by Carraway et al 
(1976) and Nagai and Frohman (1976). Alternatively, Brown and Vale (1976) 
reported inhibition of insulin secretion by neurotensin, whereas Dolais-Kitabgi 
and Freychet (1979) reported stimulation by neurotensin of insulin secretion at 
low glucose levels in isolated rat islets, but inhibition at high glucose levels. The 
latter is in sharp contrast with observations that neurotensin is only 
insulinotropic in the presence of hyperglycaemia in the conscious calf (Blackburn 
et al 1981). These workers claimed that neurotensin infused at physiologically 
attainable limits was insulinotropic, an effect which was sensitive to glucose 
within the range of 5 to 9 mmol/L. Lee and associates (1984) from the same 
group infused neurotensin at similar physiological doses and observed no effect 
on plasma insulin; however, in contrast to Blackburn and coworkers, their study 
was carried out in fasted individuals. These conflicting reports reflect the 
confusion over the effect of neurotensin on insulin secretion. In our experiments 
we tried to reproduce results reported by Blackburn et al; neurotensin was 
injected into normally fed rats whose plasma glucose levels were well within the 
range in which the insulinotropic effect of neurotensin is said to be active; yet, 
no effect on insulin secretion was observed. In the study of Brown and Vale 
(1976), intravenous injection of neurotensin was attended by an initial fall in 
insulin levels at 5 minutes, followed by a rise at 30 minutes. It  can not be ruled 
out, therefore, that in our experiments an early fall in insulin levels was missed; 
even more probably, such a fall might have been masked by the hyperglycaemia 
and hyperglucagonaemia produced by neurotensin. In order to further investigate 
the effect of neurotensin on acutely stimulated insulin secretion, the peptide was 
injected together with glucose into rats. This produced significantly higher 
levels of both glucose and insulin at 15 and 30 minutes when compared with 
control levels in rats receiving glucose alone (Figs 5:4, 5:5). That is,
neurotensin lead to the prolongation of glucose-induced hyperglycaemia and 
hyperinsulinaemia. Neurotensin stimulates -glucagon secretion-which,-as has been 
discussed above, is instrumental in the production of hyperglycaemia. The 
prolongation of the hyperglycaemic effect of intravenous glucose can thus be 
explained in the light of the hyperglucagonaemia produced by neurotensin. 
Prolongation of glucose-induced hyperinsulinaemia, on the other hand, can be 
explained by neurotensin acting either directly on the B-cell to potentiate the 
action of glucose or indirectly via glucagon secretion.
The first possibility is unlikely, since the observed potentiation by
neurotensin of glucose-induced insulin secretion at 15 and 30 minutes was 
relative and not absolute: that is, insulin levels in response to neurotensin plus 
glucose, which at 5 minutes were not significantly different from those in 
response to glucose alone, merely failed to return to normal at 15 and 30 
minutes. Therefore, this effect may have been secondary to glucagon release in 
response to neurotensin. It has been shown in Chapter III that endogenous
glucagon can act as a potent stimulator of insulin secretion. Confirmation of
this assumption was gained from the observation that the prolongation by
neurotensin of glucose-induced hyperglycaemia and hyperinsulinaemia was 
inhibited by the prior administration of antiglucagon antibodies (Figs 5:9, 5:10).
Stimulation of pancreatic somatostatin secretion in response to neurotensin 
has been reported by Saito and Saito (1980). In contrast, Dolais-Kitabgi and 
Freychet (1979) have reported inhibition of pancreatic somatostatin secretion at 
high glucose levels in the isolated rat islets. In the present study, no effect on 
plasma somatostatin levels was observed. The dose of neurotensin used by Saito 
and Saito (30 pg/Kg) was three times the dose used in our experiments. In 
addition, these workers measured portal rather than systemic somatostatin 
levels. These differences in experimental techniques may explain the
disagreement in results. Also, the basal somatostatin levels in our study (500 
pg/ml) were higher- than those reported, by -Saito and .Saito ..(277~pg/ml).__Since_. 
pentobarbitone anaesthesia was used in our experiments, it is possible that 
somatostatin concentrations reported here represented stimulated rather than 
basal levels. It has been demonstrated by Abe et al (1980) and Saito and Saito 
(1980) that the use of pentobarbital anaesthesia raised somatostatin levels in rat 
hypophyseal portal blood.
The physiological role of neurotensin in glucose homeostasis is as yet 
speculative. The demonstration of the peptide in synaptosomal fractions in the 
central nervous system, in N-cells in the small intestine as well as in the 
pancreas of diabetic rats and mice, has led: to several suggestions about its role 
in digestive physiology (for a review, see Brown and Miller 1982). The present 
results do not support the possibility that neurotensin has an incretin effect. 
According to Brown and Otte (1978), for a peptide hormone to qualify for the role 
of incretin it must fulfil the following criteria: (1) It must stimulate insulin 
secretion (2) This stimulation must take place at the physiological concentrations 
of the peptide (3) The peptide preparation must be pure (4) The peptide levels in 
the blood should show a rise during the physiological events under consideration.
Firstly, the effect of neurotensin on insulin secretion is doubtful. In the present 
study no true potentiation of insulin secretion by neurotensin was observed, 
either when the peptide was given alone or with glucose. Even in the study of 
Blackburn et al (1981) in which they claimed that neurotensin at physiological 
levels stimulated insulin secretion, the definition of physiological levels was 
arbitrary, based mainly on the absence of objective cardiovascular effects of the 
peptide. No consensus exists on the physiological plasma levels of neurotensin. 
Indeed, whether neurotensin (1-13) levels are raised postprandially is doubtful (see 
previous chapter). Secondly, the doses of neurotensin used in this study as well 
as in other studies (Carraway et al 1976; Nagai and Forhman 1976) are in the
pharmacological range and caution is therefore required before extrapolating the 
findings to explain-islet-physiology.------------------
Nevertheless, the demonstration of immunoreactive neurotensin in the 
pancreas in certain pathological conditions raises the possibility that it might 
serve a function in the physiology and/or pathophysiology of this organ. 
Fernstrom et al (1981) have demonstrated immunoreactive neurotensin in the 
pancreas of diabetic rats and mice, a condition which was reversed by the 
administration of insulin. Berelowitz and Frohman (1983) subsequently confirmed 
these data and suggested that endogenous neurotensin in the pancreas may have 
a role in islet hormone regulation, especially with regard to glucagon secretion. 
However, the exact localization of pancreatic neurotensin, ie, whether it exists 
in the endocrine or exocrine pancreas is as yet not clear. Similarly, whether 
neurotensin is secreted by special cells in the pancreas, or whether it exists in 
nerve fibres is yet to be shown. The latter possibility seems more likely, since 
Bloom and Polak (1978) have demonstrated peptidergic fibres in the pancreas, 
which secrete peptide hormones, such as VIP, somatostatin and substance P.
Neurotensin in the gastrointestinal tract is secreted in response to food 
stimuli. Whether the peptide acts locally or whether it reaches the circulation 
to act on distant organs, is a matter of dispute. However, several pieces of 
evidence are now accumulating which favour the local paracrine role. A number 
of local gastrointestinal actions of the peptide have been demonstrated, 
including inhibition of gastric emptying and secretion, inhibition of peristaltic 
activity, increasing the blood flow in the muscular layers of the ileum, which 
may be the cause of postprandial intestinal hyperaemia (Brown and Miller 1982; 
Baca et al 1981). This intestinal hyperaemia may be physiologically relevant, 
especially with regard to fat absorption (C. Shaw, Queen’s University, Belfast, 
personal communication). Augmenting the possibility of a paracrine role in the
gastrointestinal tract is the finding of selective binding sites for neurotensin in 
the longitudinal smooth-muscles of-the guinea pig intestine (Kitabgi and Freychet -  
1979) and in the rat intestinal mast cells (Lazarus et al 1977).
CHAPTER VH
FINAL DISCUSSION AND CONCLUSIONS
THE USE OF IMMUNE NEUTRALIZATION IN THE STUDY OF GLUCAGON PHYSIOLOG
Since its introduction in the 1950's, the technique of immune neutralization 
has become widely used in studying the physiology of peptide hormones. 
Antibodies to glucagon in particular have been used mainly in studying the role 
of the hormone in glucose homeostasis.
However, immune neutralization experiments are fraught with problems. 
These relate to both the antiserum and the experimental design. The antiserum 
must be highly specific to the hormone and its binding capacity and titre must be 
such that all the endogenously secreted hormone is effectively neutralized. In 
addition, the avidity of the antibodies to the peptide must be greater than that 
of tissue receptors. The experimental design, on the other hand has to take into 
account the accessibility of the hormone to be neutralized to the administered 
antibodies. This involves deciding on whether in vivo or in vitro experiments 
should be adopted and what route of administration should be used. The glucagon 
antiserum described in Chapter II was of high quality, and its characterization 
showed that it had fulfilled all the above criteria. The amount of antiserum 
administered per rat (0.5 ml) was estimated to bind up to 13 times the total 
content of glucagon in the rat pancreas, estimated by Barling and Beloff-Chain 
(1973) as 1.0 nmol; the average binding affinity of the antibodies for glucagon was 
about 60 times greater than that of the hepatic glucagon receptor of the rat 
reported by Rodbell et al (1971) to be 2.5 x 10 litre per mol. In addition, the 
antiserum was highly specific for glucagon and contained no contaminating 
insulin antibodies which might have affected the results. Only two other 
glucagon antisera of similar quality have been reported (Holst et al 1978; Barling 
and Beloff-Chain 1973). As far as the system of experiments was concerned, the 
decision was in favour of in vivo experiments. In vitro models are
plagued with the problems of inadequate circulation and the development of 
tight junctions (in’t Veld 1984), which~may further hinder the-circulation of — 
antibodies and other substances in isolated islets preparations. The 
intraperitoneal route was used for administering the glucagon antibodies. These 
reached their highest levels in plasma in 40-60 minutes, at which time they were 
capable of blocking the effects of a high dose of exogenous glucagon.
Basal plasma insulin and glucose levels of rats receiving the antiglucagon 
immunoglobulin fraction were monitored for two days, but no change could be 
detected in either of them. This failure of glucagon antibodies to produce 
hypoglycaemia was not because of their lower avidity for endogenous glucagon as 
compared to that of the hepatic receptors; nor was it because of compensatory 
adrenergic mechanisms following neutralization of glucagon. Similar findings 
have been reported by Holst et al (1978), Barling and Beloff-Chain (1973) and 
Epand and Douglas (1973). These observations throw doubt on the essentiality of 
glucagon for the regulation of blood glucose levels. Similarly, failure of 
glucagon antibodies to affect basal plasma insulin levels has been reported by 
Holst (1978) and Barling and Beloff-Chain (1973) which indicates that glucagon is 
not involved in the regulation of insulin secretion under basal conditions.
The immune neutralization model was further characterized by testing the 
ability of the antiserum to counteract the effects of a glucagon dose estimated 
to have raised the circulating hormone levels to a thousand times the basal. In 
the rats which received antiglucagon immunoglobulins, the effects of this dose 
were potently inhibited. The ability of the antiserum to neutralize the effects of 
endogenous glucagon too was examined. Arginine, an amino acid known to be a 
strong stimulator of both insulin and glucagon secretion, was injected into rats 
previously given the antiglucagon immunoglobulins. This potently inhibited 
arginine-induced insulin secretion (Chapter III).
Two major criticisms have been levelled at immune neutralization 
experiments (for a_mvlew, see EL Samols 1983). Firstly, there is no. assurance 
that antibodies will reach the interstitial space of the pancreatic islet. 
Secondly, if paracrine interactions do occur, then the hormone concentration in 
the interstitial space will be so high that it would be next to impossible for the 
administered antibodies to neutralize it. However it is known that antibodies do 
reach the interstitial space to combat, for instance, noxious substances and 
bacteria. In addition, the antiserum used in this study had such a high titre and 
avidity that it could neutralize 13 times the glucagon content of the rat 
pancreas, a fact which was confirmed by the effectiveness of its inhibition of the 
actions of both exogenous and endogenous glucagon. A reliable immune 
neutralization model enabling A-cell blockade was thus ready for use in the study 
of the role of glucagon in mediating insulin secretion.
THE ROLE OF GLUCAGON IN MEDIATING INSULIN SECRETION
The role of A-cell secretion in mediating insulin secretion in response to 
different secretagogues was studied using the immune neutralization model 
described in Chapter II. Results obtained from these experiments indicated that 
the secretagogues used could be divided into two main groups: a group whose 
action on insulin secretion was suppressed by A-cell blockade, and another whose 
action was not affected by A-cell blockade. The first group was represented by 
glucose, leucine and GIP. The second included arginine, tolbutamide and 
glibenclamide. These results underpin the notion of diversity of the mechanisms 
by which the B-cell is stimulated. The insulin secreting activity of the 
secretagogues from the first group was not inhibited, probably because these 
agents acted directly on the B-cell, an effect which would not be affected by 
suppression or neutralization of A-cell secretion. Glucose for instance, which is 
the prime physiological stimulus to insulin secretion, has been described to act 
on the B-cell by one of three mechanisms: binding to a specific glucoreceptor on 
the B-cell membrane (Matschinsky et al 1972); promotion of calcium 
permeability; or metabolism of the glucose molecule (Grodsky et al 1963). None 
of these processes is likely to be affected by A-cell blockade. Leucine, on the 
other hand has been shown to be different from other amino acids with respect 
to insulin secretion (Pek et al 1978). Leucine is thought to stimulate the B-cell 
either by promoting calcium permeability (Henquin et al 1982) or via the 
metabolism of the amino acid itself. Both these mechanisms entail a direct 
action on the B-cell (Milner 1969a; Gylf and Sehlin 1976). Similarly, GIP is 
believed to have a direct action on the B-cell, because it can only act in the 
presence of hyperglycaemia (Dupre et al 1973; Anderson 1981), which acts directly 
on the B-cell. Failure of glucagon antibodies to suppress the insulinotropic 
effect of GIP further augments the possibility that this hormone has a direct 
mode of action. Whether GIP has receptors on the B-cell, which is the logical
assumption, is yet to be seen. Recently, Whitcombe et al (1984) have 
demonstrated GIP-receptors-in the pancreas as a whole. It is not clear, however, 
whether these are located in the endocrine part of the pancreas. Data reported 
in Chapter III also confirmed the insulinotropic effect of GIP in the presence of 
hyperglycaemia. Unlike in the study of Sarson et al (1984), both GIP and glucose 
were within physiologically attainable limits, which augments the possibility that 
GIP has an incretin role.
Conversely, inhibition by antiglucagon immunoglobulins of the insulinotropic 
effects of the second group of secretagogues indicated that these agents acted 
on the B-cell via glucagon secretion. That glucagon is instrumental in arginine- 
stimulated insulin secretion has been suggested by several studies (Milner 1969b, 
Tan and Marks 1981; Flatt et al 1982). Tan and Marks (1981) have reported similar 
observations to those reported in Chapter III, ie, inhibition of arginine-stimulated 
insulin secretion by glucagon antibodies. Several other observations support the 
possibility of glucagon mediation in arginine-stimulated insulin secretion. First, 
arginine is known to be a potent stimulator of both insulin and glucagon 
secretion. Second, certain cases of diabetes are associated with a subnormal 
glucagon response to arginine (Poussier et al 1983; Del Prete et al 1978).
Inhibition of sulphonylurea-induced insulin secretion by A-cell blockade was 
reported in this study for the first time. Unlike arginine, sulphonylureas effect 
on glucagon secretion is equivocal. Both inhibition (Kajinuma et al 1974; Laube 
et al 1971) and stimulation (Loubatieres et al 1974) of glucagon secretion have 
been reported.. One fact may, however, account for these discrepancies; Samols 
et al 1970 have noticed an oscillation between stimulation and inhibition of 
glucagon secretion in response to tolbutamide. Furthermore, Efendic et al (1979) 
have shown that sulphonylureas stimulate glucagon for a short time followed by 
inhibition. Thus, probably sulphonylureas initially stimulate glucagon which in
turn stimulates insulin and possibly also somatostatin. The latter hormones, 
being potent inhibitors of-the A-oell, -then suppress glucagon secretion.—Unlike - 
tolbutamide, glibenclamide-induced insulin secretion, although strongly inhibited 
by antiglucagon immunoglobulins (P<0.0005), produced significantly higher insulin 
levels than basal. It can not be ruled out, therefore, that glibenclamide has 
another mechanism by which it stimulates the B-cell.
The mechanism of insulin secretion was further examined using a diazoxide 
model. Whereas the immune neutralization method used in Chapter III enabled 
the specific neutralization of A-cell secretion, the diazoxide method used in 
Chapter IV was not specific in its actions on islet cell function. Diazoxide has a 
multiplicity of actions, including elevation of catecholamine levels in the blood 
(Walfish et al 1968; Loubatieres et al 1968), inhibition of pancreatic glucagon 
secretion (Urdanivia et al 1979; Samols and Harrison 1975) and inhibition of 
calcium permeability into the B-cell (Henquin et al 1982). Any one of these 
mechanisms can account for the inhibitory effect of diazoxide on the B-cell, and 
as such, findings reported in Chapter IV could be interpreted in many ways. 
Nevertheless, two facts can be deduced from these findings. First, the different 
ways in which insulin secretagogues were affected by diazoxide inhibition 
supports the general concept of divergence between insulin secretion 
mechanisms. Second, although these findings seem inconclusive, when viewed in 
conjunction with data reported in Chapter IV, they lend support to some of the 
observations reported there. Thus, glucose and leucine actions on the B-cell 
were potently inhibited by diazoxide, probably because the latter interfered with 
their direct mechanisms of action, namely, promotion of calcium permeability. 
Similar findings have been reported by Fajans et al (1967) de Bruno et al (1982) 
Henquin et al (1982). Inhibition of arginine-stimulated insulin secretion, on the 
other hand, may have resulted from the inhibitory action of diazoxide on 
glucagon secretion. This has been reported by Urdanivia et al (1979) and Samols
and Harrison (1975). In contrast, tolbutamide and glibenclamide-induced insulin 
secretion were not-inhibited by diazoxide, even though -the latter is -a potent — 
inhibitor of glucagon secretion. This does not necessarily clash with the 
observation that sulphonylureas stimulate the B-cell via glucagon, because 
Urdanivia et al (1979) have shown that not all glucagonotropes are inhibited by 
diazoxide. It is still possible, therefore, that these hypoglycaemic agents acted 
on the B-cell through stimulation of glucagon secretion. However, one 
observation remains which undermines the latter possibility, namely the 
inhibition of glucagon action itself on the B-cell by diazoxide. This is difficult to 
explain, but since diazoxide inhibition of glucagon action has been shown to be 
dose-dependent, it is possible to conjecture that sulphonylureas evoked such a 
potent glucagon secretion that it overcame the inhibitory effects of diazoxide.
For a considerable time, glucagon has been thought of as the antagonist of 
insulin. According to Unger (1983) and Unger and Orci (1981), in normal
psituations, a fall in glucose levels instantly reduces insulin levels, thereby 
releasing the inhibitory effect of the latter on the A-cell. Glucagon, thus 
released, restores the glycaemia, whereupon insulin and glucose levels return to 
their original levels. However, this bihormonal concept was seriously challenged 
by the demonstration that glucagon is insulinotropic (Samols et al 1965) as well as 
by several anatomical and physiological findings suggesting that islet cells may 
interact with each other (for a review, see Samols et al 1983). Moreover, several 
findings have supported the possibility of glucagon being the mediator of insulin 
secretion with regard to certain secretagogues. Pek et al (1976) have observed 
that glucagon release precedes insulin release in response to some insulin 
secretagogues. They concluded that glucagon may modify the release of insulin 
evoked by these secretagogues. Tan and Marks (1981) have demonstrated the 
ability of glucagon antibodies to block insulin secretion in response to arginine. 
Results reported in Chapter III further showed that glucagon may also be
instrumental in mediating sulphonylurea-induced insulin secretion. These 
observations may be useful-inunderstanding the pathogenesis-of_centain-cases-of 
diabetes in which abnormal A-cell function has been observed. In addition, they 
may explain the failure of sulphonylureas to stimulate insulin secretion in some 
cases of diabetes.
THE ROLE OF NEUROTENSIN IN GLUCOSE HOMEOSTASIS
Neurotensin is found mainly in the central nervous system and the 
gastrointestinal tract. In the latter it is secreted by a special type of cell (N- 
cells) whose shape is suggestive of an endocrine role. The possibility of an 
endocrine influence on glucose homeostasis has been further augmented by the 
demonstration of hyperglycaemic and hyperglucagonaemic effects of the 
peptide. In order to assess this possibility, a radioimmunoassay for neurotensin 
has been developed to measure its circulating levels (Chapter V). Synthetic 
bovine neurotensin, which is identical in structure to human neurotensin, was 
conjugated to ovalbumin by gluteraldehyde. The latter is believed to form 
bridges between primary amino groups on both the protein and hapten. Cross- 
reactivity studies showed that the antiserum raised recognized only the whole 
molecule. This suggested that the gluteraldehyde conjugation resulted in a 
hapten-carrier conjugate in which the entire amino acid sequence of the hapten 
was available as an antigenic determinent. Most of the assays reported before 
were not whole-molecule specific. That is, they were capable of detecting NT 
(1-13) as well as its N-terminal fragments (Carraway and Leeman 1976; Kronheim 
et al 1981; Shulkes et al 1982; Rokaeus 1981; Blackburn and Bloom 1979). N- 
terminal fragments of neurotensin have been shown to be the dominant 
component of neurotensin-like immunoreactivity following the ingestion of food 
(Hammer et al 1982). This may have led to abnormally high circulating plasma 
neurotensin levels being reported.
The rest of the development and validation steps of the assay were straight­
forward. Iodination of neurotensin was made easy by the fact that the peptide 
has two tyrosyl residues at positions 3 and 11. The chloramine-T method of 
iodination was easy to implement and resulted in a labelled hormone with high 
immunoreactivity and specific activity.
The presence of plasma in the assay did not alter its sensitivity, although the 
total binding decreased. Sensitivity of the assay was 20 pg/ml.
When the assay was used to measure fasting and fat-stimulated plasma levels 
of neurotensin, the latter showed no rise from a basal level of 21 pg/ml, over a 
period of two and a half hours. This is at variance with other studies which 
reported both higher fasting neurotensin levels and elevation of neurotensin-like 
immunoreactivity after food ingestion (Blackburn and Bloom 1979; Shulkes et al 
1982; Rokaeus 1981). Failure of a fat meal to stimulate neurotensin levels has, 
however, been reported by Shaw et al (1984). In this study, a similar antiserum to 
ours was used, ie, specific only to the whole molecule. High fasting and 
stimulated levels of the peptide may have, therefore, resulted from cross- 
reactivity with circulating N-terminal fragments. Alternatively, the present 
failure to demonstrate a food-induced rise in plasma neurotensin may have 
resulted from the peptide being secreted in the portal circulation and then 
rapidly degraded by the liver, thus not reaching the systemic circulation.
Furthermore, the effect of intravenous neurotensin on blood glucose, insulin 
and glucagon levels was investigated in Chapter VI. Results confirmed the 
hyperglycaemic and hyperglucagonaemic effects of the hormone (Carraway et al 
1976; Brown and Vale 1976; Nagai and Frohman 1976). Conversely, no effect on 
insulin secretion was observed, which is at variance with data reported by 
Blackburn et al (1981). Neurotensin-induced hyperglycaemia was inhibited in rats 
which had received antiglucagon antibodies. This confirmed the role of glucagon 
as the mediator of neurotensin action on the liver.
Also, the effect of neurotensin on insulin secretion in response to intravenous 
glucose was investigated. A delay was observed in the fall of plasma insulin and 
glucose levels to basal values. However, there was no absolute potentiation of 
glucose-induced insulin secretion. Furthermore, the prolongation of glucose-
induced hyperglycaemia and hyperinsulinaemia was abolished by the prior 
administration of antiglucagon immunoglobulins, indicating the role of glucagon 
in mediating this phenomenon.
Blackburn et al (1981) have reported potentiation by neurotensin of glucose- 
induced insulin secretion, suggesting an incretin role. This observation was not 
reproduced in Chapter VI. Indeed, a fall in insulin levels in response to 
neurotensin may have been masked by the hyperglycaemic and 
hyperglucagonaemic effects of the latter.
Several observations militate against the possibility that neurotensin has an 
endocrine role. These include failure to show a rise in circulating NT (1-13) levels 
following ingestion of food, the high pharmacological doses needed to 
demonstrate the effects of the peptide on the liver and the islets and the failure 
of the injected hormone to potentiate glucose-induced insulin secretion. 
Nevertheless, the possibility of neurotensin affecting the physiology and/or 
pathophysiology of the pancreas, in a non-endocrine fashion, can not be excluded. 
This is because the pancreas of diabetic rats and mice have been shown to 
contain neurotensin (Fernstrom et al 1981; Berelowitz and Frohman 1983). Since 
peptidergic fibres containing peptide hormones have been demonstrated in the 
endocrine pancreas (Bloom and Polak 1978), it is proposed that neurotensin may 
be one of the peptidergic neurotransmitters in the pancreas. This, however, 
awaits confirmation by immunocytochemical studies.
Neurotensin in the gastrointestinal tract is secreted in response to ingestion 
of food, but probably only acts locally. This possibility is supported by the 
variety of local gastrointestinal effects of the peptide and the demonstration of 
selective binding sites for neurotensin in the longitudinal smooth muscles of the 
guinea pig intestine (Kitabgi and Freychet 1979) and the rat intestinal mast cells 
(Lazarus et al 1977).
X V  o
REFERENCES
1 Abe H, Chihara K, Chiba T^  -Matsukura-S, Fujita T—(1981) -ETTect of
intraventricular injection of neurotenin and other various bioactive
peptides on plasma immunoreactive somatostatin levels in rat hypophysial 
portal blood. Endocrinology. 108, 1939-1943.
2 Adrian T, Bloom S, Bryant M, Polak J, Heitz P, Barnes A (1976) Distribution 
and release of human pancreatic polypeptide. Gut. 17, 940-944.
3 Adrian T, Bloom S, Besterman H, Barnes A, Cooke T, Russel R, Faber R
(1977) Mechanism of polypeptide release in man. Lancet. L 161-163.
4 Aguilar-Parada E, Eisentraut A, Unger R (1969) Effect of HB419 
(glibenclamide)-induced hypoglycaemia on pancreatic glucagon secretion. 
Horm.Metab.Res.(Suppl), J_, 48-30.
5 Akpan 0, Hurley M, Lands W (1981) Insulin and glucagon secretion in 
essentially fatty acid deficient rats. Acta Diabetologica Lat. 18, 147-156.
6 Alberti K, Christensen N, Hansen A, et al. (1973) Inhibition of insulin 
secretion by somatostatin. Lancet. 2, 1299-1301.
7 Anderson D (1981) Physiological effects of GIP in man, pp 256-263. In: 
Bloom 5, Polak J (eds) Gut Hormones. Churchill Livingstone, Edinburgh, 
London, Melbourne and New York.
8 Arimura A, Meyers C, Case W, Murphy W, Schally A (1979) Suppression of 
somatostatin levels in the hepatic portal and systemic plasma of the rat by 
synthetic human pancreatic polypeptide. Biochemical and Biophysical 
Research Communications. 89, 913-918.
9 Ashcroft S, Hedeskov C, Randle P (1970) Glucose metabolism in mouse 
pancreatic islets. Biochem J. 118, 143-154.
10 Assan R, Marre M, Gormley M (1983) The amino acid-induced secretion of 
glucagon, pp 19-36. In: Lefebvre P (ed) Glucagon II:Handbook of 
Experimental Pharmacology, 66/11, Springer-Verlag, Berlin.
11 Baca I, Mittmann U, Feurle G, Muller T (1981) Effect of neurotensin on 
regional intestinal blood flow in the dog. Res.Exp.Med. 179, 53-58.
12 Barden N, Lavoi M, Dupont A, et al. (1977) Stimulation of glucagon release 
by addition of antisomatostatin serum to islets of langerhans in vitro. 
Endocrinology. 101, 635-637.
13 Barling P, Beloff-Chain H (1973) Studies on the administration of glucagon 
and insulin antibodies to rats. Horm.Metab.Res. 5, 154-159.
14 Barnet C, Whitney (1966) The effect of diazoxide and chlorothiazide on 
glucose uptake in vitro. Metabolism. 15, 88-93.
15 Basabe J, Lopez N, Viktora J, Wolff F (1971a) Insulin secretion studied in 
the perfused rat pancreas. 1. Effect of tolbulamide, leucine and 
arginine;their interaction with diazoxide and relation to glucose. Diabetes. 
20, 449-456.
16 Basabe J, Lopez N, Viktora J, Wolff F (1971b) Insulin secretion studied in 
the perfused rat pancreas. II. Effect of glucose, Glucagon, 3 5 adenosine 
monophosphate, theophylline, imidazole and phenoxybenzaminejtheir 
interaction with diazoxide. Diabetes. 20, 457-466.
17
18
19
20
21
22
23
24
23
26
27
28
29
30
31
32
33
Berelowitz M, Frohman -L (1983) Immunoreactive neurotensin in-the----------------
pancrease of qenetically obese and diabetic mice. A longitudinal study.
Diabetes. 32, 31-54.
Birnbaumer L, Rodbell M (1969) Adenyl cyclase in fat cells II. Hormone 
receptors. J.Biol.Chem. 244, 3477-3482.
Birnbaumer L, Pohl S L (1973) Relation of qlucaqon-specific bindinq sites 
to qlucaqon-dependent stimulation of adenyl cyclase activity in plasma 
membranes of rat liver. J.Biol.Chem. 248, 2056-2061.
Bishop J S, Larner J (1967) Rapid activation-inactivation of liver uridine 
diphosphate qlucose-qlycoqen transferase and phosphorylase by insulin and 
qlucaqon in vivo. J.Biol.Chem. 242, 1355-1356.
Blackburn A, Bloom S (1978) A radioimmunoassay for neurotensin in human 
plasma. J.Endocr. 83, 175-181.
Blackburn A, Bloom S, Ebeid F, Ralph D (1978) Neurotensin and the 
dumpinq syndrome. (Abstr). Gut. 19, A447.
Blackburn A, Bloom 5, Edwards A (1981) Pancreatic endocrine responses to 
exoqenous neurotensin in the conscious calf. J.Physiol. 314, 11-21.
Blackburn A, Lawaetz O, Bloom S (1983) Plasma neurotensin release and 
qastric emptying in the dumpinq syndrome. Life Sciences. 32, 833-837.
Bloom 5, Vauqhan N, Russel R (1974) Vaqal control of qlucaqon release in 
man. Lancet. 2, 546-549.
Bloom S, Polak J M (1978) Peptiderqic versus purinerqic. Lancet. 1, 93.
Blumenthal S (1977) Potentiation of the hepatic action of insulin by 
chlorpropamide. Diabetes. 26 (5), 485-489.
Bohannon N, Lorenzi M. Grodsky G, Karam J (1982) Stimulatory effects of 
tolbutamide infusion on plasma qlucaqon in insulin-dependent diabetic 
subjects. J.Clin.Endocrinol.Metab. 54 (2), 459-462. -
Bolli G, De Feo P, Compaqnucci P, Cartechini M, et al. (1983) Abnormal 
qlucose counter-requlation in insulin-dependent diabetes mellitus.
Diabetes. 32, 134-141.
Bonner-Weir S, Orci L (1982) New perspectives on the microvasculature of 
the islets of Lanqerhans in the rat. Diabetes. 31, 883-889.
Borody T, Byrnes D, Slowiaczek J, Titchen D (1981) Immuneneutralization 
of motilin. Horm.Metab.Res. 13, 470-471.
Bower B, Rayner P, Stimmler L (1967) Leucine-sensitive hypoqlycaemia 
treated with diazoxide. Arch.Dis.Child. 42, 410-415.
Bratusch-Marrian P, Waldhausl W, Gasic S, Hofer A (1984) Hepatic disposal 
of biosynthetic human insulin and porcine C-peptide in humans. 
Metabolism. 33 (2), 1984.
x w
34 Brazeau P, Vale W, Burgus R, Long N, Butcher M, Rivier J, Guillemin (1972)
A hypothalamic peptide that inhibits the secretion of pituitary growth
hormone.  -
Science. 179, 71-79.
33 Bromer W W (1983) Chemical characteristics of glucagon, pp 3-5. In:
Lefebvre P J (ed) Glucagon I. Springer-Verlag, Berlin, Heidelberg, New 
York, Tokyo.
36 Brown D, Miller R (1982) Neurotensin. British Medical Bulletin. 38 (3), 
239-245.
37 Brown J, Otte S (1978) Gastrointestinal hormones and the control of insulin 
secretion. Diabetes. 27, 782-787.
38 Brown J, Dahl M. Kwauk S, et al. (1981) Properties and actions of GIP, pp 
248-255. In: Bloom S, Polak J (eds) Gut Hormones. Churchill Livingstone, 
Edinburgh, London, Melbourne and New York.
39 Brown J, (1982a) Correction of GIP seguence, pp 17. In: Brown J (ed) 
Monographs on Endocrinology:Gastric Inhibitory Polypeptide. Springer- 
Verlag, Berlin.
40 Brown J, (1982b), pp 25-30. In: Brown J (ed) Monographs of Endocrinology. 
Gastric Inhibitory Polypeptide. Springer-Verlag, Berlin.
41 Brown M, Vale W (1976) Effects of neurotensin and substance P on plasma 
insulin, glucagon and glucose levels. Endocrinology. 98, 819-822.
42 Bur I, Mariiss E, Stauffacher W, Renold A (1971) Diazoxide effects on 
biphasic insulin release: 'adrenergic' suppression and enhancement in the 
perfused rat pancreas. J.Clin.Invest. 50,1444-1450.
43 Cahill G Jr, Aoki T, Smith R (1983) Glucagon and amino acid metabolism, 
pp 397-411. In: Lefebvre P (eds) Glucagon II. Springer-Verlag, Berlin.
44 Campillo J, Luyckx A, Torres M, Lefebvre P (1977) Effect of phosphate 
omission on arginine-induced insulin and glucagon release by the isolated 
perfused rat pancreas. FEBS Lett. 84, 141-143.
45 Carraway R, Leeman S (1973) The isolation of a new hypotensive peptide, 
neurotensin, from bovine hypothalami. J.Biol.Chem. 248, 6854-6861.
46 Carraway R, Leeman S (1975) Structural reguirements for the biological 
activity of neurotensin, a new vasoactive peptide. In: Peptides:Chemistry 
Structure and Biology, pp 679-685. Walter R, Meienhofer J (eds) Ann Arbor 
Science Publishers, Ann Arbor, Michiqan.
47 Carraway R, Leeman S (1976) Radioimmunoassay for neurotensin, a
hypothalamic peptide. J.Biol.Chem. 251,7035-7044.
48 Carraway R, Demers L, Leeman S (1976) Hyperglycaemic effect of
neurotensin, a hypothalamic peptide. Endocrinology. 99, 1452-1462.
49 Carraway R, (1982) A critical analysis of three approaches to
radioimmunoassay of peptides: Applications to the study of the neurotensin 
family. Ann N Y Acad.Sci. 400, 17-36.
50 Chey W, Kim M, Lee K, Chang T (1979) Effect of rabbit antisecretin serum 
on postprandial pancreatic secretion in doqs. Gastroenterology. 77, 1268- 
1275.
51 Claus T H, Park C R, Pilkis S J (1983) Glucagon and gluconeogenesis, pp 
315-348. In: Lefebvre P J (ed) Glucagon II. Springer-Verlag, Berlin.
52 Creutzfeldt W (1979) The incretin concept today. Diabetologia. 16, 75-85.
53 Coore and Randle P (1964) Regulation of insulin secretion studied with 
pieces of rabbit pancreas incubated in vitro. Biochem.J. 93, 66.
54 Davies P, Davies D, Levitzki A, et al. (1980) Transglutaminase is essential 
in receptor-mediated endocytosis of o^-macroglobulin and polypeptide 
hormones. Nature. 383, 162-167.
55 De Bruno F, Karbatas L, Cresto J, Aparicio M, Basabe J (1982) A 
comparative study of two insulin secretion inhibitors: Somatostatin and 
diazoxide. Horm.Metab.Res. 14, 351-356.
56 Del Prete G, Tiengo A, Nosadini R, Bottazzo G, Betterle C, Bensani G
(1978) Glucagon secretion in two patients with autoantibodies to glucagon 
producing cells. Horm.Metab.Res. 10, 260-261.
57 Demol P, Laugier R, Dagorn J, Sarles H (1979) Inhibition of rat pancreatic
secretion by neurotensin: Mechanism of action.
Arch.Int.Pharmacodyn.Ther. 242 (1), 139-148.
58 Dolais-Kitabgi J, Freychet P (1979) Neurotensin inhibit glucose but not 
glucagon-induced insulin and somatostatin release in isolated islets. 
Diabete & Metab. 5, 275-277.
59 Drash A, Wolff F (1964) Drug therapy in leucine-sensitive hypoglycaemia. 
Metabolism Clinical and Experimental. 13 (6), 487-492.
60 Dunbar J, Foa P (1974) An inhibitory effect of tolbutamide and 
glibenclamide on the pancreatic islets of normal animals. Diabetologia. 
10, 27-35.
61 Dupre7 R, Curtis J, Waddel R, Beck S (1968) Alimentary factors in the 
endocrine response to administration of arginine in man. Lancet. 2, 28-29.
62 Dupre J, Ross S, Watson D, Brown 3 (1973) Stimulation of insulin secretion 
by gastric inhibitory polypeptide in man. J.Clin.Endocrinol.Metab. 37, 
826-828.
63 Eaton R, Friedman N, Allen R, Schade D (1984) Insulin removal in man: In 
vivo evidence for a receptor-mediated process. J.Clin.Endocrinol.Metab. 
58 (3), 555-559.
64 Ebert R, Illmer K, Creutzfeldt W (1979) Release of gastric inhibitory 
polypeptide (GIP) by intraduodenal acidification in rats and humans and 
abolishment of the incretin effect of acid by GIP-antiserum in rats. 
Gastroenterology. 76, 515-523.
65 Efendic S, Enzmann F, Nylen A, Uvnas-Wallensten K, Luft R (1979) Effect 
of glucose/sulfonylurea interaction on release of insulin, glucagon and 
somatostatin from isolated perfused rat pancreas. 
Proc.Natl.Acad.Sci.(USA). 76, 5901-5904.
66 Epand R, Douglas R (1973) The effect of glucagon antibodies on plasma 
glucose and insulin levels. Biochim.Biophys.Acta. 320, 741-744.
67 Exton 3 (1979) Mechanisms involved in effects of catecholamines on liver 
carbohydrate metabolism. Biochem.Pharmacol. 28, 2237.
68 Fajans S, Floyd 3 Jr, Knopf R, et al. (1967) A difference in mechanism by 
which leucine and other amino acids induce insulin release. 
J.Clin.Endocrinol. 77, 1600-1606.
69 Fajans S, Floyd J Jr, Thifault C, Knopf R, Harrison T, Conn J (1968) 
Further studies on diazoxide suppression of insulin release from abnormal 
and normal islet tissue in man, Ann N Y Acad.Sci. 150 (2), 261-280.
70 Feil P (1983) Characterization of guinea pig antiprogestin receptor 
antiserum. Endocrinology. 112 (1), 396-398.
71 Feldman H, Rodbard D (1971) In: Mathematical theory of radioimmunoassay 
in principles of competitive protein binding assay, pp 138. Odell W, 
Daughaday W (eds) Lippnocott, Philadelphia and Toronto.
72 Felig P, Wahren J, Shrewin R, Hendler R (1976) Insulin, Glucagon and 
Somatostatin in Normal Physiology and Diabetes Mellitus. Diabetes. 25, 
1091-1099.
73 Geliu J E, Hue L, Hers H G (1976) Hormonal control of pyruvate kinase 
activity and of gluconeogenesis in isolated hepatocytes. 
Proc.Natl.Acad.Sci. (USA). 73, 2762-2766.
74 Fernstrom M, Mirski M, Carraway R, Leeman S (1981) Immunoreactive 
neurotensin levels in pancreas: Elevation in diabetic rats and mice. 
Metabolism. 30 (9), 853-855.
75 Ferris C, Hammer R, Leeman S (1981) Elevation of plasma neurotensin 
during lipid perfusion of rat small intestine. -Peptides. 2, 263-266.
76 Flatt P, Bailey C (1982) Plasma glucose and insulin responses to glucagon 
and arginine in Aston ob/ob mice: Evidence for a selective defect in 
glucose-mediated insulin release. Horm.Metab.Res. 14 (3), 127-130.
77 Floyd J Jr, Fajans S, Pek S (1978) Physiologic regulation of plasma levels
of PP in man, pp 247-253. In: Gut Hormones. Bloom S R (ed) Churchill 
Livingstone, Edinburgh. ...
78 Floyd J Jr (1979) Human pancreatic polypeptide. Clinics in Endocrinology 
and Metabolism. 8 (2), 379-399.
79 Frohman L, Reichlin M, Sokal J (1970) Immunological and biological 
properties of antibodies to a glucagon serum albumin polymer. 
Endocrinology. 87, 1055-1061.
80 Fujimoto W, Kawazu S, Ikeuchi M, Kanazawa Y (1983) In vitro paracrine 
regulation of islet B-cell function by A and D cells. Life Sciences. 32, 
1873-1878.
81 Fujita T, Yanatori Y, Murakami T (1976) Insulo-acinar axis, its vascular 
basis and its functional and morphological changes caused by CCK-PZ and 
caerulein, pp 347-357. In: Fujita T (ed) Endocrine Gut and Pancreas. 
Elsevier Scientific Publications, Amsterdam, New York.
82 Georg R, Sussman K, Leitner J, Kirsh W (1971) Inhibition of glucose- and 
tolbutamide-induced insulin release by iodoacetate and antimycin A. 
Endocrinology. 89, 169-176.
X  z> o
83 Gerich J E, Karam J H, Forsham P H (1973a) Stimulation of glucagon
secretion by epinephrine in man. J.Clin.Endocrinol.Metab. 37, 479-481.
84 Gerich J E, Langlois M, Noacco C, Karam J, Forsham P (1973b) Lack of
glucagon response to hypoglycaemia in diabetes: Evidence for an intrinsic
pancreatic alpha cell defect. Science. 182, 171-173.
85 Gerich J E, Charles M, Grodsky G (1974) Characterization of the effects of 
arginine and glucose on glucagon and insulin release from the perfused rat 
pancreas. J.Clin.Invest. 54, 833-841.
86 Gerich J (1981) Somatostatin and diabetes. Am.J.Med. 70> 619-626.
87 Gingerich R, Kramer J (1983) Identification of pancreatic polypeptide 
secretagogues in canine duodenal mucosa. Endocrinology. 112 (2), 696-700.
88 Glaser B, Floyd J Jr, Vinik A (1983) Secretion of pancreatic polypeptide in 
man in response to beef ingestion is mediated in part by an extravagal 
cholinergic mechanism. Metabolism. 32 (1), 57-61.
89 Gorus F, Malaisse W, Pipeleers B (1984) Differences in glucose handlingi)y 
pancreatic A and B cells. J.Biol.Chem.Jan. 259 (2), 1196-1200.
90 Green A, Olefsky J (1982) Evidence of insulin-induced internalization and 
degradation of insulin receptors in rat adipocyte. Proc.Natl.Acad.Sci. 79, 
427.
91 Grey N, McGuigan J, Kipnis D (1970) Neutralization of endogenous 
glucagon by high titre glucagon antiserum. Endocrinology. 86, 1383-1388.
92 Grill V, Cerasi E (1978) Interacting effects of sulphonylureas and glucose 
on cyclic AMP metabolism and -insulin release in pancreatic islets of the 
rat. J.Clin.Invest. 61, 1346-1354.
93 Grodsky G, Batts A, Bennet L, et al. (1963) Effects of carbohydrates on 
secretion of insulin from isolated rat pancreas. Am.J.Physiol. 204 (4), 
638-644.
94 Guillemin R, Gerich J (1976) Somatostatin: Physiologic and clinical 
significance. Ann.Rev.Med. 27, 379-388.
95 Gylfe E, Sehlin J (1976) Interaction between the metabolism of L-leucine 
and D-glucose in the pancratic B cells. Horm.Metab.Res. 8, 7-11.
96 Halban P, Wollheim C B, Blondel B, Renold A E (1979) Evidence for the 
importance of contact between pancreatic islet cells in glucose induced 
insulin release. Diabetes. (Suppl). 28, 394.
97 Hammer A, Leeman S (1981) Neurotensin: Properties and actions, pp 290- 
299. In: Bloom S, Polak J (eds) Gut Hormones. Churchill Livingstone, 
Edinburgh.
98 Hammer R, Carraway R, Leeman S (1982) Elevation of plasma neurotensin- 
like immunoreactivity after a meal. J.Clin.Invest. 70, 74-81.
99 Hellerstrom C (1983) The biosynthesis of glucagon, pp 125-126. In: 
Lefebvre P (ed) Glucagon I. Springer-Verlag, Berlin.
100 Heilman B, Sehlin J, Taljedal I B (1971) Effects of glucose and other
modifiers of insulin release on the oxidative metabolism of amino acids in
microdissected paneraetic islets. Biochem.J. -123, 513-521.-
101 Heilman B (1982) The mechanism of sulphonylurea stimulation of insulin 
release. Acta.Biol.Med.Germ. 41, 1211-1219.
102 Heilman B, Sehlin J, Taljedal I (1984) Glibenclamide is exceptional among 
hypoglycaemic sulphonylureas in accumulating progressively in 8-cell-rich 
pancreatic islets. Acta Endocrinologica. 105, 385-390.
103 Henquin 3 (1980) T olbutamide stimulation and inhibition of insulin release: 
Studies of the underlying ionic mechanisms in isolated rat islets. 
Diabetologia. 18,151-160.
104 Henquin J, Charles S, Nenquin M, Mathot F, Tamagawa T (1982) Diazoxide
and D600 inhibition of insulin release. Distinct mechanisms explain
specificity for different stimuli. Diabetes. 31, 776-783.
105 Henquin J, l |^eissner H (1982) Opposite effects of tolbutamide and 
diazoxide on R6+ fluxes and membrane potentials in pancreatic B cells. 
Biochem.Pharmacol. 37 (7), 1407-1415.
106 Hermansen K (1980) Secretion of somatostatin from the normal and 
diabetic pancreas: Studies in vitro. Diabetologia. 19, 492-504.
107 Hermansen K (1982) Tolbutamide, glucose, calcium and somatostatin 
secretion. Act Endocrinologica. 99, 86-93.
108 Holst J, Galbo H, Richter E (1978) Neutralization of glucagon by antiserum 
as a tool in glucagon physiology. Lack of depression of basal glucose after 
antiserum treatment in rats. J.Clin.Invest. 62, 182-190.
109 Holst J, Fahrenkrug J, Jensen S, Nielsen O (1981) Peptidergic innervation 
of the pancreas, pp 495-499. In: Bloom S and Polak J (eds) Gut Hormones. 
Churchill Livingstone, Edinburgh, London, Melbourne and New York.
110 Honey R, Weir G (1979) Insulin stimulates somatostatin and inhibits 
glucagon secretion from the perfused chicken pancreas-duodenum. Life 
Sciences. 4, 1747-1750.
111 Hunter W, Greenwood F (1962) Preparation of iodine labelled growth 
hormone of high specific activity. Nature. 194, 495-496.
112 Hurn B, Landon J (1971) Antisera for radioimmunoassay, pp 121-142. In: 
Kirkham and Hunter (eds) Radioimmunoassay Methods. Churchill 
Livingstone, Edinburgh, London.
113 In’t Veld P A, Pipeleers B G, Gepts W (1984) Evidence against the presence 
of tight junctions in normal endocrine pancreas. Diabetes. 33 (1), 101-104.
114 Toth M, Mandrino L, Gerich J (1980) Antisomatostatin gamma globulin 
augments secretion of both insulin and glucagon in vitro: Evidence for a 
physiologic role for endogenous somatostatin in the regulation of 
pancreatic A and B cell function. Diabetes. 29, 693-698.
115 Ito S, Iwanaga Y, Yamada Y, Shibata A (1982) Somatostatin-28 like 
immunoreactivity in the human gut. Hormone Met.Res. 14 (9), 500-501.
116
117
118
119
120
121
122
123
124
123
126
127
128
129
130
131
132
133
/SUU
Iwasalci Y, Ito 5, Shibata A (1980) Radioimmunoassay of neurotensin and 
the distribution and concentration of gut neurotensin in rat and dog. 
Tohoku Journal of-Experimental Medicine. 130,129-137. - -
Izzo J (1975) Degradation of insulin, pp 229-245. In: Hasselblat A, 
Bruchhausen F (eds) Insulin II. Springer-Verlag, Berlin.
Jackson J, Bressler R (1981) Clinical pharmacology of sulphonylurea 
hypoglycaemic agents. Drugs 22, 211-245 and 295-320.
Jansson L and Hellerstrom C (1983) Stimulation by glucose of the blood 
flow to the pancreatic islets. Diabetologia. 25, 45-50.
Jaspan J, Polonsky K, Lewis M, Moosa R (1979) Reduction in portal vein 
blood flow by somatostatin. Diabetes. 28, 888-892.
Jeffery W, Graham E (1983) Treatment of chlorpropamide overdose with 
diazoxide. Drug Intell.Clin.Pharm. 17 (5), 372-374.
Johnson A, Erdos E (1973) Release of histamine from mast cells by 
vasoactive peptides. Proc.Soc.Exp.Biol.Med. 142, 1252-1256.
Jolicoeur F, Barbeau A (1982) Pharmacological evidence for a 
heterogeneity of receptors underlying various central and peripheral 
effects of neurotensin. Ann N Y Acad.Sci. 400, 440-441.
Judis J (1972) Binding of sulphonylurea to serum proteins. Journal of 
Pharmaceutical Sciences. 61, 89-93.
Kadawaki S, Taminato T, Chiba T (1983) Effect of tolbutamide on insulin, 
glucagon and somatostatin release from the diabetic rat pancreas with 
special reference to glucose concentration. Endocrinology;' 112 (2)^-2187- 
2192.
Kajinuma H, Kuyuta T, Ide T (1974) Effcts of hypoglycaemic sulphonamides 
on glucagon and insulin secretion in ducks and dogs. Diabetes. 23, 412-417.
Kaplan S (1984) The insulin receptor. J.Paed. 104 (3), 327-336.
Kimmel J, Pollock H (1981) Target organs for avian pancreatic-polypeptide. 
Endocrinology. 109 (5), 1693-1699.
Kitabgi P, Freychet P (1979) Neurotensin: Contactile activity, specific 
binding and lack of effect on cyclic nucleotide in intestinal smooth muscle. 
Eur.J.Pharmacol. 55, 35-42.
Koerker D, Ruch W, Chideckel E, et al. (1974) Somatostatin: Hypothalamic 
inhibitor of the endocrine pancreas. Science. 184, 482-483.
Kohen E, Kohen C, Rabinovilde A (1983) Cell-to-cell communication in rat 
pancreatic islet monolayer cultures is modulated by agents affecting islet 
cell secretory activity. Diabetes. 32, 95-98.
Kono T, Barham F (1973) Effects of insulin on the levels of adenosine 3, 5 - 
monophosphate and lipolysis in isolated rat epididymal fat cells. 
J.Biol.Chem. 248, 7417.
Kronheim S, Sheppard M, Miller J (1981) A radioimmunoassay for 
neurotensin. Clinical Endocrinology. 14, 159-164.
ZU1
134 Langer S Z, Adler-Graschinsky E, Giorgi O (1977) Physiological 
significance of a-adrenoceptor-mediated negative feed back mechanism 
regulating noradrenaline release-during nerve stimulation.— feature- —265, 
648-650.
135 Lamer J, Galasko G, et al. (1979) Generation by insulin of a chemical 
mediator that controls protein phosphorylation and dephosphorylation. 
Science. 206, 1408-1410.
136 Larsson L I, Holst J J, Hakanson R, Sundler F (1975) Distribution and
propertie of glucagon immunoreactivity in the digestive tract of various 
mammals: An immunohistochemical and immunochemical study.
Histochemistry. 44, 281-290.
137 Larsson L I, Fahrenkrug J, Schaffalitzky de Muckadell O B (1978) 
Innervation of the pancreas by vasoactive intestinal polypeptide (VIP) 
immunoreactive nerves. Life Sci. 22, 773-780.
138 Laube H, Fussganger R, Goberna R, et al. (1971) Effects of tolbutamide on 
insulin and glucagon secretion of the isolated perfused rat pancreas. 
Horm.Metab.Res. 3, 238-242.
139 Lazarus L, Perrin M, Brown M, Rivier J (1977) Mast cell binding of 
neurotensin II. Molecular conformation of neurotensin involved in the 
stereospecific binding to mast cell receptor sites. J.Biol.Chem. 252, 
7180-7183.
140 Leclerq-Meyer V, Brisson R, Malaisse W J (1977) Effect of adrenaline and 
glucose on release of glucagon and insulin in vitro. Nature New Biol. 231, 
248-249.
141 Lee Y, Allen J, Uttenhal L, Walker M, Shenilt J, Gill S* Bloom S (1984) The 
metabolism of intravenously infused neurotensin in man and its 
chromatographic characterization in human plasma. J.EndocrinoI.Metab. 
59(0 , 45-50.
142 Leeman S, Carraway R (1982) Neurotensin: Discovery, isolation, 
characterization, synthesis and possible phyiological roles. Ann N Y 
Acad.Sci. 400, 1-16.
143 Levine R (1982) Insulin: The effects and mode of action of the hormone. 
Vitamins and Hormones. 39, 145-173.
144 Lifson N, Kraminger K G, Mayrand R R, Lander E J (1980) Blood flow to 
the rabbit pancreas with special reference to the islets of Langerhaus. 
Gastroenterology. 79, 466-473.
145 Loubatieres A, Mariani M, Alric R, Chapal J (1967) Antagonistic 
mechanism of actions of tolbutamide and diazoxide on insulin secretion, pp 
100-113. In: Butterfield W, Westering W (eds) Tolbutamide after Ten Years. 
Exerpta Medica Foundation, Amsterdam.
146 Loubatieres A, Mariani M. Alric R (1968) The action of diazoxide on insulin 
secretion, medullo-adrenal secretion and the liberation of catecholamines. 
Ann N Y Acad.Sci. 150 (2), 226-241.
147 Loubatieres A, Loubatieres-Miriani M, Alric R, Ribes G (1974) Tolbutamide 
and glucagon secretion. Diabetologia. 10, 271-276.
148 Lundquist I, Sundler F, Ahern B, Alumets J, Hakanson R (1979)
Somatostatin, pancreatic polypeptide,-- substance P and- neurotensin:—- —
Cellular distribution and effects on stimulated insulin secretion in the 
mouse. Endocrinology. 104, 832-838.
149 Luyckx A (1974) Etude de la secretion de 1'insulin et du glucagon. Faculte 
de Medecine, Universite du Liege, Liege, 122.
130 McGarry J D and Foster D W (1983) Glucagon and ketogenesis, pp 383-396.
In: Lefebvre P J (ed) Glucagon II. Springer-Verlag, Berlin.
151 McIntyre N, Holdsworth C, Turner D (1964) A new interpretation of the 
oral glucose tolerance test. Lancet. 2, 20-22.
152 Malaisse W, Malaisse-Lagae F (1968) Stimulation of insulin secretion by 
non-carbohydrate metabolites. J.Lab.Clin.Med. 72,1724-1734.
153 Malaisse W, Malaisse-Lagae F (1969) Biochemical pharmacological and 
physiological aspects of the adenycyclase-phosphodiesterase system in the 
pancreatic B cells, pp 435-444. In: Falkmer S, Heilman B and Taljedal I B 
(eds) The Structure and Metabolism of the Pancreatic Islets. Wenner-Gren 
Centre International Series, Oxford. Vol 16.
154 Malaisse W (1973) Insulin secretion: Multifactorial regulation for a single 
process of release. Diabetologia. 9, 167-173.
155 Mark N, Harold E (1978) Sulphonylureas increase the number of insulin 
receptors. Nature. 276, 184-185.
156 Marks V (1970) The biological significance of the insulinotropic effect of 
glucagon in man. Acta Isotopica. 10, 219.
157 Marks V (1981) The regulation of blood glucose, pp 3-50. In: Marks V and 
Rose F (eds) Hypoglycaemia. Blackwell Scientific Publications, Oxford.
158 Marre M, Bobbioni E, Sheppard M, Kronheim S, Miller J, Assan R (1982) The 
nervous control of rat somatostatin, glucagon and insulin secretions.
Diabete & Metabolisme (Paris). 8, 179-186.
159 Massague J, Czech M (1982) Role of disulfides in the subunit structure of 
the insulin receptor. Reduction of class I disulfides do not impair 
transmembrane signalling. J.Biol.Chem. 257, 6729.
160 Matschinsky F, Landgraf R, Ellerman J, Kotler-Brajkburg J (1972) 
Glucoreceptor mechanisms in islets of Langerhans. Diabetes. (Suppl). 21,
555.
161 Mazzaferri E, Ciofalo L, Waters L, et al. (1983) Effects of gastric 
inhibitory polypeptide on leucine- and arginine-stimulated insulin release. 
Am.J.Physiol. 245 (2), E114-120.
162 Meda P, Perrelet A, Orci L (1979) Increase of gap junction between 
pancreatic B-cells during stimulation of insulin secretion. J.Cell.Biol. 82, 
441-448.
163 Meissner H, Atwalar I (1976) The kinetics of electrical activity of B cells 
in response to a 'square wave' stimulation with glucose or glibenclamide. 
Horm.Metab.Res. 8, 11-16.
164 Milner R (1969a) The mechanism by which leucine and arginine stimulate
insulin release in vitro. Biochim.Biophys.Acta. 192, 154-156.
165 Milner R (1969b) Stimulation of insulin secretion in vitro by essential
amino acids. Lancet. _1, 1075-1076.
166 More P (1968) Discussion paper: The effects of diazoxide and
benzothiadiazine diuretics upon phosphodiesterase. Ann N Y Acad.Sci. 150 
(2), 256-260.
167 MoloneyP, Coval M (1955) Antigenicity of insulin: Diabetes induced by
specific antibodies. Biochem.J. 59, 179-185.
168 Morgan L, Morris B, Marks V (1978) Radioimmunoassay of GIP. Annals of
Clinical Biochemistry. J15, 172-177.
169 Nagai K, Frohman L (1976) Hyperglycaemia and hyperglucagonaemia 
following neurotensin administration. Life Sciences. 19, 273-280.
170 Nag&i K, Frohman L (1978) Neurotensin hyperglycaemia: Evidence for 
histamine mediation and the assessment of a possible physiological role. 
Diabetes. 27, 577-582.
171 Nicholas K, Topper Y (1983) Antiinsulin receptor serum mimicks the 
developmental role of insulin in mouse mammary explants. 
Biochem.Biophys.Res.Commun. Ill, 988-993.
172 Noe B D, Baste C A, Bauer G E (1977a) Studies on proinsulin and
proglucagon biosynthesis and conversion at the subcellular level. 1.
Fractionation procedure and characterization of the subcellular fractions. 
J.Cell.Biol. 74, 578-588.
173 Noe B D, Baste C A, Bauer G E (1977b) Studies on proinsulin and
proglucagon biosynthesis and conversion at the subcellular level. II.
Distribution of radioactive hormones and hormone precursors in subcellular 
fractions after pulse and pulse-chase incubation of islet tissue. J.Cell.Biol. 
74, 589-604.
174 Nowak S, McCaleb M, Lockwood D (1983) Extrapancreatic action of 
sulphonylureas: hypoglycaemic effects are not dependent on altered insulin 
binding or inhibition of transglutaminase. Metabolism, 32 (4), 398-402.
175 Ohneda A, Parada E, Eisentraut M, Unger R (1968) Characterization of 
response of circulating glucagon to intraduodenal and intravenous 
administration of amino acids. J.Clin.Invest. 47, 2305-2322.
176 Orci L, Gabbay K, Malaisse W (1972) Pancreatic beta-cell web: Its possible 
role in insulin secretion. Science. 175, 1128-1130.
177 Orci L, Unger R H, Renold A E (1973) Structural coupling between 
pancreatic islet cells. Experientia. 29, 1015-1018.
178 Orci L, Unger R H (1975) Functional subdivision of islets of Langerhans and 
possible role of D cells. Lancet. 2, 1243-1244.
179 Orci L (1980) Some recent findings concerning the rodent and human 
endocrine pancreas, pp 1-13. In: Andreani B, Lefebvre P and Marks V (eds) 
Current Views on Hypoglycaemia and Glucagon. London Academic Press.
180 O'Shaughnessy D (1982) Antibodies, pp 11-20. In: Bloom S, Long R (eds) 
Radioimmunoassay of Gut Regulatory Peptides. Saunders Company Ltd, 
London.
181 Ostenson C G, Grill V, Nylin A, Efendic S (1983) Modulation by IBMX, 
fasting and experimental diabetes of glibenclamide-induced islet hormone 
release from the perfused rat pancreas. Diabete & Metabolisme. 9, 58-65.
182 Patel Y, Reichlin S (1978) Somatostatin in hypothalamus, 
extrahypothalamic brain and peripheral tissues of the rat. Endocrinology. 
102, 523-530.
183 Patel Y, Amherdt M, Orci L (1979) Somatostatin secretion from monolayer 
cultures of neonatal rat pancreas. Endocrinology. 104 (1), 676-679.
184 Patton G, Dobbs R, Orci L, Vale W, Unger R (1976) Stimulation of 
pancreatic immunoreactive somatostatin (IRS) release by glucagon. 
Metabolism. (Suppl 1). 25, 1499.
185 Patton G, Ipp E, Dobbs R, et al. (1977) Pancreatic immunoreactive 
somatostatin release. Proceedings of the National Academy of Sciences 
(USA). 74, 2140-2143.
186 Patzelt C, Lebrecque A, Dujuid J, Carrol R, Keim P, Heinrikson R, Steiner 
D (1978) Detection and kinetic behaviour of preproinsulin in pancreatic 
islets. Proc.Nat.Acad.Sci. (USA). 75, 1260-1264.
187 Paulin C, Dubois P (1978) Immunohistochemical identification and 
localization of pancreatic polypeptide cells in the pancreas and 
gastrointestinal tract of the human foetus and adult man. Cell and Tissue 
Research. 188, 251-257.
188 Pek S, Fajans S, Floyd J, et al. (1972) Failure of sulphonylureas to suppress 
plasma glucagon in man, Diabetes. 21, 216-223.
189 Pek S, Tai T, Growther R, Fajans S (1976) Glucagon release precedes 
insulin release in response to common secretagogues. Diabetes. 25, 764- 
770.
190 Pek S, Santiago J, Tai T (1978) L-leucine-induced secretion of glucagon and 
insulin and the 'off response’ to L-leucine in vitro. I. Characterization of 
the dynamics of secretion. Endocrinology. 103, 1208-1218.
191 Peric-Golia L, Gardner C, Peric-Golia M (1979) The effect of- neurotensin 
on the plasma cholesterol levels in the rat. Eur.J.Pharmacol. 55, 407.
192 Pfeiffer M, Bread J, Hatter J, et al. (1983) Suppression of glucagon 
secretion during a tolbutamide infusion in normal noninsulin-dependent 
diabetic subjects. J.Clin.Endocrinol.Metab. 56 (1), 586-591.
193 Pitts J, Wood S, Horuk R, Bedarkar S, Blundell T (1980) Pancreatic
hormone storage granules: The role of metal ions and polypeptide
oligomers, pp 673-682. In: Brandenburg D, Wollmer A (eds) Insulin: 
Chemistry, Structure and Function of Insulin and Related Hormones. De 
Gruyter, Berlin, New York.
194 Polak J, Sullivan S, Bloom S, Buchan A, Facer B, Brown M, Pearse A (1977)
Specific localization of neurotensin to the N cell in human intestine by
radioimmunoassay and immunocytochemistry. Nature. 270, 183-184.
195 Polonsky K , Jaspan 3 ', Rubenstein A (1983) The metabolic clearance 
rate of glucagon, pp 353-359. In: Lefebvre P J (ed) Glucagon II. Springer- 
Verlag, Berlin, Heidelberg, New York, Tokyo.
196 Poussier P, Nakhooda A, Grose M, Marliss E (1983) Arginine-induced 
glucagon secretion in the spontaneously diabetic BB Wister rat. 
Metabolism. 32 (3)-487-491. .......
197 Quirion R, Gaudreau P, St-Pierre S, Rioux F (1982) Localization of 
neurotensin binding sites in rat kidney peptides. 3, 765-769.
198 Raskin P (1981) Insulin, glucagon and somatostatin interaction in diabetes,
pp 467-481. In: Cooperstein S, Watkins D (eds) The Islets of
Langerhans:Biochemistry, Physiology and Pathology. Academic Press. New 
York, London, Toronto, Sydney, San Francisco.
199 Ravazzola M, Orci L (1980) Transformation of glicentin-containing L-cells 
into glucagon-containing cells by enzymatic digestion. Diabetes. 29, 156- 
158.
200 Rivier C, Brown M, Vale W (1977) Effect of neurotensin, substance P and 
morphine sulphate on the secretion of prolactin and growth hormone in the 
rat. Endocrinology. 100, 751-754.
201 Robertson R, Metz S (1979) Prostaglandins, the glucoreceptors and 
diabetes. N.Engl.J.Med. 301, 1446-1447.
202 Robertson R (1979) Prostaglandins as modulators of pancreatic islet 
function. Diabetes. 28, 943-948.
203 Rocha D, Faloona G, Unger R (1972) Glucagon stimulating activity of 20 
amino acids in dogs. J.Clin.Invest. 51, 2346-2361.
204 Rodbell M, Kraus H, Pohl S, Birnbaumer L (1971) The. glucagon-sensitive 
adenyl cyclase system in plasma membranes of rat liver. Biol.Chem. 246, 
1861-1871.
205 Rpdbel^M (1972) Regulation of glucagon action at its receptors, pp 61. In: 
Lefebvre P, Unger R H (eds) Glucagon. Pergamon, Oxford, New York.
206 Rodbell M (1983) The actions of glucagon at its receptors: Regulation of 
adenylate cyclase, pp 276. In: Lefebvre P (ed) Glucagon I. Springer- 
Verlag, Berlin, Heidelberg, New York, Tokyo.
207 Rokaeus A (1981) Studies on neurotensin as a hormone. Acta Physiologica 
Scandinavica. Supplementum 501.
208 Rosell S, Burcher E, Chang D, Folkers K (1976) Cardiovascular and 
metabolic actions of neurotensin and (GLn 4)-neurotensin. Acta 
Physiol.Scand. 98 (4), 484-491.
209 Rosen S, Glutter W, Berk M, Shah S, Cryer P (1984) Epinephrine supports 
the postabsorbtive plasma glucose concentration and prevents 
hypoglycaemia when glucagon secretion is deficient in man. 
J.Clin.Invest.Feb. 73 (2), 239-242.
210 Saito H, Saito S (1980) Effects of substance P and neurotensin on
* somatostatin levels in rat portal plasma. Endocrinology. 107, 1600-1605.
211 Salhnick A, Konowitz P, Amatruda J (1983) Potentiation of insulin action 
by a sulphonylurea in primary cultures of hepatocytes from normal and 
diabetic rats. Diabetes. 32, 206-212.
212 Samols E, Marri G, Marks V (1965) Promotion of insulin secretion by 
glucagon. Lancet. 2, 415-416.
213 Samols E, Tyler J, Mialhe P (1969) Suppression of pancreatic glucagon 
release by the hypoglycaemic sulphonylureas. Lancet, j ,  174.
214 Samols E, Tyler J, Kajinuma H. Influence of the sulphonamides on 
pancreatic humoral secretion and evidence for an insulin-glucagon 
feedback system. From 'Reports on Oral Diabetes Therapy Especially with 
HB 419"; a selection of papers presented at the VII Congress of the 
International Diabetes Federation, Buenos Aires. 23-28 August 1970. 
Exerpta Medica.
215 Samols E, Tyler J, Marks V (1972) Glucagon-insullin interrelationships, pp 
151-173. In: Lefebvre P, Unger R (eds) Glucaton:Molecular, Physiology,
Clinical and Therapeutic Implications. Pergamon Press, Oxford.
216 Samols E, Harrison J (1975) Suppression of glucagon secretion by diazoxide. 
Clin.Res. 23, 330A.
217 Samole E, Harrison J (1976) Intraislet negative insulin-glucagon feedback. 
Metabolism. (Suppl 1). 25, 1443-1447.
218 Samols E, Weir G, Patel Y, Loo S, Gabbay K (1977) Autonomic control for 
somatostatin and pancreatic peptide secretion by the isolated perfused 
canine pancreas. Clin.Res. 25, 499A.
219 Samols E, Weir G (1979) Adrenergic modulation of pancreatic A, B and D 
cells: a-adrenergic stimulation of glucagon secretion in the perfused dog 
pancreas. J.Clin.Invest. 63, 230-238.
220 Samols E, Stranger 0(1981) Modulation of insulin: Local presynaptic o^ and 
postsynaptic o&2 adrenoceptors. Diabetes. (Suppl 1). 30, 44A.
221 Samols E (1983) Glucagon and insulin secretion, pp 485-511. In: Lefebvre P 
(ed) Glucagon I:Handbook of Experimental Pharmacology, 66/1. Springer- 
verlag, Berlin.
222 Samols E, Weir G, Bonner-Weir S (1983) Intraislet insulin-glucagon- 
somatostatin relationships, pp 133-173. In: Lefebvre P (ed) Glucagon II. 
Springer-Verlag, Berlin, Heidelberg, New York, Tokyo.
223 Sando H, Borg J, Steiner D (1972) Studies on the secretion of newly 
synthesized proinsulin and insulin from isolated rat islets of Langerhans. 
J.Clin.Invest. 51, 1476-1485.
224 Sarson D, Bloom S (1981) GIP and the enteroinsular axis, pp 264-268. In: 
Bloom S, Polak J (eds) Gut Hormones. Churchill Livingstone, Edinburgh, 
London, Melbourne and New York.
225 Sarson D (1982) Quality control and assay mathematics. In: Bloom S, Long 
R (eds) Radioimmunoassay of gut regulatory peptides, pp 42-50. Saunders 
Company Ltd, London.
226 Sarson D, Wood S, Kansal P, Bloom S (1984) Glucose-dependent
insulinotropic polypeptide augmentation of insulin: Physiology or
pharmacology? Diabetes. 33> 389-393.
227 Scatchard C (1949) The attraction of proteins for small molecules and ions. 
Ann N Y Acad.Sci. 51, 660-672.
228 Schade D, Eaton R (1980) The peritoneum - a potential insulin delivery 
route for a mechanical pancreas* Diabetes Care. -3 (2), 229-234.--
229 Schade D, Eaton R, Friedman N, Spencer W (1980) Prolonged peritoneal 
insulin infusion in a diabetic man. Diabetes Care. 3 (2), 314-317.
230 Schatz H, Kullek W (1980) Studies on the local (Paracrine) actions of 
glucagon, somatostatin and insulin in isolated islets of rat pancreas. FEBS 
Letters. 122 (2), 207-210.
231 Schusdziarra V, Zyznar E, Rouiller D, et al. (1980) Splanchnic
somatostatin: A hormonal regulation of nutrient homeostasis. Science.
207, 530-532.
232 Schwartz T, Rehfeld J, Stadil F, Larsson L I, Chance R, Moon N (1976) 
Pancreatic polypeptide response to food in duodenal-ulcer patients before 
and after vagotomy. Lancet. \, 1102-1105.
233 Searle G (1976) The use of isotope turnover techniques in the study of 
carbohydrate metabolism in man. Clin.Endocrinol.Metabl. 5, 783.
234 Seino S, Sakurai H, Kuzuya H, et al. (1982) Effect of glucagon antiserum on 
somatostatin, glucagon and insulin release from the isolated perfused rat 
pancreas. Peptides. J_, 175-182.
235 Selebekk B, Flaten O, Hanssen L (1980) The in vitro effect of neurotensin 
on human jejunal mast cells. Scand.J.Gastroenterol. 15, 457-460.
236 Shapiro A, Shapiro B (1979) Role of the liver in intestinal glucose 
absorption. Biochim.Biophys.Acta. 586, 123.
237 Shaw C, Buchanan K (1984) The production of region-specific neurotensin 
antisera. Digestive Diseases and Sciences. (Suppl). 29, 79 S.
238 Shaw C, Watt P, Buchanan K (1984) Post-gastric surgery neurotensin 
release: Assessment with two region-specific antisera. Digestive Diseases 
and Sciences. (Suppl). 29, 79 S.
239 Shields B (1980) In vitro biosynthesis of somatostatin. J.BioLChem. Vol 
225, No 24, 11625-11628.
240 Shoelson S, Polonsky K, Docherty H, Jaspan J, Rubenstein A (1982) 
Evidence for the presence of somatostatin-28 in plasma. Diabetes. 31, 
474-477.
241 Shulkes A, Chick P, Wong H, Walsh J (1982) A radioimmunoassay for 
neurotensin in human plasma. Clinical Chimica Acta. 125, 49-58.
242 Shulkes A, Boden R, Cook I, Gallagher N, Furness J (1984) Characterization 
of a pancreatic tumour containing vasactive intestinal peptide, neurotensin 
and pancreatic polypeptide. J.Clin.Endocrinol.Metab. 58, 41-48.
243 Simpson I, Rose B, Lowenstein W R (1977) Size limit of molecules 
permeating the junctional membrane channels. Science. 195, 294-296.
244 Sirinek K, Levine B, Crocket S, Cataland S (1980) Cholecystokinin and 
gastric inhibitory polypeptide are not glucagonotropic in dogs. J.Surg.Res. 
28, 366-372.
245 Smith P (1975) The effects of selective partial pancreatectomy on 
pancreatic islet cell morphology in the Japanese quail. 
Gen.Comp.Endocrinol. 26, 31Q-32Q.
246 Smith P H, Porte B (1976) Neuropharmacology of the pancreatic islets. 
Ann.Rev.Pharmacol.Toxicol. 16, 269-285.
247 Sternburger L (1974) Immunocytochemistry. Raven Press. New York
248 Sundler F, Hakanson R, Leander S, Uddman R (1982) Light and electron 
microscopic localization of neurotensin in the gastrointestinal tract. Ann 
N Y Acad.Sci. 400, 94-104.
249 Sutherland E W, Cori C F (1951) Effect of hyperglycaemic-glycogenolytic 
factor and epinephrine on liver phosphorylase. J.Biol.Chem. 188, 531-543.
250 Tabachnick I, Gulbenkian A, Seidman F (11964) The effects of 
benzothiaziazine diazoxide on carbohydrate metabolism. Diabetes. 13, 
408.
251 Tager H (1981) Biosynthesis of glucagon, pp 39. In: Unger R, Orci L (eds) 
Glucagon. Physiology, Pathophysiology and Morphology of the Pancreatic 
A-Cells. Elsevier, Amsterdam, Oxford, New York.
252 Tager H, Steiner D (1974) Peptide hormones. Any; Rev.Biochem. 43, 509- 
538. ~
253 Taminato T, Seino Y, Goto Y, et al. (1977) Synthetic gastric inhibitory 
polypeptide. Diabetes. 26, 480-484.
254 Tan K, Marks V (1981) Inhibition of arginine-stimulated insulin release in 
isolated islets by glucagon antiserum. Clin.Sci. 61, lp.
255 Tan K (1982) Insulin secretion: Regulation of paracrine interrelation, PhD 
Thesis, University of Surrey, Guildford, England.
256 Turner D, Marks V (1972) Enhancement of glucose-stimulated insulin 
release by an intestinal polypeptide in rats. Lancet. 1, 1095-1097.
257 Turner D, Shabaan A, Etheridge L, Marks V (1973) The effect of an 
intestinal polypeptide on insulin release in the rat in vitro and in vivo. 
Endocrinology. 93 (6),
258 Turtle J, Kipnis D (1967) An adrenergic receptor mechanism for the 
control of cyclic 3 5 adenosine monophosphate synthesis in tissues. 
Biochem.Biophys.Res.Commun. 28, 797.
259 Uhl G, Synder (1977) Neurotensin receptor binding, regional and subcellular 
distributions favour transmitter role. Eur.J.Pharmacol. 41, 89-91.
260 Unger R, Eisentraut A (1969) Enteroinsular axis. Arch.Intern.Med. 123, 
261-266.
261 Unger R, Aguilar-Parada E, Muller W, Eisentraut A (1970) Studies of 
pancreatic alpha cell function in normal and diabetic subjects. 
J.Clin.Invest. 49, 837-848.
262 Unger R, Orci L (1981) Glucagon and the A cell: Physiology and 
pathphysiology. The New England Journal of Medicine. 304 (26), 1518-1524 
and 1575-1580.
263 Unger R (1983) Insulin-glucagon relationships in the defense against 
hypoglycaemia. Diabetes. 32 (6), 575-583.
264 Urdanivia E, Pek S, Santiago 3 (1979) Inhibition of glucagon secretion by 
diazoxide in vitrg. Diabetes. 28, 26-31.
265 Villalpando S, Drash A (1979) Circulating glucagon antibodies in children 
who have insulin-dependent diabetes meilitus: Clinical significance and 
characterization. Diabetes. 28, 294-299.
266 Walfish P, Natale R, Chang C (1968) Beta adrenergic receptor mechanisms 
in the metabolic effects of diazoxide in fasted rats. Diabetes. 19 (4), 228- 
233.
267 Walker H (1977) An approach to immunoassay. Clin.Chem. 23 (2), 384.
268 Whitcomb D, O'dorisio T, Nishikawana M, Shetzline M, Cataland S (1984) 
Identification of target organs for gastric inhibitory polypeptide (GIP) with 
a new in vivo radioreceptor assay. Digestive Diseases and Sciences. 
(Suppl). 29, 8, A86.
269 Wolfe R, Allsop J, Burke 3 (1978) Increased glucose production following 
neurotensin administration. Life Sciences. 22, 1043-1048.
270 Wolfgang E, Noether-Fleig G, Fussganger R, Ditschuneit H (1984) 
Modulation by a sulfonylurea of insulin-dependent glycogenesis, but not of 
insulin binding, in cultured rat hepatocytes. Evidence for a postreceptor 
mechanism of action. Diabetes. Vol 33, March. 285-290.
271 Zawalich W (1979) Intermediary metabolism and insulin secretion from 
isolated rat islets of Langerhans. Diabetes. 28, 252-260.
